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The transcription factor Nrf2 is a master regulator of cytoprotective gene 
expression. Nrf2 is negatively controlled by Keap1, a sensor protein which 
allows Nrf2 to respond to changing cellular conditions. In the basal state, Nrf2 
binds to two sites of a Keap1 dimer allowing its ubiquitination in a Cullin-
3/Rbx1-dependent manner. In response to electrophiles and oxidants (termed 
inducers, which bind directly to Keap1) ubiquitination of Nrf2 is inhibited; 
consequently, Nrf2 accumulates and activates transcription.  
We have developed aFLIM-based assay to study the dynamic interaction 
between Keap1 and Nrf2 in single live cells. Combinations of wild type and 
mutant proteins revealed that under basal conditions the Keap1-Nrf2 complex 
exists in two conformations, one in which Nrf2 is bound to both members or the 
Keap1 dimer (‘closed’ conformation), and a second in which Nrf2 interacts with a 
single Keap1 monomer (‘open’ conformation).  We found that following exposure 
to a range of inducers the Cul3-Keap1-Nrf2 complex does not dissociate, but 
remains intact. Furthermore, we found that inducers lead to the accumulation of 
the Keap1-Nrf2 complex in the ‘closed’ conformation. Interestingly, blockage of 
the proteasome also leads to the accumulation of the complex in the closed 
conformation, suggesting that the binding of Nrf2 and its subsequent Keap1-
dependent ubiquitination follows a cyclical pattern. We believe that the 
existence of a Keap1-Nrf2 binding cycle benefits the cell, as it allows other 
signaling pathways, such as those mediated by p21 and p62, to regulate Nrf2 
activity in the absence of inducers. 
Together our results show that the interaction between Keap1 and Nrf2 is 
more dynamic than previously anticipated and that inducers function to 












































In the late 1980s, Paul Talalay and his colleagues predicted the existence 
of a protein endowed with highly reactive cysteine residue(s) that serves as the 
sensor for small-molecule inducers of cytoprotective enzymes, such as 
NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) and glutathione S-
transferases (GSTs). In a seminal study (Talalay et al. 1988) aiming to obtain 
mechanistic insights into the perplexing question of how numerous structurally 
diverse small molecules induce these proteins, a common chemical signature 
was identified, leading the investigators to conclude: “…it is gratifying that the 
capacity of an extraordinary variety of seemingly unrelated anticarcinogens to 
induce protective enzymes can be attributed to the presence, or acquisition by 
metabolism, of a simple and hitherto unrecognized chemical property: that of a 
Michael reaction acceptor.” Following the discovery of Keap1 by Masayuki 
Yamamoto and his colleagues (Itoh et al. 1999) as the repressor of transcription 
factor Nrf2 that regulates the expression of these cytoprotective genes, the first 
question was: “Does Keap1 have any (reactive) cysteine residues?” In the ensuing 
years, several different laboratories have demonstrated cysteine modifications of 
Keap1 by inducers (see Sekhar et al. 2010; Holland and Fishbein, 2010; Hayes et 
al. 2010 for recent reviews), and it is now widely accepted that cysteine residues 
of Keap1 function as sensors of a chemical signal ultimately leading to enhanced 





Nrf2 (NF-E2 p45-related Factor 2) is a bZip transcription factor and a 
member of the Cap 'n' Collar family of regulatory proteins which also includes 
NF-E2, Nrf1, Nrf3, Bach1 and Bach2 (Motohashi et al. 2002). Nrf2 is conserved in 
bilaterans with homologues found in nematodes, flies, fish and mammals, and 
was identified due to its ability to bind to NF-E2/ AP-1 enhancer elements in 
cDNA library screens (Moi et al. 1994; Itoh et al. 1995; Kobayashi et al 2002; An 
and Blackwell, 2003; Sykiotis and Bohmann 2008). Nrf2 was later shown to  
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Figure 1.1. Domain structures of Nrf2 and Keap1. (A) In Nrf2, shown are the 
positions of the Neh2, Neh4, Neh5, Neh6, Neh1, and Neh3 domains, and the location of 
the DLG and ETGE motifs within the Neh2 domain through which Nrf2 binds to Keap1. 
Neh1 contains the bZip DNA binding and heterodimerisation domain through which 
Nrf2 interacts with the small Mafs, and binds to DNA as a heterodimer. The Neh4 and 
Neh5 domains act synergistically to bind the transcriptional co-activator, CBP. The 
Keap1-independent negative regulation of Nrf2 is controlled by the Neh6 domain.(B) In 
Keap1,shown are the positions of the N-terminal region (NTR), the BTB domain, the 
intervening region (IVR), the Kelch (DGR) domain, and the C-terminal region (CTR), and 
the location of C151, C273, and C288.  Keap1 dimerises through the BTB domain that is 
also the domain through which Keap1 binds to Cullin 3 (Cul 3). The Kelch domain 
formsa 6-bladed β-propeller structure through which Keap1 interacts with the Neh2 
domain of Nrf2. 
 
 
mediate the cellular response to electrophiles and oxidants (collectively referred 
to as inducers) by binding to an enhancer element inthe promoter regions of 
cytoprotective genes (Itoh et al. 1997). Thus Nrf2 is activated by changes in the 
redox state of the cell, and functions to restore homeostasis by upregulating 
antioxidant, xenobiotic-metabolising, and other cytoprotective enzymes (see 
below). The critical importance of Nrf2 in the cellular stress response is 
highlighted by the phenotype of the Nrf2 null mice. In the absence of Nrf2, mice 
are viable and fertile but show increased sensitivity to numerous xenobiotics 
including benzo(a)pyrene, butylated hydroxytoluene, acetaminophen, diesel 
exhaust fumes, dimethylbenz(a)anthracene, cigarette smoke, dextran sulfate, 3-
nitropropionic acid and malonate (Chan and Kan 1999; Enomoto et al. 2001; 
Aoki et al. 2001; Ramos-Gomez et al 2002; Xu et al. 2006; Rangasamy et al. 2004; 
Calkins et al. 2005; Khor et al. 2006; 2008).  
The Nrf2 protein contains 605 amino acids which form 6 functional 
domains (Figure 1.1A) named Neh1-6 (Nrf2-ECH homology) (Itoh et al 1999). 
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Neh1 contains the bZip DNA binding and heterodimerisation domain through 
which Nrf2 interacts with its transcriptional partners, the small Mafs, and binds 
to DNA as a heterodimer (Itoh et al. 1995; 1997; Marini et al. 1997; Katsuoka et 
al. 2005). Domain deletion analysis identified the Neh2 domain as the negative 
regulatory domain of Nrf2. A yeast two-hybrid screen using Neh2 as bait 
identified Keap1 as the negative regulator of Nrf2 activity (Itoh et al 1999). The 
Neh3 domain binds to the chromo-ATPase/ helicase DNA binding protein family 
member CHD6, which functions as a transcriptional co-activator to promote 
transcription of ARE-dependent genes (Nioi et al. 1995). The Neh4 and Neh5 
domains act synergistically to bind another transcriptional co-activator, CBP 
(Katoh et al 2001). Finally, the Keap1-independent negative regulation of Nrf2 is 





The upstream regulatory regions of cytoprotective genes to which Nrf2-
small Maf heterodimers bind are called antioxidant response elements or 
electrophile response elements (ARE or EpRE). They were identified by the 
laboratories of Cecil Pickett and Violet Daniel in the promoter of the gene 
encoding glutathione transferase Ya subunit, before the discovery of Nrf2 
(Rushmore and Pickett 1990; Friling et al. 1990). The ARE consensus sequence is 
TGACnnnGC and was named due to its requirement in phenolic antioxidant-
induced gene regulation (Rushmore and Pickett 1990; Rushmore et al. 1991). 
Following the discovery of the ARE, multiple proteins were shown to bind to it 
(Wasserman and Fahl 1997). Thus, in addition to small Mafs, numerous other 
transcription factors have also been implicated in the regulation of ARE-
dependent gene expression and/ or binding to Nrf2, including; the Cap 'n' Collar 
proteins Nrf1, Nrf3, Bach1 and Bach2; ATF1, ATF2, ATF3, ATF4, JunD, c-Jun, c-
Fos and Fra1, which are all members of the AP-1 transcription factor super 
family; the nuclear receptors RARα, PPARγ, ERα and ERRβ; the chromarin 
remodelling factor BRG1 and the transcriptional co-repressor SMRT (Venugopal 
and Jaiswal, 1996; Johnsen et al. 1998; Ikeda et al. 2000; He at al. 2001; Kim et al 
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2001; Muto et al. 2002; Gong et al. 2002; Sankaranarayanan and Jaiswal, 2004; 
Ansell  et al. 2005; Dhakshinamoorthy et a. 2005; Ki et al. 2005; Tsuji 2005; 
Zhang et al. 2006; Iwasaki et al. 2007; Wang et al. 2007; Zhou et al 2007; Brown 





Keap1 (Kelch-like ECH associated protein 1) is a 624 amino acid protein 
which contains three main domains: a BTB dimerisation domain (Broad-
Complex, Tramtrack, and Bric à brac); a cysteine-rich IVR domain (Intervening 
region); and a Kelch domain consisting of 6 Kelch repeats through which Keap1 
binds to Nrf2 (Figure 1.1B). Keap1 is a cysteine-rich protein, containing 25 and 
27 cysteine residues within the mouse and the human homologues, respectively. 
Furthermore, 10 of these cysteines are predicted to be reactive due to the 
presence of adjacent positively-charged amino acids. This positive charge 
reduces the pKa of the neighbouring cysteine thiol group, stabilising the thiolate 
anion, and therefore maintains the cysteines in a reactive state (Snyder et al. 
1981). Together, the facts that Keap1 negatively regulates Nrf2 and contains a 
number of reactive cysteine residues made it the perfect candidate for the 
inducer sensor. This idea was supported by experimental evidence when it was 
shown that Keap1 binds directly to inducers of three different types, i.e., the 
isothiocyanate sulforaphane, the double Michael acceptor bis(2-
hydroxybenzylidene)acetone, and the steroid dexamethasone 21-mesylate (Dex-
mes); four cysteine residues (C257, C273, C288 and C297), all within the IVR 
domain of Keap1, and C613 in the C-terminal region, were modified when 
purified recombinant murine Keap1 was incubated with Dex-mes (Dinkova-
Kostova et al. 2002). It was also found that recombinant Keap1 binds Zn2+ 
stoichiometrically with an association constant of 1011 M-1, and that 
Co2+substitution for Zn2+ yields an optical spectrum consistent with tertrahedral 
metal coordination (Dinkova-Kostova et al. 2005a). 
 Once Keap1 had been identified as the chemical sensor responsible for 
Nrf2 activation, it was then asked which cysteine residue(s) were important for 
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its activity. Mutation analysis of the IVR domain showed that substitution of 
C273 or C288 with either serine or alanine rendered Keap1 unable to repress 
Nrf2 activity under basal conditions (Zhang and Hannink 2003; Levonen et al. 
2004; Wakabayashi et al. 2004). In contrast, mutation of C257 or C297, which 
had also been shown to bind inducers in vitro, had no effect on Nrf2 basal 
activity. The increased activity of Nrf2 in the presence of C273S/A or C288S/A 
mutant Keap1 was caused by reduced ubiquitination of Nrf2, and not by the 
dissociation of Keap1 from Nrf2 or Cullin 3 (Cul3) (Kobayashi et al. 2004; 2006; 
Zhang et al. 2004). Together these data suggest that C273 and C288 are 
important for the repression of Nrf2 by Keap1 under basal conditions, and that 
their modification by inducers may reduce the rate of ubiquitination and 
degradation of Nrf2. In vivo experiments using transgenic mice expressing either 
C273A or C288A Keap1 mutants confirmed that these residues are required for 
repression of Nrf2 under basal conditions (Yamamoto et al. 2008). 
 Interestingly, mutation of C151 in the BTB domain had a different effect 
on Keap1, by turning it into a constitutive repressor of Nrf2 in both basal and 
induced states (Zhang and Hannink, 2003). It was suggested that C151 is 
important for binding of Keap1 to Cul3, and that when inducers bind to Keap1, 
they may cause a dissociation of Keap1 from Cul3, and therefore stabilise Nrf2. In 
the absence of C151, inducers are unable to dissociate Keap1 and Cul3, making 
the C151 mutant Keap1 a constitutive repressor of Nrf2 (Zhang et al. 2004).  In 
vivo data confirmed that the C151S mutant is a functional repressor of Nrf2; 
however experiments with embryonic fibroblasts isolated form these mice did 
not support the idea that the C151S mutant was a constitutive repressor of Nrf2, 
as Nrf2 was both stabilised and able to induce reporter gene expression in 
response to tert-butylhydroquinone (tBHQ) (Yamamoto et al. 2008).      
 Together, the analysis of Keap1 cysteines suggested that C151, C273 and 
C288 were all important for the function of Keap1. Subsequent work showed 
that although C151 is indispensable for Nrf2 stabilisation in response to inducers 
like tBHQ, is was not required for arsenite-mediated Nrf2 activation, suggesting 
that different classes of inducers may react with Keap1 in different ways (Wang 
et al. 2008a). Following on from this, a study in zebrafish found that inducers can 
be divided into two categories: those which react with C151 (e.g., sulforaphane, 
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tBHQ), and those which are independent of C151 and dependent on C273 (e.g., 
15-deoxy-∆12,14-prostaglandin J2). This suggested that Keap1 contains multiple 
sensors (Kobayashi et al. 2009). Using murine Keap1 that was ectopically-
expressed in mammalian cells, McMahon et al. (2010) found that C151 and C288 
each comprise discrete sensors, whilst a third sensor is formed by H225, C226 
and C613. Each of the three sensors was shown to be specific for certain types of 
inducers, with C151 required for nitric oxide, sulforaphane and tBHQ reactivity, 
C288 responding to alkenals, and H225, C226 and C613 comprising a sensor for 
zinc (McMahon et al. 2010). The idea that Keap1 may sense different inducers in 
different ways is not without precedent. In yeast, the transcriptional master 
regulator of oxidative stress Yap1 responds differently to the oxidants H2O2 and 
diamide, and like Keap1, different inducers of Yap1 depend on different cysteine 
residues to activate the signalling pathway (Delaunay et al. 2000; Kuge et al. 
1997; 2001). 
 Whilst the crystal structure of full-length Keap1 is not available, several 
groups have analysed the Nrf2-binding Kelch domain of Keap1 using X-ray 
crystallography (Li et al. 2004; Padmanabhan et al. 2005; 2006; 2008; Lo et al. 
2006). Crystallisation of the Kelch domain (residues 321-609) of human Keap1 
found that it forms a 6-bladed β-propeller. Each of the blades is comprised of 
four anti-parallel β-strands which together form a twisted β-sheet. Blade I 
consists of strands from both the N- and C-terminus of the domain and this 
arrangement stabilises the closure of the ring-shaped β-propeller. Although each 
blade consists of variable number of amino acids (from 44 to 51), they all contain 
7 conserved residues which are required for forming interactions between the 
blades and for further stabilisation of the β-propeller (Li et al. 2004).  
 Each β-strand is connected to the next by loops of varying lengths which 
extend both above and below the β-propeller. Co-crystallisation of the Kelch 
domain with a peptide of Nrf2 showed that the interaction between Keap1 and 
Nrf2 takes place in a shallow pocket formed by these loops, specifically the loops 
which connect β-strands A-D and B-C (Padmanabhan et al. 2006; Lo et al. 2006). 
Nrf2 interacts with Keap1 through its ETGE motif, which in humans consists of 
residues 77-82 (Kobayashi et al. 2002). The ETGE motif forms β-hairpin 
conformation and only the side-chains of residues E79 and E82 in Nrf2 interact 
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with the Kelch domain. In Keap1, all 6 blades of the β-propeller form bonds with 
Nrf2, either with E79/E82 side chains, or with the Nrf2 peptide backbone. In 
total, 13 intermolecular interactions are formed between Keap1 and Nrf2 
(Padmanabhan et al. 2006; Lo et al. 2006). 
 Single particle electron microscopy has been used to generate a 3-
dimensional reconstruction model of full length Keap1 dimer (Ogura et al. 2010). 
This model revealed that Keap1 forms a spherical body joined by a thin linker to 
the dimersation interface. The spherical structure consists of the entire Kelch 
and IVR domains and includes part of the BTB domain. The remainder of the BTB 
domain forms the linker and dimerisation surface. Interestingly, this 
reconstruction model suggests that the Kelch and BTB domains do not form 
distinct structures separated by the IVR or 'linker' domain as previously 
assumed. In addition, the structural proximity of the IVR and the Kelch domains 
provides a possible explanation of how covalent modifications of the IVR-
residing C273 and C288 by inducers, or their substitution with other amino 
acids, may affect the Nrf2-binding affinity of the Kelch domain. In contrast, the 
assigned position of C151 is far away from the Kelch domain, suggesting that its 
modification by inducers is more likely to affect the interaction between Keap1 
and Cul3, rather than Nrf2.  
 In addition to Nrf2, Keap1 has also been shown to bind to other proteins, 
including IKKβ, p62, and PGAM5 (Lo and Hannink, 2006a; Lo et al. 2008; Lee et 
al. 2009; Komatsu et al. 2010; Lau et al. 2010; Jain et al. 2010; Kim et al. 2010). 
The binding of Keap1 to p62 is significant as it suggests that Nrf2 can be 
activated by a deficiency in autophagy, whilst the interaction with IKKβ shows 
that Keap1 could regulate other signalling pathways (in this case NF-κB) 









Models of regulation of the Keap1-Nrf2 pathway 
 
Sequester and release 
 
The first model of the Keap1-Nrf2 interaction was heavily influenced by its 
similarities with other signalling pathways. Sub-cellular localisation studies 
using GFP-fusion proteins and immunocytochemistry showed that Keap1 was a 
cytoplasmic protein, whereas Nrf2 could be found in both the nucleus and 
cytoplasm (Itoh et al. 1999). In the absence of co-expressed Keap1, Nrf2 had a 
mostly nuclear localisation; however, when Keap1 was co-expressed, it appeared 
to sequester Nrf2 from the nucleus into the cytoplasm. As Keap1 was named 
after the Drosophila actin-binding protein Kelch (Xue et al. 1993), it was logically 
asked whether Keap1 was also able to bind to actin, and whether this was 
important for the repression of Nrf2 activity. This was found to be the case, as 
was the fact that similarly to Kelch, Keap1 dimerisation through the BTB domain 
was necessary for its function as a repressor of Nrf2 (Robinson et al. 1997; 
Zipper and Mulcahy 2002; Kang et al. 2004). The sub-cellular localisation studies 
also showed that in response to inducers, Nrf2 was able to migrate to the 
nucleus, even in the presence of co-expressed Keap1 (Itoh et al. 1999). Together, 
these data led to a model in which under basal conditions, Keap1 formed a dimer 
and sequestered Nrf2 in the cytoplasm by binding to actin (Figure 1.2). Inducers 
reacted with cysteine(s) in Keap1, leading to the release of Nrf2, and potentially 
to a loss of Keap1 dimerisation, allowing Nrf2 to translocate to the nucleus and 
turn on the expression of cytoprotective genes. This model found further support 
when it was shown that in vitro, Keap1-Neh2 (molar ratio of 2:1) complexes 
could be dissociated by the inducers sulforaphane and bis(2-
hydroxybenzylidene)acetone in a concentration-dependent manner (Dinkova-




Figure 1.2. Sequester and release model of regulation of the Keap1-Nrf2 pathway. 
Dimeric Keap1 sequesters Nrf2 in the cytoplasm by binding to the actin cytoskeleton. 
Inducers react with specific cysteine residues in Keap1, leading to release of Nrf2, 
allowing the transcription factor to translocate to the nucleus and turn on the 
expression of cytoprotective genes. 
 
 
 This logical model was supported not only by the data available, but also 
by the similarity in function of Keap1 and Nrf2 with the Drosophila proteins 
Costal2 (Cos2) and Cubitus Interruptus (Ci) which function as the cytoplsmic 
repressor and transcription factor, respectively, in the hedgehog pathway 
(Sisson et al. 1997; Robbins et al. 1997). A similar sequester and release model 
had been proposed for Ci activation, which in turn was based on the precedent 
set by signalling in the NF-κB pathway (Baeuerle and Baltimore 1988; Siebenlist 
et al. 1994). In Streptomyces coelicolor, transcription factor σR controls induction 
of the thioredoxin reductase/thioredoxin operon in response to oxidants (Paget 
et al. 1998; Kang et al. 1999). Under basal conditions, σR is bound to a repressor 
protein, RsrA. Oxidants react with specific cysteine residues of RsrA leading to a 
disulfide bond formation within the repressor, loss of its ability to bind σR, and 
ultimately enhanced transcription of σR-dependent genes. Thus it appeared that 
the Keap1-Nrf2 pathway followed a well-used pattern in biology, that a 
cytoplamic repressor holds onto a transcription factor until it is “told” to release 
it by a pathway-specific signal.  
 Subsequent work using human recombinant proteins showed that in 
contrast to previous reports with the murine proteins, inducers were unable to 
dissociate the Keap1-Nrf2 complex (Eggler et al. 2005) and that upon the 
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addition of inducers more, not less Nrf2 was bound to Keap1. Together these 
data suggested that the sequester and release model may need to be modified 





The idea that Nrf2 may be controlled at the level of protein stability was 
first suggested in 2000, when it was found that inhibition of the proteasome 
produced a rapid and robust increase in mRNA of the Nrf2 target gene GCLC 
(Sekhar et al. 2000). GCLC is the catalytic subunit of γ-glutamylcysteine ligase 
(GCL), the enzyme which catalyses the rate limiting step in glutathione synthesis. 
This increase in GCLC mRNA was functionally relevant, as it resulted in a 2-fold 
increase in the cellular glutathione level. Gel shift mobility assays and a 
transcriptional reporter demonstrated that the underlying mechanism involved 
Nrf2 and the ARE sequence within the promoter of GCLC. 
 Subsequent work showed that in response to cadmium, the amount of 
Nrf2 within the cell increased in a time-dependent manner, beginning after 30 
min, and reaching 20 times the basal level after 4 hours (Stewart et al. 2003). 
The inducer-mediated accumulation of Nrf2 was coupled with an increase in 
Nrf2 protein half-life which extended from 13 to almost 100 min. Interestingly, 
the effect of cadmium on Nrf2 accumulation could be mimicked using 
proteasome inhibitors, and furthermore, overexpression of Nrf2 showed that it 
was a target of ubiquitination (Stewart et al. 2003). Together these data strongly 
suggested that Nrf2 was regulated at the level of protein stability. Similar results 
were obtained using the inducers tBHQ, sulforaphane and diethyl maleate 
(DEM), and each time the inducer was shown to stabilize Nrf2 (Nguyen et al. 
2003; McMahon et al 2003; Itoh et al. 2003), whereas the level of Nrf2 mRNA 
was unaffected by the addition of inducers (Stewart et al. 2003; Nguyen et al. 
2003; McMahon et al 2003; Itoh et al. 2003). Notably, the absence of Keap1 was 
sufficient for maximal Nrf2 accumulation, and neither DEM nor sulforaphane 
were able to significantly increase the Nrf2 levels any further (McMahon et al 
2003; Itoh et al. 2003).  
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 Although by then it was well established that Nrf2 activity was regulated 
by its stability, and that inactivation of Keap1 by inducers was required for the 
stabilisation, it was unknown exactly how Keap1 targeted Nrf2 for degradation. 
It was known that other BTB containing proteins were able to act as substrate 
adaptors for Cullin 3-based E3 ubiquitin ligases (Furukawa et al. 2003; Geyer et 
al. 2003; Pintard et al. 2003; Xu et al. 2003). As Keap1 contains a BTB domain, 
Cullin 3 (Cul3) was the perfect candidate for a Keap1-interacting protein which 
could mediate the degradation of Nrf2. Four groups independently reported that 
Keap1 was able to bind to Cul3 and ubiquitinate Nrf2 both in vivo and in vitro 
(Kobayashi et al. 2004; Cullinan et al. 2004; Zhang et al. 2004; Furukawa et al. 
2005). Overexpression of Cul3 or Keap1 decreased the level of Nrf2, and 
conversely, the use of a dominant negative Cul3 or siRNA against Cul3 lead to the 
accumulation of Nrf2 and increased transcription from an ARE transcriptional 
reporter (Cullinan et al. 2004).  Indeed, further work looking at the role of 
CAND1 suggests that the Keap1-Cul3-Rbx1 complex uses the same mechanism of 
ubiquitination as other Cullin-dependent E3 ubiquitin ligases (Lo and Hannink, 
2006b).  
 These results complemented work which firmly established that Keap1 is 
the long-sought sensor for inducers (Dinkova-Kostova et al. 2002; Wakabayashi 
et al. 2004; Levonen et al. 2004), and together the available experimental 
evidence suggested that inducers may directly alter the activity of Keap1. 
Together these data were used to form the model of Nrf2 control which has 
received the most experimental support. Under basal conditions, Nrf2 is bound 
to Keap1 and targeted for ubiquitination and proteasomal degradation by the 
Cullin3-Rbx1 E3 ubiquitin ligase (Figures 1.3 and 1.4). Inducers chemically 
react with specific cysteine residues in Keap1, leading to stabilisation of Nrf2 and 
its translocation to the nucleus where it activates transcription of ARE-
dependent genes. Stress responses mediated by other transcription factors such 
as HIF-1α and NF-κB are also regulated by the ubiquitin-proteasome system 
(UPS), suggesting that the UPS represents a conserved pathway of cellular 
adaptation to changing environmental conditions (Maxwell et al. 1999; Pause et 
al. 1997; Yaron et al. 1998; Kamura et al. 1999).  
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 If Nrf2 is regulated by its stabilisation in response to inducers, how does 
this occur mechanistically? A number of models have been proposed to solve this 
problem: the dissociation of Keap1 and Cul3; the hinge and latch model; 
nucleocytoplasmic shuttling of Keap1; the ubiquitination of Keap1; and, Nrf2 
directly sensing inducers. 
 
 
Dissociation of Keap1 and Cul3 
 
One of the first experiments to identify the role of Cul3 in the Keap1-Nrf2 
pathway found that Keap1 and Cul3 were dissociated by the inducers tBHQ and 
sulforaphane (Zhang et al. 2004). This work was extended using 
eicosapentaenoic acid (EPA) and N-iodoacetyl-N-biotinylhexylenediamine (IAB), 
and in all cases dissociation of Cul3 from Keap1 was observed (Niture and 
Jaiswal 2009; Gao et al. 2007; Rachakonda et al. 2008). In vitro assays using 
purified recombinant proteins showed that IAB could both prevent Keap1 from 
binding to Cul3, and dissociate pre-formed Keap1-Cul3 complexes (Rachakonda 
et al. 2008). Together these data suggest that inducers function to stabilise Nrf2 
by dissociating the Keap1-Cul3 complex, leading to the inhibition of Nrf2 
ubiquitination and its stabilisation (Figure 1.3). Importantly, C151 in the BTB 
domain of Keap1 was found to be necessary for this effect (Zhang et al. 2004; 
Rachakonda et al. 2008). 
 Thus multiple groups have shown that inducers are able to affect the 
binding between Keap1 and Cul3, and have demonstrated the importance of 
C151 of Keap1. Although the BTB domain of Keap1 has not been crystallised, 
models of the Keap1-Cul3 interaction have been proposed based on the known 
structure of Cul1-Rbx1-Skp1-F boxSkp2 complex (Zheng et al. 2002). One of the 
models shows that C151 is not located near either the BTB dimerisation 
interface or the Cul3 binding surface of Keap1, but instead is buried within the 
domain by four positively charged amino acids, i.e., K131, R135, and K150, and 
H154 (Fourquet et al. 2010). This positioning suggests that: firstly, the 
surrounding positively charged amino acids may contribute to the reactivity of 
C151 by stabilising the thiol anion; and secondly, because of the buried nature of  
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Figure 1.3. Dissociation of Keap1 and Cullin 3 model of regulation of the Keap1-
Nrf2 pathway. Dimeric Keap1 binds Nrf2 and serves as a substrate adaptor for Cullin 3 
(Cul3)-based ubiquitin ligase to target Nrf2 for ubiquitination and proteasomal 
degradation. Inducers react with specific cysteine residues in Keap1, leading to 
dissociation of the Keap1-Cul3 complex, inhibition of Nrf2 ubiquitination, and 
stabilisation of the transcription factor. 
 
 
the residue, binding of inducers may alter the structure of the BTB domain. 
Indeed, mutant Keap1 in which K131, R135, and K150, were substituted with 
methionine residues had substantially reduced ability to sense sulforaphane or 
tBHQ (McMahon et al., 2010). Another model of the BTB domain proposes that 
binding of inducers to C151 leads to a steric clash with residues in the adjacent 
α-helix, which may in turn alter the position ofthe Cul3 binding site and thus lead 
to Keap1-Cul3 dissociation (Eggler et al. 2009). This model is supported by in 
vitro data which showed the binding of IAB caused a change in the secondary 
structure of Keap1 (Rachakonda et al. 2008). Thus it appears that at least in 
response to certain inducers, stabilisation of Nrf2 may be brought about by a 
change in interaction between Keap1 and Cul3. 
 
 
Hinge and latch model 
 
The interacting surface of Nrf2 and Keap1 was identified as the ETGE 
motif in the Neh2 domain of Nrf2 and the Kelch domain of Keap1 (Kobayashi et 
al. 2002). X-ray crystallography confirmed that the ETGE motif was able to bind 
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Figure 1.4. Hinge and latch model of regulation of the Keap1-Nrf2 pathway.  Under 
basal conditions, monomeric Nrf2 binds to Keap1 homodimer. Each Keap1 subunit 
binds to Nrf2 through the ETGE and DLG motifs, respectively, allowing ubiquitination of 
the lysine residues in the a-helix of the Neh2 domain. Inducers react with cysteine 
residues within Keap1, leading to a conformational change in Keap1 and release of the 
weaker interaction with the DLG motif. As a result, the orientation of Nrf2 is not fixed 
and it is no longer efficiently targeted for ubiquitination and degradation. As Nrf2 is still 
bound to Keap1, any newly translated Nrf2 will not be able to bind Keap1 and will 
accumulate, translocate to the nucleus, dimerise with small Mafs, and activate ARE-
dependent transcription. The mode of binding of Nrf2 to Keap1 gives the model its 
name, with the ETGE motif being the hinge, and the DLG, the latch. 
 
 
to the beta propeller formed by the Kelch repeats (Padmanabhan et al. 2006; Lo 
et al. 2006). In the absence of this motif, Nrf2 is still able to bind Keap1 
(McMahon et al. 2006); however it becomes insensitive to Keap1-mediated 
degradation allowing it to accumulate under basal conditions and to become 
insensitive to further stabilisation by inducers (McMahon et al. 2004). Together 
these data suggest a number of points. Firstly, that binding of Nrf2 to Keap1 is 
insufficient to target Nrf2 for degradation. Secondly, that for efficient 
degradation Nrf2 must bind to Keap1 through an additional motif, and finally, 
that because inducers were unable to additionally stabilise the ETGE mutant 
Nrf2, they may function by altering the binding of Nrf2 to Keap1 without leading 
to the release of Nrf2.  
 Subsequent work identified the second binding site of Nrf2 to Keap1 to be 
within the Neh2 domain (McMahon et al. 2004). This motif, consisting of 
residues 17-32, was originally named the DIDLID element but was renamed the 
DLG motif after further work found two distinct functions for residues 17-32 of 
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Nrf2 (Katoh et al. 2005; McMahon et al. 2006). In the absence of the DLG motif, 
the Nrf2 phenotype is the same as in the absence of the ETGE motif: it is able to 
bind to Keap1, however this binding to Keap1 does not lead to the ubiquitination 
and degradation of Nrf2. This allows Nrf2 to accumulate under basal conditions 
and it is not further stabilised by the addition of inducers (Katoh et al. 2005; 
McMahon et al. 2004; 2006). Crucially, in the absence of both the ETGE and DLG 
motifs, Nrf2 is no longer able to bind to Keap1 (McMahon et al. 2006).   
 Further analysis showed that the ETGE and DLG motifs bind to Keap1 
with different affinities, with DLG binding to Keap1 with an affinity 
approximately 2 orders of magnitude lower than ETGE (Tong et al. 2006). This 
difference in affinity is caused by a difference in the number of electrostatic 
interactions between each motif and Keap1, with the ETGE motif forming 13 
compared with 8 for the DLG (Tong et al. 2007; Padmanabhan et al. 2008). 
Structural analysis of the Neh2 domain showed that in the region between the 
DLG and ETGE motifs, Nrf2 forms an alpha helix containing 6 lysine residues on 
one side of the helix (Tong et al. 2006), and deletion of these lysines greatly 
increases the half-life of the resultant mutant Nrf2 (Zhang et al 2004). Together, 
these data were reconciled into a model of Nrf2 activation called “two-site 
substrate recognition” model, “fixed-ends” model, or “hinge and latch” model  
(Figure 1.4) (McMahon et al. 2006; Tong et al. 2006; 2007; Padmanabhan et al. 
2008).  
 Under basal conditions, monomeric Nrf2 binds to a Keap1 dimer. One of 
the Keap1 monomers binds to Nrf2 through the ETGE motif, whilst the other 
monomer binds the DLG. This double binding of Nrf2 stabilises its orientation, 
allowing efficient ubiquitination of the lysine residues in the -helix of the Neh2 
domain. When inducers enter the cell, they bind to the reactive cysteine residues 
within Keap1, leading to a conformational change in Keap1 and the release of the 
weaker interaction with the DLG motif. Under these conditions the orientation of 
Nrf2 is not fixed and it is no longer efficiently targeted for ubiquitination by 
Keap1. The reduced rate of Nrf2 ubiquitination leads to a reduced rate of Nrf2 
degradation. As Nrf2 is still bound to Keap1, any newly translated Nrf2 will not 
be able to bind Keap1, and can therefore bypass the “Keap1 gate”, allowing it to 
accumulate in the cell, translocate to the nucleus, dimerise with small Mafs, and 
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activate the transcription of ARE-dependent genes. The specific mode of binding 
of Nrf2 to Keap1 gives the model its name, with the ETGE motif forming the 
hinge, and the DLG the latch. When inducers bind to Keap1, the hinge is 
maintained but the latch is released, leading to the accumulation of Nrf2. 
 This model is well supported by in vitro data, but its physiological 
relevance has yet to be determined. In addition, it is not clear from this model 
whether inducers cause a reduced rate of Keap1-mediated ubiquitination of 
Nrf2, or completely abolish it. As expected, when the half-life of Nrf2 was 
measured in the presence of inducers, it was unaffected by the presence or 
absence of Keap1; however, even under those conditions Nrf2 is a relatively 
short-lived protein, suggesting the existence of other factor(s) that regulate Nrf2 
degradation (McMahon et al. 2004). Whilst this model postulates that Keap1 
binds to Nrf2 at a 2:1 ratio, there is also evidence to suggest that Keap1 and Nrf2 
bind at a 2:2 ratio (Tong et al. 2006; Lo et al. 2006). In addition, the hinge and 
latch model predicts that Nrf2 is not released by Keap1 in response to inducers, 
however whilst tBHQ does not dissociate Nrf2 from Keap1, the heavy metals 
cadmium and chromium, and arsenic have all been shown to dissociate the 
complex, suggesting that the mechanism of control of Nrf2 by Keap1 may be 
inducer-specific (He et al. 2006; 2007; 2008). 
 
 
Keap1 nucleocytoplasmic shuttling 
 
An alternate model of Nrf2 control by Keap1 involves the 
nucleocytoplasmic shuttling of Keap1 (Figure 1.5). By studying the Nrf2-
knockout mouse it became clear that Nrf2 was required for both basal and 
inducible activity of ARE-dependent genes (McMahon et al 2001; Chanas et al. 
2002), and therefore that under basal conditions some of the cellular pool of 
Nrf2 must be nuclear. Sequence analysis of Keap1 identified a putative nuclear 
export signal in the IVR domain (Velichkova et al. 2005; Nguyen et al. 2005; 
Karapetian et al. 2005), and chemical inhibition of the nuclear exporter Crm1 led 
to the nuclear accumulation of Keap1 (Velichkova et al. 2005; Nguyen et al. 2005; 
Karapetian et al. 2005; Sun et al. 2007; Niture et al. 2009). Together these data  
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Figure 1.5. Keap1 nucleocytoplasmic shuttling model of regulation of the Keap1-
Nrf2 pathway.Keap1 enters the nucleus and removes Nrf2 under both basal and 
induced conditions. Inducers inhibit the nuclear entry of Keap1 allowing transcription of 
Nrf2-dependent genes.  
 
 
suggested that Keap1 may be able to enter the nucleus and remove Nrf2 under 
either basal or stressed conditions, and that the addition of inducers may affect 
the efficiency of this process. The problem with this model is that although all of 
the studies agree that Keap1 accumulates in the nucleus after blocking the 
nuclear transporter Crm1, they disagree about almost everything else. For 
example, the reports conflict as to whether Keap1 enters the nucleus in response 
to inducers (Velichkova et al. 2005; Nguyen et al. 2005), whether Nrf2 is 
predominantly localised in the cytoplasm or the nucleus under basal conditions 
(Nguyen et al. 2005; Sun et al. 2007), whether Cul3 can translocate to the nucleus 
(Sun et al. 2007; Niture et al. 2009), whether nuclear Keap1 activates or 
represses ARE-dependent genes (Velichkova et al. 2005; Nguyen et al. 2005), or 
which domain of Keap1 is required for nuclear localisation (Velichkova et al. 
2005; Niture et al. 2009).  
 It had also been shown that Keap1 can bind to the nuclear protein 
prothymosin-α  (Karapetian et al. 2005; Padmanabhan et al. 2008; Niture et al. 
2009) in a similar way to the binding of the ETGE motif of Nrf2 (Padmanabhan et 
al. 2008). Two groups then proposed alternate models to explain how nuclear 
Keap1, Nrf2 and prothymosin-α interact, with either prothymosin-α dissociating 
the Keap-Nrf2 complex in response to inducers, or Nrf2 dissociating the Keap1-
prothymosin-α interaction (Karapetian et al. 2005, Niture et al. 2009). It was 
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proposed that the Keap1-prothymosin-α complex forms in the cytoplasm in 
response to inducers, but this first requires the release of Nrf2 from Keap1, 
something which has been refuted elsewhere (Zhang et al. 2004; Eggler et al. 
2005; Niture et al. 2009). 
 Finally, the use of a highly specific antibody against Keap1 revealed that 
endogenous Keap1 is predominantly cytoplasmic, and does not translocate to the 
nucleus in response to either inducers or Crm1 inhibition (Watai et al. 2007). 
This study did find that a small percentage of Keap1 (5%) was present in the 
nucleus under both basal and induced conditions. Together all these data agree 
that at least a fraction of Keap1 can enter the nucleus, however they do not 
present a clear coherent model for the physiological function of nuclear Keap1. 
 
 
Ubiquitination of Keap1 
 
A further model has been proposed whereby in response to inducers, Keap1 and 
not Nrf2 becomes the target of Cul3-mediated ubiquitination  (Figure 1.6) 
(Zhang et al. 2005; Hong et al. 2005).  It was shown that both ectopic and 
endogenous Keap1 could be ubiquitinated in response to tBHQ, but not 
sulforaphane (Zhang et al. 2005). By use of mass spectrometry it was found that 
the ubiquitination of Keap1 took place on lysine-298 in response to the inducer 
IAB, in agreement with work showing that the IVR domain of Keap1 was 
required its ubiquitination (Zhang et al. 2005; Hong et al. 2005).  
Together these data raise a number of different points. They suggest not 
only an alternate mechanism of Nrf2 control, but also show that all inducers may 
not function in the same way, as tBHQ, IAB but not sulforaphane were able to 
target Keap1 for ubiquitination. Interestingly, Hong et al. also found that the 
electrophile 1-biotinamido-4-(4'-[maleimidoethylcyclohexane]-
carboxamido)butane (BMCC)was able to bind to Keap1 but this did not lead to 
the stabilisation of Nrf2, suggesting that simply binding of an electrophile to the 




Figure 1.6. Ubiquitination of Keap1 model of regulation of the Keap1-Nrf2 
pathway.Dimeric Keap1 binds and targets Nrf2 for ubiquitination and proteasomal 
degradation. Inducers cause a switch in ubiquitination from Nrf2 to Keap1 which 
becomes the target of Cul3-mediated ubiquitination and degradation, allowing the 




 Such a model of auto-ubiquitination of a substrate adaptor protein is not 
without precedent. In yeast, multiple E3 ubiquitin ligase substrate adaptors are 
ubiquitinated by the same machinery which normally targets their substrates for 
degradation; in mammals, the F-box E3 ligases Skp2 and β-TrCP are also 
ubiquitinated (Zhou and Howley 1998; Galan and Peter 1999; Li et al. 2004; 
Bashir et al. 2004; Wei et al. 2004). 
 
 
Nrf2 senses inducers directly 
 
Nrf2 contains seven cysteine residues, four of which are conserved in 
human, mouse, rat and chicken, suggesting that Nrf2 itself may be able to react 
with inducers. This possibility was tested experimentally using arsenic-based 
inducers with both purified recombinant and cell lysate derived Nrf2 (He et al. 
2009). The idea that Nrf2 may directly sense and react with inducers led to the 
formation of a Keap1-independent model of Nrf2 control. Nrf2 contains a 
number of putative nuclear import (NLS) and export (NES) signals (Li et al. 
2005; 2008; Jain et al. 2005). One such NES located within the Neh5 
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transactivation domain was shown to be redox-sensitive, and led the authors to 
propose a model whereby Nrf2 activity is regulated by its cellular localisation (Li 
et al. 2006). Under basal conditions, the combined NES signals overcome the NLS 
resulting in a mostly cytoplasmic distribution of Nrf2 (Figure 1.7). Inducers 
cause an inactivation of this export signal, shifting the balance from nuclear 
export to nuclear entry of Nrf2, allowing it to accumulate in the nucleus and turn 
on cytoprotective genes (Li et al. 2006).  Mutation of C183 to A within one of the 
NES motifs attenuated nuclear accumulation and ARE-dependent reporter gene 
expression following exposure to inducers.  
 This model accounts for both the low basal Nrf2-dependent gene 
expression and the increased expression caused by inducers, but it also conflicts 
with some previously published data. Firstly, in cells derived from Keap1-
knockout mice, the levels of Nrf2 target genes such as gclc, nqo1 and prdx1 are all 
constitutively upregulated, and cannot be further increased by inducers, 
suggesting that Keap1 and not Nrf2 is responsible for inducer sensitivity 
(Wakabayashi et al. 2003). In addition, the redox sensitivity of the Nrf2 NES 
requires much higher concentrations of inducers than those that inactivate 
Keap1, which questions the physiological relevance of these results (Nguyen et 
al. 2003; McMahon et al. 2003). However, the idea that the sub-cellular 
localisation of a redox-sensitive transcription factor is controlled by cellular 
stress is not without precedent. In yeast, transcription factor Yap1 contains a 
redox-sensitive NES similar to that described for Nrf2 (Yan et al. 1998); in 
mammals, Bach2 contains a cytoplasmic localisation signal which is overridden 





Figure 1.7. Nrf2 senses inducers directly.Under basal conditions, the nuclear export 
signal (NES) dominates over the nuclear localization signal (NLS), resulting in a 
cytoplasmic distribution of Nrf2. Inducers react with cysteine residues within Nrf2 
causing inactivation of the nuclear export signal, which shifts the balance from nuclear 




Transcriptional and translational control of Nrf2 
 
The majority of the data used to formulate the models already described 
come from experiments using overexpressed Nrf2 and Keap1 in cultured cells. 
Analysis of the endogenous action of inducers in mice showed an additional 
mechanism of ARE control, the increased transcription of Nrf2. When given to 
mice, the inducers 3H-1,2-dithiole-3-thione (D3T), β-naphthoﬂavone (β-NF), 
ethoxyquin(EQ) and oltipraz all increased the amount of Nrf2 mRNA relative to 
basal levels (Kwak et al. 2001; Ramos-Gomez et al. 2001). These results are in 
stark contrast to most cell culture data which show no increased transcription of 
Nrf2 in response to inducers (Nguyen et al. 2003; McMahon et al. 2003; Stewart 
et al. 2003; Itoh et al. 2003). This conflict between in vivo and cell culture-
derived data suggests that Nrf2 control may be complex and regulated at 
different levels simultaneously. If Nrf2 is regulated at the level of transcription, 
how is this transcription induced? A putative ARE was found in the promoter of 
Nrf2, suggesting Nrf2 may regulate its own transcription in a positive feedback 
loop (Kwak et al. 2002). This idea is supported by microarray data from mouse 
lung and liver (Li et al. 2004; Cho et al 2005). 
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 Beyond the transcriptional control of Nrf2, work using rat 
cardiomyocytes suggested that Nrf2 may also be regulated at the level of 
translation (Purdom-Dickinson et al. 2007). This work was extended to shown 
that Nrf2 mRNA contains a redox-sensitive internal ribosomal entry site (IRES) 
in the 5'-UTR (Li et al. 2010). Reporter assays showed that in response to 
sulforaphane or H2O2, translation was increased from the IRES in the Nrf2 
transcript. Sequence analysis of the IRES show it contains a putative 18S rRNA 
binding site which is conserved in the human, mouse and rat mRNA (Li et al. 
2010).  
 The idea of a redox-sensitive IRES is not without precedent (MacCallum et 
al. 2006); indeed the master regulator of the oxidative stress response in yeast 
Yap1 has been shown to contain a functional IRES within the 5'-UTR of its mRNA 
(Zhou et al. 2001). Although these data suggest that Nrf2 activity is also 
regulated at the level of transcription, it is unlikely that this type of regulation is 
responsible for the rapid increase in Nrf2 protein level after 30 min treatment 
with inducers (Stewart et al. 2003; Nguyen et al. 2003), suggesting that it may 
function in concert with increased Nrf2 stability to provide a robust long-term 
response to inducers.  
 
 
Keap1-independent control of Nrf2 
 
Under basal conditions Nrf2 has a short half life (7-15 min), however, all 
studies which showed an increase in Nrf2 stability in response to inducers found 
that even in the presence of these chemicals, Nrf2 still has a half life between 30 
and 100 minutes, suggesting it is still rapidly turned over (Stewart et al. 2003; 
Nguyen et al. 2003; McMahon et al. 2004). Analysis of mutant Nrf2 proteins 
suggested that the Neh6 domain may contain a redox-insensitive degron. Under 
basal conditions, the deletion of this degron had no effect on Nrf2 stability, and it 
was degraded in a Keap1-dependent manner. However, after addition of 
sulforaphane, the half-life of the Neh6-mutant Nrf2 increased by more than 2-
fold in comparison with the wild-type counterpart, suggesting that Neh6 may be 
important for regulating Nrf2 in the presence of inducers, or in the absence of 
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functional Keap1 (McMahon et al. 2004). Furthermore, recent work suggests that 
the Neh6 domain is regulated through a β-TRcP-GSK3-dependent pathway (Rada 
et al. 2011, Rada et al. 2012, Chowdhry et al. 2012). Similarly, work carried out in 
Keap1-knockout cells suggested that the DIDLID element in the Neh2 domain 
may be required for Nrf2 regulation in redox-stressed cells (McMahon et al. 
2006). How the Neh6 degron or the DIDLID element control Nrf2 stability in the 





The fact that Keap1 is the major regulator of the protein stability of Nrf2 
does not preclude any other signalling pathway involvement in Nrf2 regulation. 
Indeed, Nrf2 is activated by chemicals which have a number of different effects in 
the cell, in addition to modifying Keap1. For example, hydrogen peroxide 
activates many signalling pathways, including the kinase ATM (Guo et al. 2010), 
sulforaphane has been shown to inhibit HDAC6 activity (Myzak et al. 2004; 2006; 
Gibbs et al. 2009). Recently, proteomics analysis using a sulfoxythiocarbamate 
analogue of sulforaphane found that it bound to over 100 proteins (Ahn et al. 
2010). Thus it is clear that compounds which modify Keap1 could also affect the 
cellular phenotype in many other ways, and some of these effects may converge 
to affect Nrf2 activity in a Keap1-independent manner.   
 Many signalling pathways are controlled post-translationally by the 
activity of protein kinases (Karin and Hunter 1995). Thus it has been shown that 
the hypoxia stress response is activated by phosphorylation from the PI3K and 
MAPK pathways, demonstrating that stress responses can be activated by 
diverse mechanisms (Semenza, 2003). In light of this idea, it is not surprising 
that a number of protein kinases have been implicated in the regulation of Nrf2 
activity.    
 One such kinase proposed to play a role in Nrf2 regulation is protein 
kinase C. Activation of PKC increased ARE-dependent gene expression, whereas 
inhibition of PKC reduced tBHQ-mediated Nrf2 accumulation (Huang et al. 
2000). The target of PKC phosphorylation was later shown to be S40 of Nrf2, and 
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whilst mutation of this residue reduced ARE-dependent gene expression, the 
reduction was only by 50%, suggesting that PKC acts in concert with Keap1 in 
response to inducers (Huang et al. 2002; Bloom and Jaiswal 2003). 
Mechanistically, it has been suggested that phosphorylation of S40 by the PKCδ 
isoform promotes the release of Nrf2 from Keap1, leading to increased ARE-
dependent gene expression (Huang et al. 2002; Niture et al. 2009). A role for 
phosphorylation in the control of Nrf2 activation is not surprising, and is in 
keeping with many other signalling pathways (Karin 1995; DiDonato et al. 1997). 
Indeed, it has been shown that the activity of PKCδ is increased by oxidative 
stress, and that this increase is mediated by the Src family kinases (Konishi et al. 
1997; 2001; Rybin et al. 2004) and ATM (Li et al. 2004; Guo et al. 2010). 
Furthermore, PKCδ-knockout cells show a reduced accumulation of Nrf2 in 
response to inducers, providing support that this kinase may be required for full 
activation of Nrf2 (Li et al. 2004). 
 Another signalling cascade which is activated by oxidative stress and has 
been implicated in Nrf2 control is the mitogen activated protein kinase (MAPK) 
pathway. The Nrf2 inducers tBHQ, sulforaphane and cadmium have also been 
shown to modulate MAPK activity (Yu et al. 1999; 2000; Alam et al. 2000). In 
addition, inhibition of ERK, MEK or p38 leads to a decrease in ARE-dependent 
gene expression, suggesting that these kinases play a positive role in Nrf2 
activation (Yu et al. 1999; Alam et al. 2000). In contrast, it has also been shown 
that p38 negatively regulates Nrf2, suggesting that MAPK control of ARE-
dependent gene expression may be complex, and both inducer- and cell type-
specific (Yu et al. 2000). The effect of MAPK activity on ARE-dependent gene 
expression could be due to either the direct phosphorylation of Keap1 and/or 
Nrf2, or through an indirect, less specific mechanism. By use of mass 
spectroscopy, it was shown that Nrf2 is phosphorylated at several serine and 
threonine residues in cells (S215, S408, S558, T559, S577), with three out of 
these five sites fitting the MAPK consensus sequence (Sun et al. 2009). 
Interestingly, phosphorylation of S40 was not identified in this study. Mutation 
of individual phosphorylation sites had no effect on Nrf2 activity, whereas 
mutation of all 5 sites caused only a modest decrease in ARE-dependent gene 
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expression, suggesting that MAPK plays only a limited role in the activation of 
Nrf2.   
 An alternate role of protein kinase-mediated control of Nrf2 has been 
proposed to solve the problem of how the increased Nrf2 levels are brought 
down to basal levels when the inducers are removed. It has been proposed that 
the return of elevated Nrf2 back to basal levels is controlled by GSK3β and the 
Src family member, Fyn kinase (Jain et al. 2006; 2007). The authors propose that 
in response to inducers such as H2O2, Nrf2 accumulates in the nucleus, whilst Fyn 
is depleted from the nucleus, and GSK3β is inactivated. After a few hours, a 
delayed response to H2O2 is initiated, and GSK3β is phosphorylated, leading to 
phosphorylation and nuclear accumulation of Fyn which in turn phosphorylates 
Nrf2 at Y568. The phosphorylation of Nrf2 leads to its nuclear export, allowing it 
to be degraded by Keap1 (Jain et al. 2006; 2007). However, there are currently 
no data showing how GSK3β is either repressed or activated by inducers. 
 The inducer tBHQ has also been shown to activate PI3K, inhibition of 
which caused a significant decrease in ARE-dependent gene expression (Lee et 
al. 2001; Kang et al. 2001). Significantly, in the absence of inducers, 
constitutively active PI3K has also been shown to increase the activity of the 
Nrf2 target gene NQO1, and the levels of glutathione (Healy et al. 2005). It is 
interesting to note that in Nrf2-knockout cells both Akt and ERK1/2 show 
decreased responsiveness to PDGF and/ or insulin, suggesting the existence of a 
reciprocal interaction between Nrf2 and PI3K signalling (Reddy et al. 2008). In 
addition, Nrf2 has also been shown to be phosphorylated by GSK3β, PERK and 
CK2, suggesting that the regulation of Nrf2 has the potential to be very complex, 
and could be fine-tuned by a number of different mechanisms (Salazar et al. 
2006; Cullinan et al 2003; Cullinan and Diehl 2004; Pi et al. 2007). 
 In light of the data suggesting that Nrf2 is controlled by protein kinases, it 
is important to note that, as previously mentioned, in cells derived from Keap1-
knockout mice or following knockdown of Keap1 by siRNA, Nrf2 target genes are 
constitutively activated, and their expression cannot be further increased by 
inducers (Wakabayashi et al. 2003; Devling et al. 2005; MacLeod et al. 2009). 
This implies that Keap1 plays by far the greatest role in regulating Nrf2 activity. 
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Any role of other pathways may simply fine-tune ARE-dependent gene 
expression and become important only in the absence of functional Keap1.           
 
The cytoprotective functions of Nrf2-target gene products 
 
Based on numerous individual biochemical studies and global gene 
expression profiling, it is now evident that the Keap1-Nrf2 pathway controls the 
gene expression of a family of cytoprotective proteins that is characterized by 
extraordinary diversity. The available microarray data describing Nrf2-target 
genes in rodent liver, lung, small intestine, and mouse embryonic fibroblasts 
(MEFs), as well as in human cell lines and tissues were recently summarised 
(Hayes et al. 2010). Below is a brief outline of the cytoprotective roles of two 
major groups of Nrf2 target gene products that: (i) are involved in the 
metabolism and transport of a wide array of endo- and xenobiotics; and (ii) have 
antioxidant functions. Notably, the distinction between these two groups is not 
unequivocal, and some enzymes that are listed in the first category also could be 
classified under the second. Thus, specific glutathione S-transferases exhibit 
glutathione peroxidase activity towards hydroperoxides (Hurst et al. 1998). 
NQO1 protects against generation of reactive oxygen intermediates that are 
formed during oxidative cycling of quinones (Prochaska et al. 1987), and it has 
also been shown to scavenge superoxide directly (Siegel et al. 2004).  
 
 
Proteins involved in the metabolism and transport of endo- and xenobiotics 
 
Historically, this group represents the earliest recognized class of Nrf2-
dependent genes. NQO1 is one of the most robust responders to both 
pharmacological (by small-molecule inducers) and genetic (deletion of Keap1) 
activation of Nrf2 (Benson et al. 1980; Yates et al. 2009). NQO1 is a widely-
distributed FAD-dependent flavoprotein that catalyses the obligatory 2-electron 
reductions of quinones, quinoneimines, nitroaromatics, and azo dyes, using 
either NADH or NADPH equally efficiently as the hydride donor (for recent 
reviews see Ross and Zhou, 2010; Dinkova-Kostova and Talalay, 2010). In doing 
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so, NQO1 reduces the opportunities for generation of reactive oxygen 
intermediates mediated by redox cycling, and for depletion of intracellular 
sulfhydryl pools. Induction of NQO1 levels decreases, whereas depletion 
increases the susceptibility to oxidative stress. Human polymorphisms that lead 
to low NQO1 activity are associated with increased predisposition to disease, 
especially childhood leukemia (Smith et al. 2002), and represent a strong 
prognostic factor in breast cancer survival and metastasis (Fagerholm et al. 
2008). In addition, NQO1 binds and protects the tumor suppressor p53 against 
proteasomal degradation (Asher et al. 2001, 2002), and thus has even broader 
cytoprotective roles, beyond its enzymatic functions.  
The aldo-keto reductases (AKRs) are some of the most inducible Nrf2-
target genes in human cells and tissues (Burczynski et al 1999; Devling et al. 
2005; Gasper et al. 2007; Chambers et al. 2009; MacLeod et al. 2009). The AKRs 
catalyse the NAD(P)H-dependent reductions of the carbonyl groups of numerous 
aliphatic and aromatic aldehydes and ketones, retinals, ketoprostaglandins, and 
ketosteroids, leading to either their detoxification or activation (see Jin and 
Penning, 2007 for a comprehensive review). In doing so, the AKRs prepare the 
carbonyl group for subsequent conjugation, such as glucuronidation and 
sulfation, and ultimately for excretion. The sulfated and glucuronidated 
conjugates then become substrates for sulfotransferases (SULTs) and uridine 
diphosphoglucuronosyltransferases (UGTs), respectively, two other classes of 
Nrf2-target genes. In addition to products of the reactions catalysed by the AKRs, 
the SULTs catalyse the sulfation of various other xenobiotics, as well as 
endogenous hormones and neurotransmitters using 3’-phosphoadenosine 5’-
phosphosulfate (PAPS) as the sulfuryl donor (reviewed by Coughtrie, 2002). 
Interestingly, in humans the SULTs are highly expressed in the developing fetus 
at levels equivalent to or exceeding those in the adult, and may represent its 
primary detoxification system (Stanley et al. 2005). Also characterized by very 
broad substrate specificity, the members of the UGT family catalyse the 
glucuronidation of numerous endogenous and exogenous lipophilic molecules, 
such as steroids, bile acids, bilirubin, dietary substances, environmental 
pollutants, increasing their water solubility and facilitating their subsequent 
excretion (see Tukey and Strassburg, 2000 for a comprehensive review). Specific 
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human polymorphisms in the UGTs are responsible for the clinical manifestation 
of Crigler-Najjar's and Gilbert's syndromes, illustrating the critical role of these 
enzymes in the glucuronidation of bilirubin. 
In rodents, the glutathione S-transferases (GSTs) are among the most 
inducible Nrf2-dependent genes. Whereas in humans the gene expression of the 
GSTs might be regulated differently (Hayes et al. 2010), their cytoprotective 
functions are undebatable. The vital importance of the GSTs is evidenced by their 
wide distribution, with specific isoforms abundant in the cytoplasm, 
endoplasmic reticulum, and the mitochondria (for comprehensive reviews see 
Hayes et al. 2005; Mannervik et al. 2005). The GSTs catalyse the conjugation of a 
wide variety of substrates with glutathione, thereby playing critical roles in the 
detoxification of xenobiotic electrophiles, such as environmental pollutants, 
chemical carcinogens, chemotherapeutic agents, as well as endogenous α,β-
unsaturated aldehydes, epoxides, and hydroperoxides. In addition to their 
detoxification roles, the GSTs also participate in the biosynthesis of leukotrienes, 
prostaglandins, testosterone, and progesterone, and in the degradation of 
tyrosine.  
The conjugation products of the GSTs, the SULTs, and the UGTs are 
exported out of the cell by members of the multidrug resistance-associated 
protein (MRP) family. The MRPs are ATP-dependent membrane-associated 
organic anion transporters; MRP4 is also involved in the export of nucleosides 
and prostaglandins (Borst et al. 2000; Reid et al. 2003). MRP2 is the major 
transporter responsible for the export of bilirubin glucuronides into bile; its 
deficiency in humans leads to Dubin-Johnson syndrome. Pharmacological or 
genetic (liver-specific Keap1-knockout) activation of Nrf2 causes upregulation of 
several MRPs; especially striking is the effect of Keap1 deletion on MRP4 (~80-
fold) and MRP5 (~40-fold) (Yates et al. 2009). Interestingly, the same genetic 
model revealed that the absence of Keap1 (and therefore the constitutive 
activation of Nrf2) in the liver also leads to increases in the levels of several 
members of the cytochrome P450 family of drug metabolizing enzymes; such 
increases have been observed with some (e.g., 3H-1,2-dithiole-3-thione), but not 
other (e.g., CDDO-Im) pharmacological activators of Nrf2 (Kwak et al. 2003; 
Osburn et al. 2008; Yates et al. 2009). 
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Proteins with antioxidant functions 
 
Both the catalytic and the regulatory subunits of γ-glutamylcysteine ligase 
(GCL), the enzyme that catalyses the rate-limiting step in the biosynthesis of 
glutathione, the principal endogenous small-molecule antioxidant, are regulated 
by Nrf2 (Wild et al. 1999). In addition, χ-CT, the core subunit of the 
cystine/glutamate membrane transporter, which is responsible for the uptake of 
cystine that in turn is rapidly reduced to cysteine and used for the synthesis of 
glutathione (Bennai and Ishii, 1982), is also an Nrf2 target (Ishii et al. 2000). In 
addition to its essential role for the conjugation of electrophiles catalysed by the 
GSTs, glutathione is used by glutathione peroxidases to enzymatically reduce 
hydrogen peroxide to water. Glutathione reductase, which catalyses the 
reduction of oxidized glutathione and the regeneration of reduced glutathione, is 
also Nrf2-dependent, as is glucose 6-phosphate dehydrogenase, which provides 
NADPH to glutathione reductase (Kwak et al. 2003). The transcriptional 
regulation of glutathione peroxidase 2 (and possibly also glutathione peroxidase 
1) is Nrf2-dependent (Lubos et al. 2010). Nrf2 also regulates the gene expression 
of other NADPH-generating enzymes, i.e., malic enzyme and phosphogluconate 
dehydrogenase (Thimmulappa et al. 2002). NADPH is used as a source of 
reducing equivalents for the selenocysteine-containing thioredoxin reductases, 
which are also Nrf2-target genes, as are the thioredoxins themselves. In addition 
to being direct antioxidants in quenching of reactive oxygen intermediates, the 
thioredoxins undergo reversible oxidation of their conserved cysteine residues 
through the transfer of reducing equivalents to disulfide substrates. In doing so, 
the thioredoxins modulate the activities of many cellular proteins, including 
those involved in signaling cascades (Powis and Montford, 2001). Reduction of 
oxidized thioredoxins is then catalysed by thioredoxin reductases (Mustacich 
and Powis, 2000; Holmgren and Lu, 2010).  
Thioredoxin (together with NADPH) also plays a critical role in the 
completion of the catalytic cycle of the peroxiredoxins (Prxs). The Prxs are 
ubiquitous peroxidases that use a conserved Cys residue (called the peroxidatic 
Cys) to reduce peroxide substrates, such as H2O2. Their high catalytic efficiencies 
(on the order of ~107 M-1s-1) are achieved by activation not only of the 
 41 
peroxidatic Cys thiolate, but also of the peroxide substrate, and by a hydrogen 
bonding network created by four residues (Pro, Thr, Arg and the peroxidatic 
Cys) that are conserved in the active sites of all Prxs, which stabilizes the 
transition state of the peroxidatic SN2 displacement reaction (Hall et al. 2010). 
During the catalytic cycle of a eukaryotic dimeric Prx, the peroxidatic Cys of one 
subunit is oxidized by the substrate to sulfenic acid (-SOH), which then reacts 
with a second conserved Cys residue (called the resolving Cys) of the other 
subunit to form an intermolecular disulfide bond. It is the reduction of this 
disulfide bond that is carried out by thioredoxin/NADPH to complete the cycle. 
Intriguingly, during the reduction of their substrates, the peroxidatic Cys of the 
Prxs can be overoxidized to sulfinic acid (-SOOH) that, in turn is reduced back to 
Cys by the ATP-dependent sulfinic acid reductase sulfiredoxin (Srx) (Biteau et al 
2003; Woo et al. 2003). Srx is the only known enzyme that catalyses the 
reduction of sulfinic acid in mammals, and the Prxs are its only identified 
substrates (Woo et al. 2005). Both have been reported to be Nrf2-target genes 
(Ishii et al. 2000; Osburn et al. 2008; Singh et al. 2009). 
Nrf2 participates in the regulation of the gene expression of heme 
oxygenase 1, which, in concert with bilirubin reductase, generates the 
antioxidants carbon monoxide and bilirubin (Ryter and Choi, 2010). The 
upstream regulatory regions of the gene encoding heme oxygenase 1 contain 
multiple AREs, which are responsible for its quick and robust inducibility by 
various small-molecule Nrf2 activators (Prestera et al. 1995). Free iron, also a 
product of the heme oxygenase 1 catalysis, is then efficiently sequestered by 
another Nrf2-regulated gene product, i.e., ferritin (Pietsch et al. 2003), that has 
the remarkable capacity to store 4500 (Fe3+) ions in a bioavailable and nontoxic 
form (Harrison and Arosio, 1996). Nrf2 also takes part in the transcriptional 
regulation of another class of metal-binding-proteins, the metallothioneins 
(Katsuoka et al. 2005). The metallothioneins are small cysteine-rich (20 cysteine 
residues out of a total of 61 or 62 amino acids) proteins that have an exceedingly 
high metal and sulfur content, up to 10% w/w (Henkel and Krebs, 2004). These 
highly conserved multifunctional proteins protect against the toxicity of heavy 
metals and oxidative damage, and in addition, limit inflammation, modulate 
immune responses, and contribute to tissue repair.   
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Thus the large and functionally diverse family of Nrf2-dependent 
cytoprotective proteins bestows the cell with multiple layers of protection by 
providing: (i) antioxidant enzymes (e.g., heme oxygenase 1, NAD(P)H:quinone 
oxidoreductase 1); (ii) conjugating enzymes (e.g. glutathione S-transferases and 
uridine diphosphoglucuronosyltransferases); (iii) proteins that enhance export 
of xenobiotics and/or their metabolites (e.g., solute carrier- and ATP-binding 
cassette transporters); (iv) enzymes that participate in the synthesis and 
regeneration of glutathione (e.g., γ-glutamylcysteine synthetase, glutathione 
reductase); (v) enzymes that promote the synthesis of reducing equivalents, i.e., 
NADPH (e.g., glucose 6-phosphate dehydrogenase, 6-phosphogluconate 
dehydrogenase); (vi) enzymes that inhibit inflammation (e.g., leukotriene B4 
dehydrogenase); (vii) proteins that do not have enzymatic activities, but are 
nevertheless essential for cytoprotection (e.g., ferritin which has an enormous 
capacity to protect against iron overload, metallothioneins); (viii) proteins that 
participate in the repair and removal of damaged proteins (e.g., subunits of the 
26S proteosome); and (ix) proteins that regulate the expression of other 
transcription factors and growth factors. A recent study that used a high-
throughput chromatin-immunoprecipitation with parallel sequencing 
methodology identified more than 600 Nrf2-target genes, further confirming the 
essential role of Nrf2 as a central regulator of cell protective and survival 
responses (Malhotra et al. 2010). In addition, genetic versus chemoprotective 
activation of Nrf2 has been shown to result in overlapping, yet distinct gene 
expression profiles (Yates et al. 2009). It is also becoming increasingly evident 
that a portion of the protective effects of Nrf2 activation is mediated indirectly 
through cross-talks with other pathways, such as the aryl hydrocarbon receptor 









Chemistry of inducers 
 
The Keap1-Nrf2 pathway can be upregulated by various cellular stresses 
(e.g., oxidative stress, shear stress, endoplasmic reticulum stress) and 
structurally diverse small molecules (inducers) of endogenous (e.g., 15-deoxy-
∆12,14-prostaglandin J2, nitro oleic acid, nitric oxide, hydrogen peroxide, hydrogen 
sulfide) as well as exogenous origin. The development and use of a quantitative 
bioassay which evaluates the ability of small molecules to induce the prototypic 
Nrf2-target NQO1 in Hepa1c1c7 murine hepatoma cells (Prochaska and 
Santamaria 1988; Fahey et al. 2004) led to the classification of inducers into ten 
distinct chemical classes: (i) oxidizable diphenols, phenylenediamines, and 
quinones, (ii) Michael reaction acceptors (olefins or acetylenes conjugated with 
electron-withdrawing groups), (iii) isothiocyanates and sulfoxythiocarbamates, 
(iv) thiocarbamates, (v) dithiolethiones, (vi) conjugated polyenes, (vii) 
hydroperoxides, (viii) trivalent arsenicals, (ix) heavy metals, and (x) vicinal 
dimercaptans.  Remarkably, more than 20 years following its first application, at 
time long before Keap1 or Nrf2 had been discovered, this assay remains a major 
screening tool for potential inducers, and arguably, allows the most reliable 
comparisons of inducer potencies. Specific examples of molecules that belong to 
three of the most prominent classes of inducers are given below. 
 
 
Oxidizable diphenols, phenylenediamines, and quinones 
 
Some of the first compounds for which inducer activity was demonstrated 
belong to this class. Experiments conducted in the late 1970s found that dietary 
administration of the phenolic antioxidant BHA [2(3)-tert-butyl-4-
hydroxyanisole] (Figure 1.8) to mice reduced the formation of mutagenic 
metabolites of benzo[a]pyrene, and induced the cytoprotective enzymes GST, 
epoxide hydrolase, and NQO1 in many tissues (Benson et al. 1978; 1979; 1980). 
Structure-activity studies with the demethylation product of BHA, tert-
butylhydroquinone (tBHQ), and a series of mono- and dialkyl ethers of tBHQ 
showed that the free phenol was more potent than the alkyl ethers (Prochaska et  
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Figure 1.8.  Chemical structures of the phenolic antioxidant BHA [2(3)-tert-butyl-4-
hydroxyanisole] and BHT [3,5-di-tert-butyl-4-hydroxytoluene], and the metabolites 
tBHQ (tert-butylhydroquinone), and tBQ (tert-butylquinone). 
 
 
al. 1985a,b; De Long et al. 1985). Furthermore, when simpler diphenols and 
phenylenediamines were evaluated, it became clear that the criticalfeature for 
inducer activity was the oxidative lability of these compounds (Prochaska et al. 
1985b). Following the discovery of the Michael acceptor class of inducers, taken 
together the two findings led to the hypothesis that the diphenols need to be 
oxidized first to their corresponding quinones, which are the ultimate inducers. 
Further support to this hypothesis was provided by molecular orbital 
calculations which showed linear correlations between inducer potency for 
NQO1, and: (i) the ability of diphenols to release electrons, and (ii) the electron 
affinity of their corresponding quinones (Bensasson et al. 2008). A two-step 
mechanism in the upregulation of the Keap1-Nrf2 pathway was proposed which 
involves oxidation of the diphenols to their corresponding quinone derivatives, 
followed by modification of specific highly reactive cysteine residues of Keap1. 
This theoretical conclusion was recently tested experimentally. By use of UV 
spectroscopy, it was found that in the presence of oxygen and transition metals, 
tBHQ is rapidly oxidized to its corresponding quinone, tBQ. In addition, tBQ, but 
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not tBHQ, reacts with cysteine residues of purified recombinant murine Keap1. 
The cellular response to tBHQ or tBQ in terms of ARE-dependent transcription 
was then examined using the AREc32 reporter cell line. This reporter is derived 
from the human breast cancer cell line MCF7 that has been stably transfected 
with a luciferase reporter gene under thetranscriptional control of eight 
tandemly arrayed copiesof the ARE (Wang et al. 2006). Exposure of these cells to 
the hydroquinone tBHQ for 30 min induced ARE-luciferase (measured 24 hours 
later) only in the presence of transition metals, whereas induction by the 
quinone tBQ occurred in the absence of metals (Wang et al. 2010). Endogenous 
para- and ortho-hydroquinones, such as catechol estrogens, dopamine, and L-
DOPA, also induce ARE-dependent gene expression, and induction is 
substantially potentiated by the presence of transition metals. Taken together, 
the available data strongly suggest that oxidizable diphenols are not inducers 
themselves, but their oxidation to the corresponding electrophilic quinones (the 




Michael reaction acceptors 
 
The discovery that many compounds that induce cytoprotective enzymes 
are molecules bearing Michael acceptor group(s) and that inducer potency 
correlates with reactivity in the Michael reaction (Talalay et al. 1988) was a 
critical milestone in the understanding of the mechanism of action of inducers. 
The Michael acceptor functionality is essential for the inducer activity of many 
natural products such as cinnamates, curcuminoids, chalcones, avicins, and 
withanolides (Talalay et al. 1988; Spencer et al. 1991; Dinkova-Kostova et al. 
1998; 1999; 2001; Chang et al. 1997; Misico et al. 2002; Gu et al. 2002; 2003; Su 
et al. 2003) (Figure 1.9). Furthermore, the introduction of highly activated 
Michael acceptor groups (by simultaneous conjugation to both cyano- and 
carbonyl moieties) in the molecules of oleanolic- and betulinic acid-derived 
semisynthetic triterpenoids (Figure 1.10) has led in the identification of the 
most potent inducers known to date that are active at sub- to low-nanomolar  
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Figure 1.9.  Chemical structures of the phenolic Michael acceptor-containing curcumin, 
2,2’-dihydroxychalcone, and ferulic acid methyl ester. The CD (Concentration that 
Doubles the NQO1 enzyme activity) values are shown in parentheses. 
 
concentrations (Dinkova-Kostova et al. 2005b; Liby et al. 2007a).  Recently, 
simpler tricyclic derivatives bearing highly activated Michael acceptor moieties 
on rings A and C were developed which retain the inducer potency of the 
pentacyclic analogues, and the tricyclic molecule TBE-31 [(±)-(4a,8a,10aβ)-
1,2,4a,6,8a,9,10,10a-octahydro-8a-ethynyl-1,1,4a-trimethyl-2,6-
dioxophenanthrene-3,7-dicarbonitrile] (Figure 1.11) was found to be the most 
potent compound in this series both in vitro and in vivo (Liby et al. 2008a). 
Evaluation of its monocyclic “building blocks” representing ring A [MCE-5 
(3,3,5,5-tetramethyl-6-oxocyclohex-1-enecarbonitrile)] and ring C [MCE-1 ((±)-
3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile)], respectively 
revealed that the contribution to inducer potency of ring C is 100-fold greater 
than that of ring A, and that potency is further enhanced by spatial proximity to 
an acetylenic group (Dinkova-Kostova et al. 2010).  
Critically, the simultaneous presence of rings A and C within a contiguous 
three-ring system results in exceptionally high inducer potency, much higher 
than would have been expected based on the additive effect of the two 
monocyclic Michael acceptors. Thus, TBE-31 is ~30-fold more potent than the  
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Figure 1.10.  Chemical structures of the naturally-occurring triterpenoid oleanolic acid 
and its cyano enone-containing semisynthetic derivatives CDDO, CDDO-methyl ester, 
and TP-225. The CD values are shown in parentheses. 
 
 
monocyclic ring-C compound MCE-1, and ~1000-fold more potent than the 
monocyclic ring-A compound MCE-5 (Dinkova-Kostova et al. 2010). Curiously, 
the synergistic effect on inducer potency resulting from the presence of two 
Michael acceptors on a single molecule is not restricted to the tricyclic 
cyanoenones.  Thus bis(2-hydroxybenzylide)acetone is ~30-fold more potent 
than trans-4-(2-hydroxyphenyl)-3-buten-2-one (Dinkova-Kostova et al. 1998; 
2001). Curcumin is ~10-fold more potent than ferulic acid methyl ester 
(Dinkova-Kostova et al. 1999). This finding strongly suggests that both 
electrophilic carbons react simultaneously with two cysteine residues within 






Isothiocyanates and sulfoxythiocarbamates 
 
The isothiocyanates occur naturally as inert glucosinolate precursors that 
are abundant in cruciferous vegetables (Fahey et al. 2001; Halkier and 
Gershenzon, 2006). Upon injury of the plant, the glucosinolates come into 
contact with the otherwise compartmentalised enzyme myrosinase which 
catalyses their conversion to a range of hydrolytic products, including 
isothiocyanates. The central carbon atom of the isothiocyanate (–N=C=S) group 
(Figure 1.12A) is highly electrophilic and reacts avidly with sulfhydryl groups to 
give dithiocarbamate products.  The isothiocyanate sulforaphane [1-
isothiocyanato-4-(methylsulfinyl)butane] was isolated as the principal NQO1 
inducer from broccoli extracts in an activity-guided fractionation using the 
Hepa1c1c7 bioassay (Zhang et al. 1992). Systematic examination of the levels of 
inducer activity at specific developmental stages of the plant revealedthat the 
seeds are the richest source of glucoraphanin, the glucosinolate of sulforaphane, 
and 3-day-old broccoli sprouts contain 20 to 50 times higher levels than the 
mature plant (Fahey et al. 1997). Inducer potency among isothiocyanates 
correlates with their intracellular accumulation (Ye and Zhang, 2001), for which 
conjugation with cellular glutathione provides a major driving source (Zhang 
and Talalay, 1998; Zhang, 2000; 2001); export of the conjugates then occurs by a 
transporter-mediated mechanism (Zhang and Callaway, 2002). 
Following the discovery of sulforaphane, a series of naturally-occurring 
and synthetic isothiocyanates were evaluated for inducer activity (Posner et al. 
1994). It was found that an analogue of sulforaphane, in which the sulfoxide 
(S=O) group was replaced by a keto (C=O) group, retained the same inducer 
activity (Figure 1.12A). This finding was recently revisited, and two new series 
of analogues were synthesized, containing either a sulfoxide or a keto moiety, 
respectively, in which the strongly electrophilic isothiocyanate group was 
replaced with the weaker electrophilic sulfoxythiocarbamate group (Ahn et al. 
2010). Unlike isothiocyanates which form reversible conjugates with sulfhydryl 
groups, the reaction with sulfoxythiocarbamates is essentially irreversible 
(Figure 1.12B). Using this property, combined with a click chemistry approach 
with one of theanalogues, S-ethyl (4-hex-5-ynyloxy-benzyl)-(5-oxo-hexyl)- 
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Figure 1.11.  Chemical structures of the tricyclic bis(cyano enone) TBE-31 [(±)-
(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-
octahydrophenanthrene-2,6-dicarbonitrile] and its monocyclic derivatives MCE-5 
[(3,3,5,5-tetramethyl-6-oxocyclohex-1-enecarbonitrile)] and MCE-1 [(±)-3-ethynyl-3-
methyl-6-oxocyclohexa-1,4-dienecarbonitrile]. The CD values are shown in parentheses. 
 
thiocarbamate sulfoxide, that contains an alkynyl end group, it was found that 
C273, C288, and C613 of Keap1 were modified when cells were exposed to this 
compound (Ahn et al. 2010). 
 
 
Inducers as chemoprotective agents 
 
Many inducers that belong to different chemical classes have been shown 
to protect against chronic degenerative diseases in various animal models of 
carcinogenesis, cardiovascular disease, and neurodegeneration. The phenolic 
antioxidants BHA [2(3)-tert-butyl-4-hydroxyanisole] and BHT [3,5-di-tert-butyl-
4-hydroxytoluene] inhibit experimental carcinogenesis caused by a wide range 
of chemical carcinogens (Frankfurt et al. 1967; Wattenberg et al. 1979). Related 
hydroquinone- and catechol-containing molecules, which could be viewed as 
“pro-drugs” that are converted to the ultimate inducers by oxidation reactions, 
are being developed as neuroprotective agents, with the interesting idea of their  
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Figure 1.12.  (A) Chemical structures of the isothiocyanate sulforaphane [1-
isothiocyanato-4R-(methylsulfinyl)butane] and its carbonyl derivative 1-isothiocyanato-
4R-(methylcarbonyl)butane. The CD values are shown in parentheses. (B) Reaction of S-
ethyl (4-hex-5-ynyloxy-benzyl)-(5-oxo-hexyl)-thiocarbamate sulfoxide with a cysteine 




activation occurring via the pathological activity that they are intended to 
combat (Lipton, 2007). The double Michael acceptor curcumin inhibits tumour 
development in animal models of oral, gastric, intestinal, colonic, hepatic, and 
cutaneous carcinogenesis (reviewed in Surh and Chun, 2007; Hatcher et al. 
2008). Fumaric acid, another Michael acceptor-containing inducer, is protective 
against hepatic (Kuroda et al. 1983; 1987; 1989; Akao and Kuroda, 1990), 
gastric, and pulmonary (Kuroda et al 1982) carcinogenesis in rodents. In 
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humans, orally administered dimethyl fumarate reduces the appearance of new 
inflammatory lesions in patients with relapsing-remitting multiple sclerosis 
(Schimrigk et al. 2006; Kappos et al. 2008). Michael-acceptor-bearing 
semisynthetic triterpenoids inhibit the development of hepatic (Yates et al. 
2006), pulmonary (Liby et al. 2007b; 2008b; 2009), mammary (Liby et al. 
2008c), pancreatic (Liby et al. 2010), and cutaneous (Dinkova-Kostova et al. 
2008) tumours. CDDO (bardoxolone) and CDDO-Me are currently in clinical trials 
with patients with chronic kidney disease, diabetic nephropathy, hepatic 
dysfunction, lymphoid tumours, and advanced metastatic or unresectable solid 
tumours. In addition to protection against carcinogenesis, neuroprotective 
effects have also been reported for CDDO-methylamide in mouse model of 
Alzheimer’s disease (Yang et al. 2009; Dumont et al. 2009) and for CDDO-ethyl 
amide and CDDO-trifluoroethyl amide in a mouse model of Huntington's disease 
(Stack et al 2010). 
The early studies demonstrating the chemoprotective effects of 
isothiocayantes date from the 1960s. Thus, feeding of α-naphthyl isothiocyanate 
to rats, dose-dependently reduced chemically-induced hepatocarcinogenesis 
(Sasaki 1963; Sidransky et al. 1966; Lacassagne et al. 1970). Benzyl-, phenyl-, 
and phenethyl isothiocyanate suppressed the carcinogenic effects of polycyclic 
aromatic hydrocarbons in a rat mammary carcinogenesis model, and benzyl 
isothiocyanate effectively inhibited the formation of gastric and pulmonary 
tumours in mice (Wattenberg 1977; 1983; 1985; 1987; Kuroiwa et al. 2006). 
Orally administered isothiocyanates also inhibited chemically-induced lung 
(Morse et al. 1989a,b; 1991; 1992; Hecht et al. 1991) and esophageal (Siglin e al. 
1995; Stoner et al. 1998) carcinogenesis. In an orthotopic rat bladder cancer 
model, feeding of mustard seed preparation as a source of sinigrin, the 
glucosinolate precursor of allyl isothiocyanate, inhibited bladder cancer growth 
and completely blocked muscle invasion (Bhattacharya et al. 2010). 
Sulforaphane or sulforaphane-rich broccoli extracts have been shown to protect 
rodents against mammary (Zhang et al. 1994), gastric (Fahey et al. 1997), 
pulmonary (Conaway et al. 2005), pancreatic (Kuroiwa et al., 2006), cutaneous 
(Gills et al. 2006; Xu et al. 2006; Dinkova-Kostova et al. 2006), colonic (Chung et 
al. 2005; Myzak et al. 2006; Hu et al. 2006; Shen et al. 2007) and bladder 
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(Munday et al. 2008) carcinogenesis. Sulforaphane has neuroprotective effects in 
rodent models of brain ischemia/reperfusion (Zhao et al 2006; Ping et al 2010), 
traumatic brain injury (Zhao et al. 2005; 2007a; Dash et al. 2009), stroke (Zhao 
et al 2007b), and endotoxin exposure (Innamorato et al 2008). Chemoprotective 
effects of sulforaphane-containing broccoli extracts have been observed in rat 
models of hypertension (Wu et al. 2004; Noyan-Ashraf et al. 2006) and heart 
ischemia/reperfusion (Mukherjee et al. 2008; 2010). 
Because 3-day-old broccoli sprouts are a rich source of glucoraphanin, the 
glucosinolate precursor of sulforaphane, extracts of this vegetable have been 
used in human studies as delivery vehicles of either sulforaphane or 
glucoraphanin. In six healthy human subjects, the susceptibility to erythema 
caused by ultraviolet (UVB) radiation was reduced by ~40% (compared to 
vehicle-treated skin) at sites that received topical treatment with broccoli sprout 
extract delivering a daily dose of 200 nmol of sulforaphane on three successive 
days before the day of radiation (Talalay et al., 2007). A randomized, placebo-
controlled, double-blind clinical Phase 1 study of safety, tolerance, and 
pharmacokinetics of an extract delivering either: (i) 25 mol of glucoraphanin, 
(ii) 100 mol of glucoraphanin, or (iii) 25 mol of sulforaphane, p.o. at 8-h 
intervals, for seven days, found no evidence of systematic, clinically significant, 
adverse events that could be attributed to ingestion of the extract (Shapiro et al. 
2006). A randomized, placebo-controlled, double-blind chemoprevention trial in 
200 healthy human subjects was conducted in Qidong Province in the People’s 
Republic of China (Kensler et al. 2005). The study examined the effect of a 
broccoli sprout extract delivering 400 mol of glucoraphanin that was given p.o. 
once a day for two weeks, on the metabolic disposition of aflatoxin and the 
combustion product phenanthrene. The study found an inverse association for 
excretion of dithiocarbamates (the metabolic products of isothiocyanates) and 
aflatoxin-DNA adducts, as well as for excretion of dithiocarbamates and 
phenanthrene tetraols. A 12-month dietary intervention study in human 
volunteers diagnosed with high-grade prostatic intraepithelial neoplasia was 
conducted in which subjects were randomly assigned to either a broccoli-rich- 
(400 g per week) or a pea-rich (400 g per week) diet, in addition to their usual 
diet (Traka et al. 2008). Needle biopsy tissues were obtained before and after the 
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intervention, and global gene expression profiles were compared. Pathway 
analyses showed that consumption of broccoli-rich-, but not pea-rich diet, 
resulted in perturbations of pathways associated with carcinogenesis and 
inflammation, i.e., TGF receptor-β, EGF receptor-, and insulin signaling pathways. 
Another curious property of sulforaphane is its bactericidal activity against 
Helicobacter pylori infections, which are strongly associated with gastric cancer 
(Fahey et al. 2002). In a randomized placebo-controlled intervention study, 48 
Helicobacter pylori-infected patients were assigned to diets containing daily 
doses of 70 grams of either broccoli (delivering 420 mol of glucoraphanin) or 
alfalfa sprouts for eight weeks (Yanaka et al. 2009). Intervention with broccoli, 
but not with alfalfa sprouts, decreased bacterial colonization (evaluated by the 
levels of urease and Helicobacter pylori stool antigen), and reduced gastric 
inflammation (indicated by the levels of serum pepsinogens I and II). Taken 
together, the human studies strongly suggest that sulforaphane has promise as a 
chemoprotective agent against various pathologies that have both oxidative 
stress and inflammatory components. 
Indeed, Nrf2 inducers also have anti-inflammatory effects, and 
furthermore, there is a linear correlation between these two activities over a 
very broad range (six orders of magnitude) of concentrations (Dinkova-Kostova 
et al. 2005b; Liu et al. 2008). In contrast to the NQO1 inducer activity which is 
fully dependent on Nrf2, the anti-inflammatory properties of these molecules are 
only partially Nrf2-dependent. In addition, global gene expression and 
proteomics studies have revealed that such molecules have multiple targets. 
Whereas it is not presently clear how exactly the anti-inflammatory and Nrf2-
inducer activities are mechanistically related, there is no doubt that both 









The dual role of the Keap1-Nrf2 pathway in carcinogenesis 
 
Due to the ability of the Keap1-Nrf2 pathway to protect cells from the 
harmful effects of electrophiles and oxidants by regulating both the basal and 
inducible levels of cytoprotective proteins, it has been considered a 
chemopreventive pathway. Indeed, studies involving chemical carcinogenesis in 
knockout mice show that Nrf2 protects against tumour formation in the stomach, 
bladder and skin (Ramos-Gomez et al. 2001; Fahey et al. 2002; Iida et al. 2004; 
2007; Xu et al. 2006). Nrf2 has also been shown to be downregulated in skin 
tumours in mice, and multiple studies of prostate cancer in humans (Xu et al. 
2006, Frohlich et al. 2008). The mechanism by which Nrf2 is protective against 
tumourigenesis may in part be due to its ability to reduce the amount of reactive 
oxygen intermediates and DNA damage in cells (Frohlich et al. 2008; Aoki et al. 
2001; Li et al. 2004; Reddy et al. 2008). Loss of Nrf2 activity in tumours could be 
caused by either inactivating mutation(s) in Nrf2, or by increased degradation 
mediated by Keap1. However, a large-scale analysis of many cancer-associated 
genes found that additional copies of the KEAP1 gene were found in over 10% of 
tumours analysed, whereas it was lost in just 3% (Kan et al. 2010). This copy 
number variation analysis clustered KEAP1 with known oncogenes like KRAS and 
BRAF, suggesting that KEAP1 may be a putative oncogene. In addition, in breast 
cancer the low expression of Nrf2 was associated with increased Cul3, 
suggesting an alternate mechanism by which tumours may be able to reduce the 
expression of cytoprotective genes (Loignon et al. 2009). 
 Mutations have also been found in Nrf2. Interestingly these mutations are 
exclusively in the ETGE and DLG motifs of Neh2 domain, and lead to a reduction 
of Nrf2 degradation and an increase in ARE-dependent gene expression in both 
lung and head and neck tumours (Shibata et al. 2008a). Further work found Nrf2 
to be overexpressed in 91.5% of head and neck squamous cell carcinomas, and 
that high Nrf2 expression is correlated with aggressiveness and chemoresistance 
of endometrial tumours (Stacy et al. 2006; Jiang et al. 2010). In addition, 
inactivating mutations of Keap1 have been identified in tumours of the lung, 
breast and gallbladder (Padmanabhan et al. 2006; Singh et al. 2006; Ohta et al. 
2008; Sjöblom et al. 2006; Nioi and Nguyen 2007; Shibata et al. 2008b). Together 
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these data suggest that constitutive activation of the Nrf2 pathway can be 
beneficial for tumour survival. Indeed in breast cancer patients, the Kaplan-
Meier survival curves show that low Keap1 levels, and presumably active Nrf2, 
are associated with poor survival (Lee et al. 2009). Moreover, a mutant Nrf2 gene 
expression signature is associated with poor prognosis in head and neck cancer 
(Shibata et al. 2010). 
 It has been suggested that the beneficial activity of Nrf2 which protects 
normal cells from oxidative stress can be subverted by cancer cells to protect 
them from the stress-inducing conditions found in the tumour 
microenvironment. Active Nrf2 may promote tumorigenesis by maintaining the 
redox balance and generating antioxidants in cancerous cells through 
upregulation of ARE-dependent genes. In addition, it has also been shown 
experimentally that Nrf2 can protect tumours and cell lines from 
chemotherapeutic drugs, desensitising them to etoposide, carboplatin, cisplatin, 
doxorubicin, 5-fluorouracil and Paclitaxel (Singh et al. 2006; Wang et al. 2008b; 
Ohta et al. 2008; Shibata et al. 2008a; 2008b; Loignon et al. 2009; Jiang et al. 
2010). The ability of Nrf2 to protect cells from chemotherapeutics may in part be 
due to its ability to upregulate drug efflux pumps (Hayashi et al. 2003; Maher et 
al. 2007; Mahaffey et al. 2009). This tumour protective role of Nrf2 has been 
referred to as its 'dark side' (Wang et al. 2008b), and the cancer preventing/ 
cancer protecting dichotomy suggests that the role of Nrf2 in cancer in not 
straightforward and may be context-dependent. Furthermore, in Keap1-
knockdown mice, which have constitutively high Nrf2 levels, the activated Nrf2 
did not promote tumourigenesis, reinforcing the idea that the Keap1-Nrf2 
pathway plays a complex role in cancer (Taguchi et al. 2010). In this way 
parallels can be drawn between the action of the Keap1-Nrf2 pathway and TGF-β 
or NF-κB signalling in cancer, as all three pathways have pleiotropic effects on 
the tumour phenotype (Derynck et al. 2001; Perkins, 2004).   
 In addition to the well-documented role that Nrf2-mediated 
cytoprotective gene expression plays in cancer, emerging data suggests that the 
Keap1-Nrf2 pathway may play a larger role in tumourigenesis. A number of 
reports have suggested that Nrf2 may play a role in cell cycle regulation. For 
example, the knockdown of Nrf2 reduces the rate of proliferation in both the 
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mouse liver and in cells lines, whilst the loss of Keap1 increases proliferation  
(Beyer et al. 2008; Ohta et al. 2008; Homma et al. 2009). The loss of Nrf2 has 
been shown to induce cell cycle arrest at the G1-S checkpoint. This was caused 
by reduced phosphorylation of pRB and increased p21 expression. Interestingly, 
co-treatment of Nrf2 knockdown cells with the antioxidant NAC reduced p21 
expression, but had no effect on pRb status, suggesting that Nrf2 may regulate 
the cell cycle by both redox-dependent and redox-independent mechanisms 
(Homma et al. 2009). In reciprocal experiments carried out in pRB null cells, 
both Nrf2 and its target genes were expressed at lower levels, suggesting the 
existence of a co-regulatory mechanism between Nrf2 and pRB (Frohlich et al. 
2008). In alveolar epithelial cells, loss of Nrf2 causes cell cycle arrest at the G2/ 
M checkpoint, which could not be rescued by GSH supplementation, again 
pointing to a redox independent effect of Nrf2 on the cell cycle (Reddy et al. 
2008). In the same study loss of Nrf2 was shown to impair Akt, ERK1/2 and 
Stat3 signaling in response to PDGF and/ or insulin. In a hepatectomy model, loss 
of Nrf2 led to decreased IGF-1 and insulin receptor (IR) signalling resulting in 
reduced PI3K and Akt activation (Beyer et al. 2008). This reduction in IGF-1/ IR-
PI3K-Akt signalling in Nrf2 null livers was thought to be a result of increased 
oxidative stress. In addition, activation of Nrf2 signalling has been shown to 
positively regulate mTOR signalling, via the transcriptional control of the mTOR 
activator RagD, and the Notch pathway through an ARE element in the Notch1 
promoter  (Shibata et al. 2010; Wakabayashi et al. 2010b). Thus Nrf2 is able to 
regulate multiple pathways involved in cancer proliferation and cell cycle 
progression. Together these data may also indicate why inactivating somatic 
mutations of Nrf2 are rare in tumours. If in the absence of Nrf2 p21 and pRB are 
activated, whilst PI3K, Akt, ERK, p38 and Stat3 signalling are all reduced, it may 
be beneficial for tumour development to maintain functional or hyperactive Nrf2 
activity in order to aid cell proliferation.   
 Although Nrf2 may play a role in promoting cell proliferation, this activity 
may be balanced by the up-regulation of negative regulators of the cell cycle. 
ChIP-PCR and qRT-PCR assays found the cell cycle inhibitors p21 and p15 to be 
direct targets of induced Nrf2-mediated transcription (Malhotra et al. 2010). In 
addition to promoting cell cycle arrest, p21 is also involved in other cellular 
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processes including sensescence, apoptosis and the response to oxidative stress 
(Esposito et al. 1998; Gartel and Tyner 2002; Abbas and Dutta 2009). Recently it 
has also been shown that p21 plays a role in regulating Nrf2 activity. p21 binds 
to the ETGE and DLG motifs in Nrf2 and thus competes with the binding of 
Keap1, leading to Nrf2 stabilisation due to reduced ubiquination (Chen et al. 
2009). In p21-null mice and cell lines, the level of Nrf2 and its target genes is 
significantly reduced under both basal and induced conditions, confirming the 
importance of p21 in ARE-mediated gene expression (Chen et al. 2009). p21 has 
been shown to be regulated by both p53-dependent and independent 
mechanisms. Interestingly, the activation of p53 suppresses Nrf2-dependent 
transcription by directly binding to the promoters of ARE-dependent genes 
suggesting alternate regulation of Nrf2 by the p21-p53 axis (Faraonio et al. 
2006). Together these data have been combined to form a model whereby the 
interaction between p53, p21 and Nrf2 form a dynamic response to cellular 
stress (Wakabayashi et al. 2010a). Wakabayashi et al. (2010a) proposed that in 
the case of mild stress, p21-induced cell cycle arrest and Nrf2-mediated 
upregulation of ARE-dependent genes may be sufficient to protect cells from 
damage. In contrast, if the level of damage is severe, p53 may suppress 
cytoprotective protein expression and promote apoptosis.           
 In addition to the upregulation of cytoprotective genes, Nrf2 may also 
protect cells from tumourigenesis by inhibiting cell migration. The knockdown of 
Nrf2 leads to anchorage-independent growth, a change in cell morphology, and 
significantly increased migrating capacity in A549 cells (Rachakonda et al. 2010). 
This phenotype is caused by a loss of E-cadherin and an increase in the 
expression of the E-cadherin repressor Slug. Slug in turn is induced by Smad-
dependent signalling. Endogenous Nrf2 was shown to interact with Smad3 and 
Smad4 in cells, leading to a reduction in Smad-mediated transcription 
(Rachakonda et al. 2010). Smads are the downstream effectors of the TGF-β 
signalling pathway which has previously been shown to negatively regulate Nrf2 
(Bakin et al. 2005; Coulouarn et al. 2008). Indeed, a TGF-β expression signature, 
which included down regulation of Nrf2, was associated with the invasive form 
of hepatocellular carcinoma (Coulouarn et al. 2008). Together these data show 
that Nrf2 and TGF-β negatively regulate each other, and add a significant new 
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twist to the role of Nrf2 in cancer. The loss of E-cadherin is a rate-limiting step in 
the progression of invasive carcinoma and a fundamental event in the epithelial 
to mesenchymal transition which is associated with metastasis (Perl et al. 1998; 
Gupta and Massagué 2006). The idea that Nrf2 indirectly regulates the 
transcription of E-cadherin suggests that this transcription factor plays a far 
wider role in the cell than that of redox regulator, or conversely that the redox 
state regulates multiple diverse aspects of the cellular phenotype.  
 In addition, in both BRCA1 and ATM deficient cells, Nrf2 and its target 
genes are repressed, suggesting that the activity of the Keap1-Nrf2 pathway can 
be further regulated by other pathways, specifically those commonly mutated in 
the inherited forms of breast cancer (Bae et al. 2004; Li et al. 2004). Moreover, a 
number of Nrf2 target genes have been implicated in either preventing or 
promoting tumorigenesis. For example, NQO1 has been shown to stabilise p53 
(Asher et al. 2001; 2002), thioredoxin-1 has been implicated in HIF-1 
transcriptional activity (Huang et al. 1996; Welsh et al. 2002), and HO-1 has anti-





The Keap1-Nrf2 pathway allows adaptation and survival following 
various conditions of chemical and physical stress by controlling the gene 
expression of a large and diverse family of cytoprotective proteins. These 
proteins orchestrate a network of reactions that, in almost all cases, collectively 
result in protection against electrophiles and oxidants, and in enhanced cell 
survival. The role of this pathway in cancer prevention and chemoresistance to 
the toxic and neoplastic effects of many agents is well established. In addition, it 
is becoming increasingly clear that the Keap1-Nrf2 pathway plays a much 
broader role in determining the fate of the cell through its context-dependent 







The primary aim of the thesis is to establish a FRET (fluorescence 
resonance energy transfer) system in which to study the interaction between 
Keap1 and Nrf2. In order to achieve this, we will ectopically express Keap1 and 
Nrf2 proteins cloned in frame with either EGFP or mCherry. We will clone the 
fluorophores both N- and C-terminally to Keap1 and Nrf2 in order to find a 
combination of fusion proteins that generate a FRET signal.  
Once a pair of fusion proteins has been produced which generate a FRET 
signal, we will carry out a number of experiments to determine whether or not 
they behave like the endogenous system at the population level. This will include 
making sure that the Keap1 fusion protein is able to target the Nrf2 fusion 
protein for proteasomal degradation in the basal state; that the function of the 
Keap1 fusion protein is inhibited by inducers; and that the Nrf2 fusion protein 
can promote the transcription of ARE-dependent genes.  
When the FRET system has been established, we will use it to test the 
hypothesis that inducers activate Nrf2 by either promoting its dissociating from 
Keap1 or by an alternative mechanism which does not require release of Nrf2 
from Keap1. To do this we will study the FRET interaction between Keap1 and 
Nrf2 in the basal state, and in the presence of inducers that differ in potency and 
target different cysteine residues of Keap1. If inducers lead to the release of Nrf2 
from Keap1 we will see a reduction, or a complete loss, of the FRET signal in the 
induced state relative to the basal state. 
The second aim of the thesis is to establish an ectopic system in which to 
study the interaction between Keap1 and Cullin-3 using FRAP (fluorescence 
recovery after photobleaching). This will allow us to test the hypothesis that 
Keap1 is released from Cullin-3 in response to inducers that directly bind to Cys-
151 located in the BTB domain of Keap1, the site of interaction with Cullin-3. To 
test this hypothesis, we will carry out FRAP experiments in the basal state and in 
the presence of inducers which target different cysteine residues of Keap1. If 
Keap1 is released from Cullin-3 in response to certain inducers, we will observe 





































Materials and methods 
 
 
Chemicals and inducers 
 All chemicals used to make buffers and other solutions were from Sigma 
unless specified. Inducers and compounds added to cells for the microscopy 
experiments were sourced as follows: sulforaphane (LKT laboratories Inc., St. 
Paul, MN, USA), STCA (gift from Dr. Young-Hoon Ahn, Johns Hopkins University, 
USA), CDDO (gift from Dr Michael B. Sporn, Dartmouth College, USA), H2O2 
(Sigma), MG132 (InSolution, Merck). 
 
Cell lines 
 HEK293 cells were grown in α-MEM supplemented with 10% fetal bovine 
serum (both from Gibco) and seeded onto gelatin-coated plastic dishes (0.1% 
gelatin dissolved in water for 30 min). They were allowed to grow until they 
were confluent, and were split using a 1/5 dilution factor twice a week. For 
experiments using cell lysates, 200,000 cells were added per well of a 6-well 
plate. For microscopy experiments, 200,000 cells were seeded onto Willco glass 
bottom dishes. 
RL34 cells were grown in DMEM supplemented with 10% fetal bovine 
serum (both Gibco).They were allowed to grow until they were confluent, and 
were split using a 1/10 dilution factor twice a week. For experiments using cell 
lysates, 150,000 cells were added per well of a 6-well plate. 
 
Transfection 
 For each 6-well-plate well or Willco dish to be transfected, 100 μl of opti-
MEM was added to two Eppendorf tubes, one labeled “A”, one labeled “B”. To the 
tube labeled “A”, the DNA was added (see table below for quantities). To the tube 
labeled “B”, 3.75μl Lipofectamine 2000 (Invitrogen) was added. These were 
incubated for 12 min at room temperature, after which the contents of the two 
tubes were mixed and incubated for a further 15 min at room temperature. After 
this final incubation, 200 μl of the final solution was added to each well of cells. 
The cells to be transfected were first washed with 2 ml PBS, and then 1.5 ml 
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Opti-MEM (Invitrogen) was added to each well. The cells were incubated with 
the DNA + lipofectamine solution for 4.5 hours, after which the Opti-MEM was 
replaced with complete media. 
 







Cell handling during microscopy-based experiments  
 For FLIM, FRAP and time-lapse experiments, HEK293 cells were washed 
with PBS, and imaged in 2 ml phenol red free CO2-independent DMEM 
supplemented with 10% fetal bovine serum (both from Gibco). For experiments 
carried out in the presence of inducers, 1 ml of media was removed from the 
dish, and transferred to an Eppendorf tube. To this tube 2 μl of a 1000x stock of 
inducer was added. This media solution was thoroughly mixed before being 
added back to the cells. 
 
FLIM/ FRET imaging 
 FLIM/ FRET imaging was carried out using an inverted multiphoton 
laser-scanning microscope (Bio-Rad Radiance 2100MP) with a 60x oil 
immersion NA 1.4 Plan-Apochromat objective (Nikon). Lasersharp 2000 
software was used to run the microscope. The microscope was equipped with a 
Solent Scientific incubation chamber to maintain the cells at 370C. Two-photon 
excitation of EGFP was achieved using a Chameleon laser at 900 nm. The FLIM 
capability was provided by Time Correlated Single Photon Counting (TCSPC) 
electronics (SPC-830, Becker & Hickl). The laser power was adjusted to give a 
mean photon count rate of 105-106 photons/ s, with the gain set at 33.3%. FLIM 
measurements were carried out over a 256 x 256 pixel area for 90 s.  
 
FLIM Lifetime calculation 
 The .sdt file was imported into the SPCImage software (Becker & Hickl) 
and a region of interest was drawn around the area of the cell to be analysed 
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(corresponding to either the nucleus or the cytoplasm). The “bin” parameter was 
increased to 3, the “shift” was fixed at 0, and all other parameters were left at the 
default unchecked positions (Threshold = 5, Scatter = unfixed, Offset = unfixed). 
The image was then analysed using a single component exponential decay 
model. The region in which the lifetime data was to be presented was fixed 
between 1900 and 2600 ps for all cells. 
 
FLIM FRET efficiency calculation 
 The FRET efficiency was also calculated in the SPCImage software (Becker 
& Hickl), using the same region of interest defined to calculate the lifetime. The 
“bin” parameter was increased to 3, the “shift” was fixed at 0, and all other 
parameters were left at the default unchecked positions (Threshold = 5, Scatter = 
unfixed, Offset = unfixed). The image was then analysed using a two-component 
exponential decay model. To do this, the t2 value was fixed at 2375 ps, whilst the 
t1 value was left unchecked. The region in which the FRET efficiency was to be 
presented was fixed between 0 and 30% for all cells. 
 
FRAP 
 FRAP was carried out using a DeltaVision Spectris wide-field fluorescence 
microscope with a 60x oil immersion NA 1.4 Plan-Apochromat objective 
(Olympus), using the photokinetic experiment function of the SoftWoRx 
software. A small region in the cell was photobleached with a 488 nm laser 
(100% laser power for 0.1 s), and a time-lapse sequence of EGFP images were 
taken (exposure time 0.05 s, bin 2x2) to record the fluorescence recovery. The 
image data were analysed using SoftWoRx software to calculate the T½ recovery 
time for each cell. 
 
Time-lapse 
The time-lapse experiment was carried out using a DeltaVision Spectris 
wide-field fluorescence microscope with a 60x oil immersion NA 1.4 Plan-
Apochromat objective (Olympus), using SoftWoRx software. Images of EGFP and 
mCherry were taken every 10 min for 6 hours. 
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Generation of cell lysates 
 The dish of cells was placed on ice, where the media was removed, and 
each well was washed three times with 2 ml PBS. The PBS was aspirated, and 
200 μl of RIPA buffer was added to the cells. The cells were then scraped from 
the dish manually, transferred to an Eppendorf tube, and lysed on an orbital 
rotator at 40C for 30 min. The debris was then removed by centrifugation at 
13,000 rpm for 5 min at 40C, and the supernatant was collected and transferred 
to a new tube. From the supernantant, 10 μl was aliquoted for use in the BCA 
protein assay, and to the remainder, protein loading buffer (5x solution: 100mM 
Tris-Cl pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol, 3.6 Mβ-mercaptoethanol, 
0.05% bromo-phenol blue)was added. The tubes were then heated to 900C for 3 
min, after which the samples were ready to be loaded onto SDS-page gels.   
 
Protein concentration determination 
 A 10-μl sample of the protein lysates was diluted 1/5 with lysis buffer. BSA 
protein standards were generated through serial two-fold dilutions of a 2 mg/ml 
standard soluntion, and loaded onto a 96-well plate. 10 μl of each diluted sample 
was loaded in triplicate onto the 96-well plate. The BCA reagent was mixed and 
added to the standards and samples according to the manufacturers instructions. 
After 30 min incubation at room temperature with gentle shaking, the 
absorbance was measured on a spectrophotometer at 562 nm. A standard curve 
of protein concentration versus absorbance was generated using the data from 
the standards, and from this, the concentration of each sample was calculated. 
 
Co-immunoprecipitation lysis and pull-down  
 Cell lysates were generated according to the protocol above, with the 
following exception. The cells were lysed in 400 μl of modified RIPA buffer, 
which did not contain SDS or NP-40. To create the bait, 150 ng of GFP antibody 
was incubated with 40 μl Dynabeads Protein G (Invitrogen) in 300 μl of PBS-T. 
This solution was mixed for 90 min at room temperature on an orbital rotator, 
after which the antibody-conjugated beads were purified using a MagnaRack 
(Invitrogen). 350 μl of cell lysate was incubated with the antibody-conjugated 
dynabeads for 1 hour at room temperature on an orbital rotator. The cell lysate 
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was then removed, and the bound proteins were eluted from the dynabeads by 
incubating them in 50 μl of 2.5x protein loading buffer for 20 min at room 
temperature, followed by heating the samples to 700C for 10 min. 
 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 An equal amount of each protein sample (usually 5 μg) was loaded into 
each lane of an SDS-PAGE gel, which consisted of a stacking gel formed on top of 
a resolving gel. The gel was run at 100V for 2 hours in Tris-glycine 
electrophoresis buffer (25mM Tris base, 250mM glycine 0.1% SDS) to allow the 
proteins to separate according to size. The progress of the electrophoresis was 
monitored using a protein ladder. 
 
The gel composition is shown in the table below. 
8% Resolving Gel Volume (ml) 
Water 2.3 
30% acrylamide mix 1.3 
1.5 M Tris (pH 8.8) 1.3 
10% SDS 0.05 





5% Stacking Gel Volume (ml) 
Water 1.4 
30% acrylamide mix 0.33 
1.0 M Tris (pH 6.8) 0.25 
10% SDS 0.02 




Transfer to membrane 
 The protein samples were transferred from the SDS-PAGE gel to PVDF 
membrane (Immobilon-P, Millipore) using an electrophoresis chamber run at 
60V for 1 hour in Tris-glycine transfer buffer (25mM Tris base, 250mM glycine 





The membranes were washed with PBS-T (PBS + 0.1% Tween), blocked 
in 5% milk for 2 hours at room temperature, and incubated overnight with 5 ml 
of the antibody solution at 40C. The membranes were then incubated with the 
appropriate secondary antibody (conjugated to HRP) for 1 hour at room 
temperature. The signal was then visualized using an HRP-dependent 
chemiluminescence reaction, and was developed on photographic film   
 
The table below shows the antibodies used in this thesis: 
Antibody Source Concentration 
Anti-Nrf2 McMahon et al. 2003 1/1000 
Anti-Keap1 McMahon et al. 2006 1/2000 
Anti-GFP Abcam (6556) 1/1000 




Cells were lysed in 200 μl digitonin (0.8 g/l in 2 mM EDTA, pH 7.8) and 
incubated at room temperature for 1 hour with constant agitation.  The cell 
lysate was centrifuged at 3,000 rpm for 4 min, after which the supernatant was 
collected to be used in the assay. 25 and 50 μl of the supernatant was loaded 
onto a 96-well plate. The assay buffer was constructed according to the 
established protocol (Prochaska and Santamaria, 1988) and added to the cells. 
The enzyme activity of NQO1 was determined by using menadione as a substrate 
in the presence or absence of the potent inhibitor dicumarol. The absorbance at 




 The general cloning strategy used to generate the fusion proteins was the 
same for all of the constructs. Firstly, the cDNA encoding the gene of interest was 
amplified using PCR to introduce the restriction enzyme consensus sequences 
required for cloning. The product of this PCR reaction was then purified by 
running it on an agarose gel. The band corresponding to the PCR product was 
then cut from the gel, and the DNA was purified from this agarose slice. The 
 67 
extracted DNA was then digested with the correct pair of restriction enzymes, 
along with the destination vector. The digested vector and PCR product were 
then purified again from an agarose gel, before being ligated together and 
transformed into competent bacteria. Transformed bacterial colonies were then 
picked and grown over night. From these 5 ml mini-cultures, the plasmids were 
purified, and the success of the ligation was determined by restriction digests 
and sequencing.  
 
Sources of vector and gene of interest cDNA 
 The pEGFP-N1, pEGFP-C1, pmCherry-N1 and pmCherry-C1 (all from 
Clontech) were kind gifts from Dr. David Lleres (University of Dundee). The 
mouse Keap1, Nrf2, Cul3, Nrf2ΔDLG and Nrf2-doubleETGE cDNA vectors, and the 
EGFP-Keap1 vector were all kind gifts from Dr. Mike McMahon (University of 
Dundee). The Nrf2 mutantvectors contain the following mutations: Nrf2ΔDLG 
(D29A:L30G:G31E), Nrf2-doubleETGE (I28E:D29E:L30T:V32E) (McMahon et al. 
2006). The Keap1-mono plasmid was a kind gift from Prof. Masi Yamamoto 
(Tohoku University, Japan). This plasmid encodes full-length Keap1 with the 
following mutations (H96A:K97A:V98A:V99A:L100A) (Suzuki et al. 2011).  
 
Bacterial transformation 
An Eppendorf tube containing 50 μlDH5α compenent cells was thawed on 
ice. Once liquid, 10-100 ng of DNA were added to the compentent cells and 
incubated on ice for 30 min. The bacteria were then subjected to a heat shock of 
45 seconds at 420C, followed by 2 min on ice. Finally, 450 ul of SOC media was 
added to the cells, which were then incubated at 370C in a shaking incubator for 
1 hour. From this bacterial culture, 20-200 μl was taken and plated on antibiotic 
plates (200 μl if the transformed plasmid was the product of a ligation reaction, 
20-50 μl for other plasmids).   
 
Plasmid preparation 
 For small quantities of plasmid DNA, the Macherey-Nagel NucleoSpin 
Plasmid kit was used. A single transformed bacterial colony was selected and 
grown overnight at 370C in 5 ml LB media plus the appropriate antibiotic. This 
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culture was then centrifuged at 3,500 rpm for 10 min on a benchtop centrifuge. 
The pellet was then resuspended, and the DNA was extracted from the bacteria 
according to the manufacturers instructions. 
 For large quantities of plasmid DNA, the Invitrogen PureLink HiPure Maxi 
Plasmid DNA purification kit was used. A single transformed bacterial colony 
was selected and grown for 8 hrs at 370C in 5 ml LB media plus the appropriate 
antibiotic. After 8 hours, this 5 ml culture was added to 195ml of LB media plus 
antibiotic and grown overnight at 370C. The cells were then harvested by 
centrifugation at 4,000g for 10 min in an angle rotor. The pellet was then 
resuspended, and the DNA was extracted from the bacteria according to the 
manufacturers instructions. 
 
Polymerase chain reaction (PCR) 
 All PCR reactions were carried out using Pfx DNA polymerase 
(Invitrogen). The reaction mixtures were prepared on ice, and an example is 
shown in the table below. 
 
 Volume (μl) 
10 x PCR buffer 5 
10 mM dNTPs 1.5 
Forward Primer (10 μM) 1.5 
Reverse Primer (10 μM)  1.5 
DNA template (1ng/ μl) 1 




 A sample PCR amplification protocol for a 2-kb target sequence is shown 
below.  The length of time required for the extension phase was calculated based 
on the target length (where each 1 kb requires 1 minute extension). The primer 
annealing temperature was determined by the Tm of the primers specific to each 







 Temperature (0C) Time 
Stage 1 94 2 min 
Stage 2 (35 cycles)  -  Denaturation 94 15 sec 
                                      -  Primer annealing 60 30 sec 
                                      -  Extension 68 2 min 
Stage 3 68 5 min 
 
A list of primers used to clone the plasmids used in this thesis is shown in the 
table below.  
 
Primer Sequence 
















Keap1 into pmCherry-N1 
FORWARD 
ATTGGTACCATGCAGCCCGAACCCAAGCTTAG 




Cul3 into pmCherry-C1 
FORWARD 
GCCGCTCGAGCTATGTCGAATCTGAGCAAAGGC 




Purification of DNA from agarose gel 
 The DNA sample was run on low melting agarose gel for 1 hour at 60V to 
enable good band separation. The correct size bands were then cut with a clean 
scalpel blade, and collected in an Eppendorf tube. The DNA from the agarose 
slice was purified using the QIAquick Gel extraction kit. In the final step, the DNA 
was eluted into 50 μl Buffer EB. 
 
Restriction digestion 
 All restriction digests were prepared on ice. A sample reaction is given 
below. Once prepared, the reaction was incubated at 370C for 2 hours. The 
reaction products were directly run on an agarose gel, either to extract the DNA 
for use in a ligation, or to determine the size and identity of the plasmid or 
plasmid inserts.  
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 Volume (μl) 
Plasmid DNA  (1 μg/ μl) 2 
XhoI (10 units / μl) 0.5 
KpnI (10 units / μl) 0.5 
10 x Buffer 5 
Water 42 
Total 50 
 The table below shows the vector backbone and restriction enzymes used 
to construct the plasmids in this thesis. The mutant Nrf2 and Keap1 vectors were 
cloned in the same way as the wild type proteins, thus for simplicity only the 
wild type vectors are shown below. 
 
Plasmid Vector Restriction enzymes 
EGFP-Nrf2 pEGFP-C1 XhoI and KpnI 
Nrf2-mCherry pmCherry-N1 KpnI and AgeI 
Keap1-mCherry pmCherry-N1 KpnI and AgeI 
Keap1-EGFP pEGFP-N1 KpnI and AgeI 
mCherry-Cul3 pmCherry-C1 XhoI and KpnI 
  
Ligation 
Prior to the ligation, the concentrations of insert and vector DNA were 
quantified using a spectrophotometer. In the ligation reaction, the total amount 
of DNA used was 10-100 ng. Two parallel ligation reactions were run, one in 
which there were the same number of insert and vector molecules (1:1), and one 
in which there were 10 times more insert than vector molecules in the reaction 
(10:1). The ligation was carried out at 200C for 1 hour, after which 1 μl was used 











The table below shows a sample ligation reaction, where the vector was 1.8 










Insert 1 5.6  0 1 
Vector 1.8 1  1.8 1.8 
5 x Buffer 4 4  4 4 
Ligase 1/10 
Unit 
1 1  1 0 
Water 12.2 8.4  13.2 13.2 




 Averages, standard deviation and p-values were all calculated using Excel 
(Microsoft). In chapters 3, 4 and 6, the p-values of the EGFP lifetime data and the 
NQO1 assay were calculated using two-tailed Student’s T-tests. In chapter 5, 
where the lifetime of EGFP was calculated before and after the addition of 
inducers, all p-values were calculate using two-tailed paired T-tests. 
 
Evaluation of methodology 
Analysing the Keap1-Nrf2 pathway using FRET provides a number of 
advantages over other methods which have been previously reported in the 
literature, as well as a number of limitations which are inherent to the technique. 
The principle advantage of studying protein interactions using FRET is 
that it allows the experimenter to study protein complexes in individual live 
cells. The consequence of this is that protein interactions can be studied in the 
correct physiological environment. This contrasts with in vitro techniques such 
as co-immunoprecipitation which show that proteins can interact, but not 
necessarily that they do interact in living cells. In addition, as FRET can be 
quantified in individual cells, it can be used to uncover cellular heterogeneity 
which may be masked when studying interactions at the cell population level.  
These advantages of using FRET are coupled with a number of limitations. 
For example, in the majority of cases, FRET experiments involve the 
overexpression of the proteins which are being studied. This may result in a level 
of expression which is non-physiological and would not be seen in the 
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endogenous system. This is of particular concern when studying Keap1 and Nrf2, 
as both proteins are normally present at very low levels in the endogenous 
system. In order to measure the protein interaction using FRET, the fluorescent 
signal must be visible, and thus Keap1 and Nrf2 must be overexpressed beyond 
physiological levels. This has a number of knock-on effects. For example, whilst 
Keap1 and Nrf2 are both being overexpressed in our model, other factors 
required for the degradation of Nrf2, such as Cullin-3, are not. This may mean 
that some of the ectopic Keap1-Nrf2 complexes are unbound by Cullin-3 and 
thus may not be involved in the ubiquitination pathway. In addition, FRET 
requires an excess of the acceptor (in this case Keap1-mCherry) and thus in the 
majority of cells Keap1 is present at a much higher level than Nrf2. This, coupled 
with the transient transfection of the expression plasmids, means that the 
relative levels of the fusion proteins will be different in different cells, and most 
likely will differ from those found in the endogenous system. If the relative levels 
of Keap1 and Nrf2 are important for the regulation of the pathway in vivo, this 
property will not be observed using FRET, as the acceptor, Keap1-mCherry, must 
be in excess in order to optimise the quality of the data being collected. In 
addition, in order to study protein-protein interactions using FRET, large 
fluorescent tags must be added to the proteins that are being studied (26.9 kDa 
for EGFP, and 28.8 kDa for mCherry). These bulky tags may interfere with the 
function of the proteins in a number of ways. They may directly alter the function 
of the protein to which they are attached by inhibiting the correct folding of the 
protein, or alternatively, their size may restrict the access of other factors to 
binding domains on the protein of interest.  Both of these possibilities would lead 
to an alteration in the behaviour of the proteins which are being studied, and 
may lead to the incorrect conclusions.  Despite of these limitations, the facts that: 
the fusion proteins interact in the cell at basal state, Keap1 is able to efficiently 
target Nrf2 for degradation and to respond appropriately to inducers of several 
different types, strongly indicate that the ectopically-expressed proteins 





Selection of inducers 
It has previously been shown that Keap1 contains multiple cysteine 
residues which can be modified by inducers, and that inducers themselves can be 
divided into 10 different classes (Baird and Dinkova-Kostova, 2012). For this 
reason we will use a variety of different inducers which target different cysteine 
residues of Keap1 in order to gain a thorough understanding of the mechanism 
of Nrf2 activation. Thus, sulforaphane will be used as an inducer specific to the 
Cys-151 sensor of Keap1, and STCA will be used to specifically target the Cys-273 
and Cys-288 sensors (McMahon et al. 2010, Ahn et al. 2010). In addition, the 
concentration of inducer required to stabilise Nrf2 is highly variable, which 
could reflect the mechanism through which it functions, and for this reason we 
will also use inducers with a wide range of potencies. Thus CDDO (which may 
target Cys-226 of Keap1, Kaidery et al. 2012) has been selected as a highly potent 
inducer, used at 0.1 μM, which contrasts sharply with the weak inducer H2O2, 
which will be used at 400 μM (Dinkova-Kostova et al. 2005b, Fourguet et al. 



























Chapter 3: Establishment of a FLIM-based 




















 The current models describing the spatio-temporal regulation of Nrf2 by 
Keap1 suggest that the interaction is dynamic, and that inducers either lead to a 
change in the binding characteristics of the proteins, or to a change in 
localisation, or both. The data to support these models are either obtained from 
whole cell populations that had been analysed by western blotting, or through 
the use of recombinant proteins in vitro. Microscopy is ideally suited to 
overcome the limitations of these approaches and to examine dynamic cellular 
processes, as it can be used to study individual cells and thus can capture cellular 
heterogeneity which may be lost by analysing large populations of cells at the 
same time (Spiller et al. 2010). In addition, there are a number of microscopy-
based techniques which enable the user to study protein-protein interactions in 
live cells, and thus in the correct physiological environment.   
 The use of microscopy to study protein-protein interactions is due in 
large part to the discovery of green fluorescent protein (GFP) from the 
bioluminescent jellyfish Aequorea victoria by Shimomura and colleagues 
(Shimomura et al. 1962). GFP is a barrel-shaped protein formed from 11 β-
strands which is able to fluoresce, that is, when exposed to blue light the protein 
absorbs the blue photons and in turn emits green light. The chromophore 
responsible for the fluorescence is composed of 3 amino acid residues (Ser-Tyr-
Gly) that are found in an α-helix which is threaded through the centre of the 
protective barrel (Tsien 1998). The F64L mutation within the GFP sequence 
allows the protein to efficiently fold at 370C (producing the GFP variant 
enhanced GFP, or EGFP) and importantly, it means that GFP can be expressed in 
mammalian cells where, along with its differently coloured mutants, it has been 
used to study protein localisation in live cells and in real time  (Tsien 1998).  
 In addition to its use in visualising protein localisation, GFP has also been 
used to study protein-protein interactions in cells through the process of 
fluorescence resonance energy transfer (FRET). FRET is defined as the 
radiationless transfer of energy from an excited donor fluorophore to an 
acceptor (Miyawaki 2011). In practical terms, in order to use FRET to determine 
whether two proteins interact in cells they must first be cloned into expression 
vectors as fusion proteins in frame with fluorescent proteins whose excitation 
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and emission spectra overlap (like GFP and mCherry). When these expression 
vectors are co-expressed in cells it is possible to determine whether the proteins 
interact due to the presence or absence of FRET. If the proteins interact, then the 
two fluorphores may come sufficiently close together (1-10 nm) that the 
excitation of GFP leads to the emission of red light from mCherry. Alternatively, if 
the proteins do not interact, then excitation of GFP will lead to emission of only 
green light, and thus no FRET (Miyawaki 2011). There are three commonly used 
approaches to study protein-protein interations using FRET: sensitised emission, 
acceptor photobleaching, and fluorescence lifetime imaging (FLIM). 
 Sensitised emission involves the stimulation of the donor fluorphore (eg. 
GFP) and the measurement of fluorescence from the acceptor (eg. mCherry). The 
disadvantage of using this method is that it has a lower sensitivity compared 
with the other approaches. The reason for this is that the fluorophores have wide 
absorbtion and emission spectra, and thus when exciting GFP at its optimal 
frequency, mCherry will also be excited at a low level, and equally when 
measuring the emission from mCherry a small amount of the signal will be due to 
GFP emission at the longer wavelengths. This cross-contamination of 
fluorescence in both the excitation and emission channels leads to a “noisy” 
signal and low resolution data.  
 The second method by which FRET can be studied is acceptor 
photobleaching. As a FRET interaction consists in the transfer of energy from the 
green to red fluorophores, it results in a decrease in the intensity of the green 
signal within the cell. This decreased intensity can be measured by bleaching and 
therefore destroying the acceptor fluorophore with a laser. This leads to the loss 
of FRET (due to the destruction of the acceptor) and a concomitant increase in 
the intensity of the donor fluorescence. The disadvantages of this method are 
that it only collects data from a small region of the cell (the area which is 
bleached) and also that the photobleaching is destructive and therefore the cell 
can only be imaged once  
 The third method which can be used to measure FRET is FLIM. In this 
method, it is not the intensity of the GFP signal which is measured but the 
amount of time which the fluophore spends in the excited state (Miyawaki 2011, 
Lleres et al. 2007). When a fluophore is stimulated by a photon of light, it is  
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Figure 3.1. Exponential decay of EGFP lifetime. The image above is a screen shot 
taken from the SPCImage software, which was used to measure the lifetime of EGFP 
fluorescence in a HEK293 cell transfected with EGFP-Nrf2 and mCherry. The graph 
show the lifetime data for one pixel within the cell, with frequency plotted on the y-axis 
on a log scale, and the lifetime plotted on the y-axis. 
 
 
raised to an excited state in which it spends a short period of time before 
emitting a photon of different coloured light and returning to the ground state. 
For a population of fluophores (like a population of GFP molecules in a cell) the 
combined time spent in the excited state follows an exponential decay pattern 
(Figure 3.1). FRET is a biased process which preferentially takes place between 
fluorophores with a longer lifetime, and thus, when FRET occurs, the longer 
lifetime fluorophores are removed from the GFP population (as their energy is 
transferred to mCherry and thus emitted as red light), which means that overall 
the remaining GFP population has a reduced lifetime. The advantage of this 
method is that it is independent of intensity and thus of any differences in levels 
of fluorophore expression among cells, is both highly sensitive and quantitative, 
and gives FRET data across the entire cell. FLIM has been used to study a wide 
variety of cellular processes, including signal transduction through the PKCα and 
Ras pathways, and DNA damage (Ng et al. 1999, Rocks et al. 2005, Morris et al. 
2009). For these reasons, I have chosen to study the interaction between Keap1 
and Nrf2 primarily using FLIM.   
Other microscopy-based techniques which have been used to study 
protein-protein interactions include: fluorescence recovery after photobleaching 
(FRAP, see Chapter 6) and, bimolecular fluorescence complementation (BiFC). 
BiFC is a method in which a fluorescent protein is expressed in two 
complementary parts, one fused to each protein of interest. On their own, the 
halves of the fluorophore cannot fluoresce, however, if the proteins of interest 
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interact then the two complementary parts of the fluorophore may come 
sufficiently close together so that they bind to form a complete protein which can 
fluoresce (Kerppola 2006). The disadvantage of this system if that once formed 
from its complementary components, the fluorescent protein cannot dissociate 
and therefore this method cannot be used to study dynamic protein interactions, 




 The aim of this part of the project was to generate Keap1 and Nrf2 fusion 
proteins which together produce a FRET interaction that could be studied using 
























 In order to study the interaction between Keap1 and Nrf2 using FRET, we 
first needed to generate fusion proteins in which the EGFP and mCherry 
fluorophores were at the appropriate distance and orientation to allow FRET. As 
it is not possible to determine the relative positions of the EGFP and mCherry 
fluorophores within the Keap1-Nrf2 complex a priori, due to a lack of structural 
information, we generated a number of different fusion proteins in which both 
fluorophores were added N- or C-terminally to Keap1 and Nrf2, and a process of 
trial and error was used to test which combination would give rise to FRET.  
 Despite the fact that the fusion proteins accurately modelled the 
endogenous system, evidenced by the localisation of Nrf2 and Keap1 in the basal 
state and the stabilisation of Nrf2 in response to the inducer CDDO (Figure 3.2), 
the majority of these combinations produced no FRET interaction, and an 
example of this is shown in Figure 3.3. In this experiment, we transiently 
transfected expression plasmids for EGFP-Keap1 along with either free mCherry 
(Figure 3.3A-B) or Nrf2-mCherry (Figure 3.3C-D).  The cells in which free 
mCherry was co-transfected are the negative controls, as in these cells there will 
be no expected interaction between EGFP and mCherry and thus no FRET. When 
Nrf2-mCherry was co-transfected along with EGFP-Keap1 we would have the 
potential to see FRET, as Nrf2 will interact with Keap1, bringing the EGFP and 
mCherry into a single protein complex.  
 In the first column of Figure 3.3 the EGFP images of the cells are 
presented, showing the localisation and the fluorescence intensity of EGFP-
Keap1. From this image the lifetime of EGFP is derived, and this is shown in 
pictorial form in the second column. The colour of the cell in the lifetime image 
corresponds to the EGFP lifetime depicted in the legend directly below the 
image, with the shortest lifetime of 1.9 ns in red, progressing to the longest 
lifetime of 2.6 ns in blue. The third column of Figure 3.3 shows a graphical 
representation of the lifetime data. In the graphs, the lifetime value in 
picoseconds from each pixel of the image is plotted on the x-axis, and the 
frequency is plotted on the y-axis.  
 Figure 3.3 clearly shows that the lifetime of EGFP-Keap1 is unaffected by 









Figure 3.2. The ectopic expression of Nrf2 and Keap1 fusion proteins accurately 
models the endogenous system. A. Nrf2-mCherry and EGFP-Keap1 constructs were 
transfected into HEK293 cells, which were subsequently imaged in a time-lapse 
experiment where a single cell was imaged every 10 minutes for 5 hours. At 0 minutes, 
EGFP-Keap1 is localised in the cytoplasm and Nrf2 is undetectable. After the addition of 
0.1 μM of the inducer CDDO, Nrf2 becomes stabilised as shown by the increase in red 
fluorescence from 70 minutes. After 300 minutes of CDDO treatment Nrf2-mCherry 
fluorescence is found in both the cytoplasm and nucleus. B. Western blot showing the 
stabilisation of endogenous Nrf2 in HEK293 cells in response to 2 hours of treatment 
with 0.1 μM CDDO. Similarly, in HEK293 cells co-transfected with expression plasmids 
for mCherry-tagged Nrf2 (either N- or C-terminally) and EGFP-Keap1, treatment with 
0.1 μM CDDO also leads to the stabilisation of the ectopically expressed Nrf2 fusion 
proteins. 
 
combination of fusion proteins. In both the presence and absence of Nrf2-
mCherry, the lifetime image has a blue colour, corresponding to a lifetime of 
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2336 ps for the EGFP-Keap1 + free mCherry control, and 2346 ps in the presence 
of Nrf2-mCherry (Table 3.1). 
 Whilst these early experiments did not provide us with any FRET data, 
they were useful in providing us with guidance for future experiments. For 
example, as Keap1 targets Nrf2 for degradation it is always present at a much 
higher level when Keap1 and Nrf2 are co-expressed. In order to detect FRET, an 
excess of the acceptor (mCherry) has to be present, so that all of the EGFP donor 
proteins upon excitation have an opportunity to transfer energy to the acceptor. 
If the opposite is true, then the excess of EGFP will mean that only a fraction of 
the donor molecules can transfer their energy to mCherry, and thus any 
reduction in lifetime will become difficult to detect as many of the EGFP proteins 
within the cell will show no reduction in lifetime due to their inability to find free 
acceptor molecules. This means that the system could be optimised if Keap1 is 
fused to mCherry (and thus will be in excess), and EGFP is fused to Nrf2. 
 Deciding whether the fluorophores should be located at the N- or C-
terminus of Keap1 and Nrf2 required a trial and error approach because the 
structure of the complex of the Keap1 dimer bound to Nrf2 is currently 
unknown. The availability of this structure would guide the design of FRET pairs 
of proteins as it would allow us to determine the distance between the N- and C-
termini of each protein. This is important as FRET is a distance-dependent 
process, and only takes place when the fluorophores are between 10-100 Å from 
each other (Miyawaki 2011, Lleres et al. 2007).  The availability of an accurate 
structure of the Keap1-Nrf2 complex may have allowed us to exclude certain 
fusion protein combinations, for example, if the N-terminus of Keap1 was 300 Å 
away from the C-terminus of Nrf2, then this FRET pair could be ruled out due to 
the insurmountable distance between the fluorophores. 
 
      Lifetime (ps)    N    SD      T-test  
EGFP-Keap1 + mCherry            2336    3    17  
EGFP-Keap1 + Nrf2-mCherry            2349    5    10 p = 0.225 
 
Table 3.1. FLIM data for EGFP-Keap1 transfected cells. The table shows the lifetime, 
number of cells imaged and standard deviation of the lifetime for both EGFP-Keap1 + 
mCherry, and EGFP-Keap1 + Nrf2-mCherry co-transfected cells. The lifetime of EGFP-
Keap1 is unaffected by the presence of Nrf2-mCherry (p = 0.225) showing that this 
combination of fusion proteins does not generate a FRET interaction. 
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Figure 3.3. Fluorescence lifetime imaging of EGFP-Keap1. HEK293 cells were 
transfected with either EGFP-Keap1 + mCherry (A, B) or EGFP-Keap1 + Nrf2-mCherry 
(C, D). The left column shown the EGFP image from which the lifetime data are derived. 
The middle column shows a pictorial representation of the EGFP lifetime where the 
colour of the cell corresponds to the lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as 
indicated on the legend below the image. The right column shows the lifetime data from 
 83 
each pixel of the image plotted on a graph, with lifetime on the x-axis and frequency on 
the y-axis. Graphs A-D show the lifetime of EGFP-Keap1 is the same in the absence (A, B) 
and presence of Nrf2-mCherry (C, D) implying that there is no FRET interaction between 
the two fusion proteins. 
 
 
At the beginning of 2010, a paper was published by Ogura et al. 
presenting the first structure of a full length Keap1 dimer. This single particle 
electron microscopy generated structure suggested that the C-terminus of Keap1 
was significantly closer to the Nrf2 binding site than the N-terminus. Although 
there is currently no structure available for Nrf2, it binds to Keap1 through its 
Neh2 domain at the N-terminus, suggesting that EGFP fused here may be in close 
proximity to the C-terminus of Keap1. Together, these data suggested that the 
fusion of mCherry to the C-terminus of Keap1, and EGFP fused to the N-terminus 
of Nrf2 would give the best chance of producing a FRET-generating interaction. 
The one caveat to this approach is that previous work in our laboratory 
has suggested that the fusion of peptides to the C-terminus of Keap1 interferes 
with the function of the protein. In order to prevent producing a non-functional 
fusion protein, we cloned mCherry to the C-terminus of Keap1 together with a 
specifically designed linker domain. It has previously been shown by Arai et al. 
that use of the helix-forming peptide linker A(EAAAK)nA can separate two 
functional domains (Arai et al. 2001). Thus we added between the C-terminus of 
Keap1 and the mCherry peptide the sequence AEAAAKEAAAKA, which will form 
an alpha-helix with two twists, to separate the mCherry peptide from Keap1, and 
allow both proteins to maintain their function.   
In order to verify that Keap1-mCherry and EGFP-Nrf2 expression 
plasmids are in-frame and correctly translated in cells, we transfected the 
plasmids into HEK293 cells and generated cell lysates. These lysates were then 
analysed by western blot with antibodies targeting Keap1 and mCherry, and also 
against Nrf2 and EGFP. As shown in Figure 3.4, the pairs of antibodies correctly 
bind to the fusion proteins demonstrating that Keap1-mCherry and EGFP-Nrf2 
are both correctly expressed in cells.   
Next, we wanted to determine whether the addition of the fluorophores 
interfered with the function of Keap1 or Nrf2. Firstly, we wanted to check that  
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Figure 3.4. Identification of Keap1-mCherry and EGFP-Nrf2 fusion proteins. 
HEK293 cells were transfected with the indicated combination of plasmids, and cell 
lysates were generated 24 hours after transfection. An equal amount of protein was 
loaded on each lane, and the proteins were resolved on SDS-PAGE gels and probed with 
the antibodies specified above. The blots show that the Keap1-mCherry plasmid encodes 
a protein consisting of both Keap1 and mCherry, whilst the EGFP-Nrf2 plasmid encodes 




the proteins folded correctly and were able to interact. In order to do this we 
carried out a co-immunoprecipitation (co-IP) experiment in which cells were 
transfected with either EGFP-Nrf2 of Keap1-mCherry or both, and were then 
lysed and immunoprecipitated with an anti-GFP antibody. The input and IP 
samples were then probed with antibodies against mCherry and GFP, and the 
results show that Keap1-mCherry and EGFP-Nrf2 are able to interact with one 
another in the same way as the native proteins (Figure 3.5).    
 Once it had been established that the fluorophores did not inhibit the 
interaction between Keap1 and Nrf2, it was then necessary to ascertain whether 
their presence preserved the function of the proteins, namely the ability of Nrf2 
to promote transcription of target genes and the ability of Keap1 to target Nrf2 
for degradation, and to respond to inducers. In order to assay the transcriptional 
activity of EGFP-Nrf2, we transiently transfected it into RL34 cells and measured 
the ability of the ectopic fusion protein to promote the transcription of one of the 
best-characterised Nrf2 target genes, NQO1 (Figure 3.6). The level of NQO1  
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Figure 3.5. Co-immunoprecipitation of EGFP-Nrf2 with Keap1-mCherry. HEK293 
cells were transfected with the indicated plasmids, and cell lysates were generated 24 
hours after transfection. The lysate was split into two parts, one for the IP and one for 
the input. The IP sample was generated by treating the lysates with anti-GFP conjugated 
dynabeads to pull-down any proteins which interact with EGFP-Nrf2. The pulled-down 
lysates and untreated input samples were loaded onto SDS-PAGE gels which were 




activity was 2.46 times higher when EGFP-Nrf2 was co-transfected along with 
mCherry, compared with the mCherry control (p = 2.67E-11), demonstrating 
that the fusion protein is transcriptionally active. The co-expression of Keap1-
mCherry reduced the level of NQO1 activity down to the control level, showing 




Figure 3.6. The transcriptional activity of EGFP-Nrf2. RL34 cells were transfected 
with the specified plasmids, and 48 hrs later cell lysates were generated. From these 
lysates the activity of the Nrf2 target gene quinone reductase 1 (NQO1) was determined. 
The samples (n=6 per plasmid combination) were normalised for total protein content, 
and show that expression of EGFP-Nrf2 increases NQO1 activity 2.5-fold, and that co-
expression of Keap1-mCherry represses this increase (* p = 2.67x10-11 when comparing 
mCherry to EGFP-Nrf2 + mCherry;  p = 7.82x10-11  when comparing EGFP-Nrf2 + mCherry to 
EGFP-Nrf2 + Keap1-mCherry). 
 
 
The primary function of Keap1 is to target Nrf2 for ubiquitination in the 
basal state, and this activity is inhibited by inducers. In order to determine 
whether Keap1-mCherry is able to target Nrf2 for degradation, we co-expressed 
both expression plasmids in cells, and measured the level of Nrf2-EGFP by 
western blot in both the basal and induced state (Figure 3.7). In the basal state, 
the co-expression of Keap1-mCherry maintained EGFP-Nrf2 at a very low level 
(lane 4). However, after 4 hours of treatment with the inducer STCA or the 
proteasome inhibitor MG132, Nrf2 was stabilised (lanes 5 and 6), showing that 
in the basal state EGFP-Nrf2 is targeted for proteasomal degradation by Keap1-
mCherry, and that both an inducer which directly targets Keap1, and an inhibitor 
which blocks the proteasomal degradation of Nrf2 lead to the stabilisation of 
EGFP-Nrf2. 
 Next, it was important to determine whether the localisation of the fusion 
proteins was correct. In order to do this we ectopically expressed EGFP-Nrf2 and 
Keap1-mCherry and imaged the cells using confocal microscopy (Figure 3.8). In  
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Figure 3.7. Stabilisation of EGFP-Nrf2 by inducers and inhibition of the 
proteasome. HEK293 cells were transfected with the indicated combination of 
plasmids, and then treated with either 10 μM of the inducer STCA or 10 μM of the 
proteasomal inhibitor MG132. After 4 hours of treatment with either STCA or MG132, 
cell lysates were generated. The samples were run on SDS-PAGE gels and probed with 
the antibodies specified above. In the absence of Keap1-mCherry, EGFP-Nrf2 is not 
degraded and is present in the cells (lane 2). When Keap1-mCherry is co-expressed 
along with EGFP-Nrf2, the level of EGFP-Nrf2 within the cell is low (lane 4), but can be 
increased through either the addition of the inducer STCA (lane 5) or inhibition of the 
proteasome (lane 6). Together these data show that the Keap1 and Nrf2 fusion proteins 
function in the same way as the endogenous system. The images shown are 
representative of three independent experiments. 
 
 
the absence of Keap1-mCherry, EGFP-Nrf2 is predominantly localised in the 
nucleus as would be expected (Figure 3.8A, B). However, upon the addition of 
Keap1-mCherry, the localisation of EGFP-Nrf2 changes to mirror that of Keap1-
mCherry, namely it is mainly cytoplasmic (Figure 3.8C, D). Together these data 
suggest that the normal localisation of Nrf2 and Keap1 is unaffected by the 
presence of the fluorescent proteins. 
 Finally we wanted to show that when EGFP-Nrf2 is stabilised it 
translocates to the nucleus in a similar fashion to endogenous Nrf2. Confocal  
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Figure 3.8. Cellular localisation of Nrf2 and Keap1 fusion proteins. HEK293 cells 
were transfected with the specified expression plasmids and the localisation of the 
resulting fluorescence was monitored using confocal microscopy. The EGFP channel is 
shown in the left column, and the mCherry channel in the right column A, B. In the 
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absence of Keap1, EGFP-Nrf2 is localised mainly in the nucleus, with mCherry dispersed 
throughout the cell. C, D. When Keap1-mCherry is co-expressed, it alters the localisation 
of the mCherry fluorescence to the cytoplasm, and also sequesters EGFP-Nrf2, changing 
its localisation from nuclear to mainly cytoplasmic. 
 
 
microscopy was used to image a cell cluster which had been transfected with 
EGFP-Nrf2 and Keap1-mCherry. In the basal state, Nrf2 is mostly cytoplasmic, 
however when the same cells were imaged after 2 hours of treatment with 
MG132, Nrf2 is clearly localised throughout the entire cell, including the nucleus, 
whilst the localisation of Keap1 is unaffected (Figure 3.9).   
Taken together, these data show that even with the addition of the EGFP 
and mCherry tags, Nrf2 and Keap1 behave like the endogenous proteins when 
analysed at the whole cell population level. Keap1 is able to bind to Nrf2, target it 
for proteasomal degradation, and respond to inducers. Nrf2 is able to migrate to 
the nucleus and activate target gene transcription, suggesting that Keap1-
mCherry and EGFP-Nrf2 replicate a number of the important features of the 
endogenous signalling pathway and provide a useful model system in which to 
study the interactions between these proteins. 
 We were then able to transfect the Keap1-mCherry and EGFP-Nrf2 
expression vectors into HEK293 cells and look for a FRET interaction. Table 3.2 
and Figure 3.10 A-B show that in control cells, in which Keap1-mCherry is not 
present, the lifetime of EGFP fluorescence is 2375 ps. When Keap1-mCherry is 
co-expressed, the lifetime graphs are clearly shifted to the left, corresponding to 
a reduction in the EGFP lifetime to 2155 ps (Figure 3.10C-D). This reduction in 
lifetime is statistically significant (p = 2.09E-22), and an indication of a FRET 
interaction. This means that when EGFP is fused to the N-terminus of Nrf2 and 
mCherry is fused onto the C-terminus of Keap1, the fluorophores are sufficiently 
close and in the correct orientation for FRET to occur. Thus we have established 
a single cell system in which to study how the interaction between Keap1 and 
Nrf2 changes, if at all, in response to inducers.  
 It has previously been shown that ten distinct classes of chemicals can act 
as inducers of the Keap1-Nrf2 pathway, and that these inducers target 3 different 
sensors in Keap1 (McMahon et al. 2010). For this reason we wanted to test a  
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Figure 3.9.Cellular localisation of Nrf2 and Keap1 fusion proteins in response to 
MG132. HEK293 cells were transfected with the specified expression plasmids and the 
localisation of the resulting fluorescence was monitored in the same cluster of cells both 
in the basal and induced state using confocal microscopy. In the basal state, EGFP-Nrf2 
(top left) and Keap1-mCherry (bottom left) are both localised predominantly in the 
cytoplasm. After 2 hrs treatment with 10μM of the proteasomal inhibitor MG132 the 
cellular distribution of EGFP-Nrf2 changes, as it becomes localised throughout both the 
cytoplasm and nucleus (top right), whilst the Keap1-mCherry localisation is unaffected 
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Figure 3.10. Fluorescence lifetime imaging of EGFP-Nrf2. HEK293 cells were 
transfected with either EGFP-Nrf2 + mCherry (A, B) or EGFP-Nrf2 + Keap1-mCherry (C, 
D). The left column shows the EGFP image from which the lifetime data are derived. The 
middle column shows a pictorial representation of the EGFP lifetime where the colour of 
the cell corresponds to the lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated on 
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the legend below the image. The right column shows the lifetime data from each pixel of 
the image plotted on a graph, with lifetime on the x-axis and frequency on the y-axis. 
Graphs A-D clearly show that the lifetime of EGFP-Nrf2 in the presence of mCherry alone 
(A, B) is significantly longer than in the presence of Keap1-mCherry (C, D) indicating 
that there is a FRET interaction between the two fusion proteins. This lifetime change is 
shown in the images in the second column, in which A and B are blue and C and D are 




range of inducers in our FRET system to determine whether the inducer type 
affects the mechanism by which they activate the pathway (Figure 3.11). 
 The first inducer tested was the isothiocyanate sulforaphane (SFN), which 
reacts with Cys-151 of Keap1 (McMahon et al. 2010). The cells were treated with 
5 μM SFN for 1 hour before being imaged. This gave time for the SFN to enter the 






























Figure 3.11. Structures and potencies of the Nrf2 inducers used throughout this 
study.   The CD values (Concentration that Doubles the specific acidity of NQO1 in 
Hepa1c1c7 cells) are shown in parentheses illustrating the broad range of inducer 
potencies. 










































Figure 3.12. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of the 
inducer sulforaphane. HEK293 cells were transfected with either EGFP-Nrf2 + 
mCherry (A, B) or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 5μM of the 
inducer sulforaphane for 1 hour before being imaged. The left column shows the EGFP 
image from which the lifetime data are derived. The middle column shows a pictorial 
representation of the EGFP lifetime where the colour of the cell corresponds to the 
lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated on the legend below the 
image. The right column shows the lifetime data from each pixel of the image plotted on 
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a graph, with lifetime on the x-axis and frequency on the y-axis. Graphs A-D clearly show 
that the lifetime of EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly 
longer than in the presence of Keap1-mCherry (C, D) indicating that there is a FRET 
interaction between the two fusion proteins 1 hour after sulforaphane treatment. This 
lifetime change is shown in the images in the second column, in which A and B are blue 
and C and D are yellow, corresponding to a reduced lifetime of EGFP-Nrf2 in the 
presence of Keap1-mCherry. 
 
lifetime of EGFP-Nrf2 (Figure 3.12A-B). This means that any changes in lifetime 
found in the EGFP-Nrf2 and Keap1-mCherry co-transfected cells will be due to a 
change in FRET, and not due to a non-specific change in lifetime caused by the 
inducer itself. In the absence of SFN, the lifetime of EGFP-Nrf2 was 2375 ps, and 
upon the addition of SFN, it was 2385 ps (Tables 3.1, 3.2). When SFN was added 
to EGFP-Nrf2 and Keap1-mCherry co-transfected cells, the lifetime of EGFP 
fluorescence was again significantly reduced compared to the control (Figure 
3.12C-D, Table 3.3), showing that in response to SFN, Nrf2 is not released from 
Keap1. 
 
      Lifetime (ps)    N   SD      T-test  
EGFP-Nrf2 + mCherry            2375   13   12  
EGFP-Nrf2 + Keap1-mCherry            2155   14   20 p = 2.09E-22 
 
Table 3.2. FLIM data for EGFP-Nrf2 transfected cells. The table shows the lifetime, 
number of cells imaged and standard deviation of the lifetime for both EGFP-Nrf2 + 
mCherry, and EGFP-Nrf2 + Keap1-mCherry co-transfected cells. The lifetime of EGFP-
Nrf2 is significantly reduced by the presence of Keap1-mCherry (p = 2.09E-22) showing 
that this combination of fusion proteins generates a FRET interaction. 
 
 
 We then studied the effect of the SFN analogue STCA, which activates 
Keap1 through a different sensor to SFN, as STCA binds directly to Cys-273 and -
288 of Keap1 (Ahn et al. 2010). As with SFN, the addition of 10 μM STCA for 1 
hour had no effect on the control lifetime of EGFP (Figure 3.13A-B). Similarly, in 
EGFP-Nrf2 and Keap1-mCherry co-transfected cells, the lifetime of EGFP 
fluorescence was still significantly reduced in the presence of STCA (Figure 
3.13C-D). This is interesting as it suggests that inducers which target different 
sensors of Keap1 function through a similar mechanism, and that this 
mechanism does not involve the release of Nrf2 by Keap1.   
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Figure 3.13. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of  the 
inducer STCA. HEK293 cells were transfected with either EGFP-Nrf2 + mCherry (A, B) 
or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 10μM of the inducer STCA for 1 
hour before being imaged. The left column shows the EGFP image from which the 
lifetime data are derived. The middle column shows a pictorial representation of the 
EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, ranging 
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from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right column 
shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on 
the x-axis and frequency on the y-axis. Graphs A-D clearly show that the lifetime of 
EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly longer than in the 
presence of Keap1-mCherry (C, D) indicating that there is a FRET interaction between 
the two fusion proteins 1 hour after STCA treatment. This lifetime change is shown in 
the images in the second column, in which A and B are blue and C and D are yellow, 
corresponding to a reduced lifetime of EGFP-Nrf2 in the presence of Keap1-mCherry. 
 
 
In addition to assaying the effects of inducers which target different 
cysteine residues of Keap1, we also wanted to see whether the size of the inducer 
altered the mechanism by which Keap1 regulates Nrf2. In order to do this, we 
chose the bulky inducer CDDO, a triterpinoid with a 5-ringed structure and 
contrasted this with the small molecule hydrogen peroxide. Like SFN and STCA, 
neither 0.1 μM CDDO nor 400 μM H2O2 had any effect on the lifetime of EGFP-
Nrf2 in control cells (Table 3.3, Figure 3.14A-B, Figure 3.15A-B). Interestingly, 
the mechanism by which inducers stabilise Nrf2 is also independent of the size of 
the inducer, as for both the bulky CDDO and the small H2O2, the lifetime of EGFP 
fluorescence in Nrf2 and Keap1 co-transfected cells was still reduced relative to 
the control, showing that the two proteins maintain their interaction in response 
to these inducers (Table 3.3, Figure 3.14C-D, Figure 3.15C-D). 
 
 Inducer Lifetime (ps)  N SD T-test 
EGFP-Nrf2 + mCherry        2385  7 30 
EGFP-Nrf2 + Keap1-mCherry 
5 μM 




EGFP-Nrf2 + mCherry        2370  7 18 
EGFP-Nrf2 + Keap1-mCherry 
10 μM 




EGFP-Nrf2 + mCherry        2371  7 20 
EGFP-Nrf2 + Keap1-mCherry 
0.1 μM 




EGFP-Nrf2 + mCherry        2382 12 25 
EGFP-Nrf2 + Keap1-mCherry 
400 μM 




Table 3.3. FLIM data for EGFP-Nrf2 transfected cells treated with inducers. The 
table shows the lifetime, number of cells imaged and standard deviation of the lifetime 
for both EGFP-Nrf2 + mCherry, and EGFP-Nrf2 + Keap1-mCherry co-transfected cells 
treated with 4 different inducers. The lifetime of EGFP-Nrf2 is significantly reduced by 
the presence of Keap1-mCherry in all cases, showing that this combination of fusion 
proteins generates a FRET interaction in the presence of each of the 4 inducers. 
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Figure 3.14. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of the 
inducer CDDO. HEK293 cells were transfected with either EGFP-Nrf2 + mCherry (A, B) 
or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 0.1μM of the inducer CDDO for 1 
hour before being imaged. The left column shows the EGFP image from which the 
lifetime data are derived. The middle column shows a pictorial representation of the 
EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, ranging 
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from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right column 
shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on 
the x-axis and frequency on the y-axis. Graphs A-D clearly show that the lifetime of 
EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly longer than in the 
presence of Keap1-mCherry (C, D) indicating that there is a FRET interaction between 
the two fusion proteins 1 hour after CDDO treatment. This lifetime change is shown in 
the images in the second column, in which A and B are blue and C and D are yellow, 
corresponding to a reduced lifetime of EGFP-Nrf2 in the presence of Keap1-mCherry. 
 
 
 One caveat to the data presented so far is that the concentration of 
inducers used has been derived from data using the endogenous Keap1-Nrf2 
system. Because out FRET system is an over-expression system, it is possible 
that higher concentrations of inducer may be required to simulate the 
endogenous system. Therefore, we used two of the inducers tested previously, 
SFN and STCA, at a 10 times higher concentration (Figures 3.16, 3.17, Table 
3.4). Interestingly, the addition of inducers at these high concentrations had a 
small effect on the control lifetime, reducing it from 2375 ps to 2355 ps for SFN 
and 2343 ps for STCA treated cells. This reduced lifetime is not unexpected as it 
has previously been shown that changes in the intracellular environment (such 
as a change in level of cations) can lead to changes in fluorescence lifetimes (Jung 
et al. 2005). That notwithstanding, in EGFP-Nrf2 and Keap1-mCherry co-
transfected cells we still see a significant decrease in the EGFP lifetime, showing 
that even when the cells are treated with extremely high concentrations of 
inducers, Nrf2 and Keap1 do not dissociate (Table 3.4).     
 
 Inducer Lifetime (ps)  N SD T-test 
EGFP-Nrf2 + mCherry        2355  3  7 
EGFP-Nrf2 + Keap1-mCherry 
50μM 




EGFP-Nrf2 + mCherry        2343   3 23 
EGFP-Nrf2 + Keap1-mCherry 
100 μM 




Table 3.4. FLIM data for EGFP-Nrf2 transfected cells in the presence of inducers. 
The table shows the lifetime, number of cells imaged and standard deviation of the 
lifetime for both EGFP-Nrf2 + mCherry, and EGFP-Nrf2 + Keap1-mCherry co-transfected 
cells treated with high concentrations of the inducers sulforaphane (SFN) and STCA. The 
lifetime of EGFP-Nrf2 is significantly reduced by the presence of Keap1-mCherry in both 
cases, showing that this combination of fusion protein generates a FRET interaction in 
the presence of a high concentration of either SFN or STCA. 
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Figure 3.15. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of the 
inducer H2O2. HEK293 cells were transfected with either EGFP-Nrf2 + mCherry (A, B) 
or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 400μM of the inducer H2O2 and 
imaged immediately for 1 hour. The left column shows the EGFP image from which the 
lifetime data are derived. The middle column shows a pictorial representation of the 
EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, ranging 
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from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right column 
shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on 
the x-axis and frequency on the y-axis. Graphs A-D clearly show that the lifetime of 
EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly longer than in the 
presence of Keap1-mCherry (C, D) indicating that there is a FRET interaction between 
the two fusion proteins after H2O2 treatment. This lifetime change is shown in the 
images in the second column, in which A and B are blue and C and D are yellow, 































 We have developed a system for studying the Keap1-Nrf2 pathway in live 
cells which accurately models the activity of the endogenous proteins. In the 
basal state, EGFP-Nrf2 is expressed at a low level, and is localised in the 
cytoplasm due to its interaction with Keap1-mCherry (Figures 3.7, 3.8). In 
response to inducers, EGFP-Nrf2 becomes stabilised allowing it to accumulate 
and translocate to the nucleus (Figures 3.7, 3.8). 
 Interestingly, we found that in response to inducers, the Keap1-Nrf2 
interaction is maintained, as shown by the reduced lifetime in response to SFN, 
STCA, H2O2 and CDDO (Table 3.3). These data complements previously 
published reports where numerous biochemical techniques have been used to 
study the effect of inducers on the Keap1-Nrf2 complex. Isothermal titration 
calorimetry, native electrophoretic mobility shift assay (EMSA) and co-
immunoprecipitation experiments have all shown that Keap1 and Nrf2 do not 
dissociate in response to inducers (Zhang et al. 2004, Eggler et al. 2005). 
However, all of these studies rely on the use of either recombinant proteins or 
the use of cell lysates derived from populations of cells as their experimental 
samples. To our knowledge our FRET/ FLIM data are the first to show the 
interaction between full length Keap1 and Nrf2 in single live cells and thus in the 
physiological cellular environment. Importantly, our data confirm that inducers 
do not lead to the release of Nrf2 from Keap1.    
We chose to study the effects of inducers after 1 hour of treatment as it 
has previously been shown that Nrf2 is stabilised by multiple inducers within an 
hour (McMahon et al. 2003, Nguyen et al. 2003). In addition, it is known that 
after 1 hour of treatment, sulforaphane accumulates massively within the cell 
(with its peak intracellular concentration reaching ~200 μM), suggesting that 
this is a good time point at which to study its effects on Keap1 (Zhang and 
Talalay 1998). Interestingly, current data suggest that H2O2 is detoxified by the 
cell within 1 hour, and also that the intramolecular disulphide bonds formed 
within Keap1 by H2O2 may be resolved within 1 hour of treatment (Desaint et al. 
2004, Fourquet et al. 2010). For these reasons, we imaged H2O2-treated cells 
only during the first hour following treatment, and not after 1 hour as we did for  
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Figure 3.16. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of the 
inducer sulforaphane. HEK293 cells were transfected with either EGFP-Nrf2 + 
mCherry (A, B) or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 50μM of the 
inducer sulforaphane for 1 hour before being imaged. The left column shows the EGFP 
image from which the lifetime data are derived. The middle column shows a pictorial 
representation of the EGFP lifetime where the colour of the cell corresponds to the 
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lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated on the legend below the 
image. The right column shows the lifetime data from each pixel of the image plotted on 
a graph, with lifetime on the x-axis and frequency on the y-axis. Graphs A-D clearly show 
that the lifetime of EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly 
longer than in the presence of Keap1-mCherry (C, D) indicating that there is a FRET 
interaction between the two fusion proteins 1 hour after sulforaphane treatment. This 
lifetime change is shown in the images in the second column, in which A and B are blue 
and C and D are yellow, corresponding to a reduced lifetime of EGFP-Nrf2 in the 
presence of Keap1-mCherry. 
 
 
sulforaphane, STCA and CDDO, in order to accurately study the effect of H2O2 on 
the Keap1-Nrf2 interaction.   
 It has previously been shown that Keap1 contains multiple cysteine 
residues which can be modified by inducers, and that inducers themselves can be 
divided into 10 different classes. For this reason we wanted to use a variety of 
different inducers which target different cysteine residues of Keap1 in order to 
gain a thorough understanding of the mechanism of Nrf2 activation. Thus, 
sulforaphane was used as an induced specific to the Cys-151 sensor of Keap1, 
whilst STCA was chosen as an inducer which specifically targets the Cys-273 and 
Cys-288 sensor (Kobayashi et al. 2009, McMahon et al. 2010, Ahn et al. 2010). In 
addition, the concentration of inducer required to stabilise Nrf2 is highly 
variable, which could reflect the mechanism through which it functions, and for 
this reason we wanted to use inducers with a wide range of potencies. Thus 
CDDO (which may target Cys-226, Kaidery et al. 2012) was chosen as a highly 
potent inducer, used at 0.1 μM, which contrasts sharply with the weak inducer 
H2O2, which was used at 400 μM (Dinkova-Kostova et al. 2005b, Fourguet et al. 
2010).  Interestingly, our data suggest that inducers which target different 
cysteines of Keap1 and with differing potencies share one important property: 
they stabilise Nrf2 by inhibiting its Keap1-dependent ubiquitination, and not 
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Figure 3.17. Fluorescence lifetime imaging of EGFP-Nrf2 in the presence of the 
inducer STCA. HEK293 cells were transfected with either EGFP-Nrf2 + mCherry (A, B) 
or EGFP-Nrf2 + Keap1-mCherry (C, D) and treated with 100μM of the inducer STCA for 1 
hour before being imaged. The left column shows the EGFP image from which the 
lifetime data are derived. The middle column shows a pictorial representation of the 
EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, ranging 
 105 
from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right column 
shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on 
the x-axis and frequency on the y-axis. Graphs A-D clearly show that the lifetime of 
EGFP-Nrf2 in the presence of mCherry alone (A, B) is significantly longer than in the 
presence of Keap1-mCherry (C, D) indicating that there is a FRET interaction between 
the two fusion proteins 1 hour after STCA treatment. This lifetime change is shown in 
the images in the second column, in which A and B are blue and C and D are yellow, 





















































Chapter 4: High-resolution analysis of the 




























In addition to being the most accurate method with which to measure 
FRET interactions, a second advantage of using FLIM is its high resolution, which 
enables the user to visualise protein complex dynamism in live cells. This is 
possible as the EGFP lifetime can be used to calculate the FRET efficiency 
throughout the cell, from which the distance between the fluorophores can be 
calculated.   
 Equation 4.1 shows how the FRET efficiency (E) is derived from the 
fluorescence lifetime data. The constantτd is the EGFP lifetime taken from cells 
transfected with EGFP-Nrf2 + mCherry (Table 3.2) and is used for all cells. The 
variableτda is calculated on a pixel-by-pixel basis in cells transfected with EGFP-
Nrf2 + Keap1-mCherry. Within the SPCImage software, the FRET efficiency is 
calculated by analysing the lifetime data using a two-component exponential 
decay model, where the first compenent is free (τda) and the second is fixed (τd) 
at 2375 ps (Figure 4.1and Equation 4.1).  
 
 
                                                            E = 1 – (τda/τd),                                          Equation 4.1 
 
Where,  E = FRET efficiency 
  τda = Lifetime of donor in the presence of acceptor 
  τd = Lifetime of donor alone 
 
 
 This FRET efficiency data can then be used to calculate the distance 
between the fluorophores, and thus provides data of the physical arrangement of 
the protein complex in live cells (Equation 4.2). Therefore, a FRET efficiency of 
30% does not specify that 30% of the fluorophores are involved in a FRET 
interaction, but instead refers to the distance between the fluorophores. Thus, 
the comparison between a FRET efficiency of 30% with that of 20% would 








r = R0 x [(1/E) – 1]⅙Equation 4.2 
 
Where,          r = Distance between the fluorophores 
  R0 = Forster distance at which 50% energy transfer takes place 
  E = FRET efficiency 
 
[For the EGFP/ mCherry FRET pair the value of R0 has been calculated as 4.7nm 
(Lleres et al. 2007)] 
 
 
 Interestingly, it has previously been shown by Lleres et al. 2009 that in 
the case of fluorescently labelled histones the FRET efficiency distribution can be 
sub-divided into distinct regions. This means that the distance between the 
fluorophores is not constant for all FRET interactions, and suggests that the 
proteins may be found in multiple protein complexes which are each associated 
with a distinct FRET efficiency. 
 
 
Figure 4.1. FRET efficiency as calculated by SPCImage software. The image above is 
a screen shot taken from the SPCImage software, which was used to calculate the FRET 
efficiency from the EGFP lifetime data. In contrast to the lifetime data, the FRET 
efficiency is calculated using a 2 component multiexponential decay model (box at top 
right), with the t2 value fixed at 2375 ps (checked box on the right) as calculated from 






The aim of this part of the project was to calculate the FRET efficiency of 
the EGFP-Nrf2/ Keap1-mCherry interaction, and to use these data to probe the 








In addition to observing a significant lifetime difference for EGFP-Nrf2 in 
the presence and absence of Keap1-mCherry, and thus a FRET interaction 
between Nrf2 and Keap1, we also wanted to calculate the FRET efficiency to see 
if the lifetime data contained within it evidence of a dynamic interaction. It has 
previously been shown by Lleres et al. 2009 that fluorescence lifetime changes 
can be coupled with changes in the conformation of the protein complexes, and 
that these complexes can be seen by studying the FRET efficiency (E). Using 
Equation I, we were able to calculate E for EGFP-Nrf2 in the presence and 
absence of Keap1-mCherry (Figure 4.2). For all of the cells analysed, τda was the 
EGFP lifetime specific to each pixel in an individual cell, and τd was the average 
lifetime of EGFP-Nrf2 in the absence of Keap1-mCherry, which was 2375 ps 
(Table 3.2). 
 Figure 4.2 shows representative FRET efficiency data. The first column 
shows the EGFP image from which the FRET efficiency is derived. The second 
column shows the false-colour image of the cell, in which the colour corresponds 
to the amount of E as defined by the legend below the image (blue = 0%, red = 
30% FRET efficiency). The third column shows a graph of the data presented in 
the FRET efficiency image, in which the value of E from each pixel has been 
plotted on the x-axis. Figure4.2A, B show that in the absence of Keap1-mCherry, 
the value of E is 0 across almost the entire cell. This corresponds to a blue image 
in the second column.  
 As expected (from the lifetime data), in the cytoplasm of EGFP-Nrf2 + 
Keap1-mCherry co-transfected cells, E > 0.Surprisingly, the data for E revealed 
the presence of two distinct populations of interacting fluorophores. The graphs 
in Figure 4.2C, D clearly show 2 distinct peaks of FRET efficiency, one centred at 
13%and the other at 21%. This pattern was highly reproducible and although 
the relative areas of the peaks varied among cells, both populations of E were 
always present. The image data in the second column of Figure 4.2C, D show 
that the distribution of these different populations of E was uniform throughout 
the cell.The fact that these data showed two different FRET interactions indicates 
that the Keap1-Nrf2 complex exists in two distinct conformations in cells.  










































Figure 4.2. FRET efficiency derived from EGFP-Nrf2 lifetime data. HEK293 cells 
were transfected with either EGFP-Nrf2 + mCherry (A, B) or EGFP-Nrf2 + Keap1-
mCherry (C, D) and imaged 24 hours later. The left column shown the EGFP image from 
which the FRET efficiency data are derived. The middle column shows a pictorial 
representation of the FRET efficiency where the colour of the cell corresponds to the 
FRET efficiency, ranging from 0% to 30% as indicated on the legend below the image. 
The right column shows the FRET efficiency from each pixel of the image plotted on a 
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graph, with FRET efficiency on the x-axis and frequency on the y-axis. Graphs A-B show 
that the FRET efficiency in EGFP-Nrf2 and mCherry co-transfected cells is 0%, which 
corresponds with the blue colour of the cells in A and B.  In EGFP-Nrf2 and Keap1-
mCherry co-transfected cells (C, D), the FRET efficiency graphs show two distinct peaks, 
one at 13% and the other at 21% FRET efficiency, suggesting that there are two 
different FRET interactions between the EGFP and mCherry fluorophores within the 
Keap1-Nrf2 complex. These different FRET efficiency populations are shown pictorially 
in the central column of C and D, where the green and yellow colours are distributed 
evenly across the cells. 
 
 
This result was unexpected, and suggested that the system may be more 
dynamic than previously anticipated. 
 Our first step to determine the identity of the different FRET efficiency 
populations was to consider what is already known about the interaction 
between Keap1 and Nrf2. It has been shown that Nrf2 binds to a Keap1 dimer 
through two distinct motifs; a high affinity ETGE motif, and a low affinity DLG 
motif (McMahon et al. 2006, Tong et al. 2006a)(Figure 4.3A). In the absence of 
the ETGE motif, Nrf2 does not bind to Keap1, therefore, our first approach was to 
use a deletion mutant of the DLG motif to see if this has any effect on the FRET 
efficiency of the interaction (Figure 4.3B).  
 As shown in Figure 4.4, EGFP-Nrf2∆DLG was able to bind to Keap1-
mCherry and generate FRET. In the presence of free mCherry alone, the lifetime 
of EGFP-Nrf2∆DLG was 2382 ps, whilst when Keap1-mCherry was expressed in 
place of mCherry the lifetime was significantly reduced to 2227 ps (p= 1.25E-12, 
Tables4.1, 4.2). Interestingly, the loss of the DLG motif increased the lifetime of 
EGFP relative to wild-type Nrf2 (2155 ps vs. 2227 ps), suggesting that the change 
in the interaction between Nrf2 and Keap1 in the absence of the DLG motif is 
coupled to a change in FRET. Although the two proteins still interact giving rise 
to FRET, the longer lifetime of EGFP in the mutant suggests that the FRET 
efficiency may also have changed.   
 When we calculate E for EGFP-Nrf2∆DLG and Keap1-mCherry co-
transfected cells, we can see that the interaction at 13% has been maintained, 
whilst the 21% FRET efficiency population is lost relative to wild type Nrf2 
(compare graphs in Figure 4.5C,D with Figure 4.2C,D). Together, these data 















Figure 4.3. Cartoon representations of Keap1-Nrf2 complexes. The different 
combinations of wild type and mutant Nrf2 and Keap1 proteins used in Chapter 4, and 
the ways in which they interact, are shown schematically in the cartoons. In all images, 
Keap1 is shown in blue, mCherry in red, Nrf2 in yellow and EGFP in green. A. Shows the 
interaction of wild-type Nrf2 with Keap1, where Nrf2 is bound to Keap1 through both its 
high affinity ETGE and low affinity DLG motifs. B. Shows the interaction between 
Nrf2ΔDLG and wild-type Keap1. This mutant of Nrf2 interacts with the Keap1 dimer 
through only its high affinity ETGE motif.C. Shows the interaction between Nrf2-
doubleETGE and wild-type Keap1. This mutant interacts with Keap1 through two high 
affinity ETGE motifs.D. Shows the interaction between Nrf2ΔDLG and Keap1-mono-















































Figure 4.4. Fluorescence lifetime imaging of EGFP-Nrf2∆DLG. HEK293 cells were 
transfected with either EGFP- Nrf2∆DLG + mCherry (A, B) or EGFP- Nrf2∆DLG + Keap1-
mCherry (C, D). The left column shows the EGFP image from which the lifetime data are 
derived. The middle column shows a pictorial representation of the EGFP lifetime where 
the colour of the cell corresponds to the lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as 
indicated on the legend below the image. The right column shows the lifetime data from 
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each pixel of the image plotted on a graph, with lifetime on the x-axis and frequency on 
the y-axis. Graphs A-D clearly show that the lifetime of EGFP-Nrf2∆DLG in the presence 
of mCherry alone (A, B) is significantly longer than in the presence of Keap1-mCherry (C, 
D) indicating that there is a FRET interaction between the two fusion proteins. This 
lifetime change is shown in the images in the second column, in which A and B are blue, 
and C and D are green, corresponding to a reduced lifetime of EGFP-Nrf2∆DLG in the 
presence of Keap1-mCherry. 
 
 
      Lifetime (ps)    N   SD      T-test  
EGFP-Nrf2∆DLG + mCherry 
 
            2382     8   18 
EGFP-Nrf2∆DLG +  
Keap1-mCherry 
            2227   11   19 
 
 
p = 1.25E-12 
EGFP-Nrf2∆DLG +  
Keap1-mono-mCherry 




           2369    5   21 
EGFP-Nrf2-doubleETGE + 
Keap1-mCherry 
           2093  13   18 
 
 
p = 3.97E-15 
 
Table 4.1. FLIM data for EGFP-Nrf2∆DLG and EGFP-Nrf2-doubleETGE transfected 
cells. The table shows the lifetime, number of cells imaged and standard deviation of the 
lifetime for both EGFP-Nrf2∆DLG and EGFP-Nrf2-doubleETGE transfected cells. The 
lifetime of EGFP-Nrf2∆DLG is significantly reduced by the presence of either Keap1-
mCherry (p = 1.25E-12) or Keap1-mono-mCherry (p =1.30E-8) showing that these 
combinations of fusion proteins generate FRET interactions. The lifetime of EGFP-Nrf2-
doubleETGE is also significantly reduced by the presence of Keap1-mCherry (p = 3.97E-
15) showing that these fusion proteins generate a FRET interaction. 
 
corresponds to a FRET efficiency of 13%, whilst when the DLG motif is present, 
and Nrf2 can bind to Keap1 through both its DLG and ETGE motifs 
simultaneously, the 21% FRET efficiency population can be formed. 
Interestingly, because both the 13% and the 21% FRET efficiency populations 
are present in wild type Nrf2 transfected cells, the data suggest that the Keap1-
Nrf2 complex forms two distinct conformations, one in which only the ETGE 
motif of Nrf2 is bound to the Keap1 dimer (represented by the 13% FRET 
efficiency population) and a second in which both the DLG and ETGE motifs are 
bound to Keap1 (representing the 21% FRET efficiency population), and that 













































Figure 4.5. FRET efficiency derived from EGFP- Nrf2∆DLG  lifetime data. HEK293 
cells were transfected with either EGFP-Nrf2∆DLG  + mCherry (A, B) or EGFP- Nrf2∆DLG  
+ Keap1-mCherry (C, D) and imaged 24 hours later. The left column shown the EGFP 
image from which the FRET efficiency data are derived. The middle column shows a 
pictorial representation of the FRET efficiency where the colour of the cell corresponds 
to the FRET efficiency, ranging from 0% to 30% as indicated on the legend below the 
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image. The right column shows the FRET efficiency from each pixel of the image plotted 
on a graph, with FRET efficiency on the x-axis and frequency on the y-axis. Graphs A-B 
show that the FRET efficiency in EGFP-Nrf2∆DLG and mCherry co-transfected cells is 
0%, which corresponds with the blue colour of the cells in A and B.  In EGFP- Nrf2∆DLG 
and Keap1-mCherry co-transfected cells (C, D), the FRET efficiency graphs shows one 
peak at 13% FRET efficiency, indicating that there is a single FRET interaction between 
the EGFP and mCherry fluorophores within the Keap1-Nrf2∆DLG complex. This FRET 
efficiency population is shown pictorially in the central column of C and D, where the 
green colour is distributed evenly across the cells. 
 
 
One caveat to this conclusion is that because the Keap1 dimer contains 
two mCherry fluorophores, it may be possible for the EGFP-Nrf2 which is bound 
to Keap1 through both the DLG and ETGE motifs to FRET with both fluorophores 
simultaneously. Thus a single conformation of the Keap1-Nrf2 complex may be 
able to give rise to two FRET interactions leading to two different FRET 
efficiency populations. 
 In order to test this possibility, we designed a second mutant of Nrf2 
which binds to Keap1 more tightly due to the addition of a second ETGE motif in 
place of the original DLG motif (Figure 4.3C). If the two FRET efficiency 
populations come from a single conformation of the Keap1-Nrf2 complex, then 
the tighter binding of EGFP-Nrf2-doubleETGE will have no effect on the FRET 
efficiency when transfected along with Keap1. However, if the two FRET 
efficiency populations represent two distinct conformations of the Keap1-Nrf2 
complex, one in which only the ETGE motif is bound, and the other in which both 
the ETGE and DLG motifs are bound to a Keap1 dimer, then the addition of a 
second ETGE motif should lead to an increase in the complex in which both 
motifs are bound, as the additional ETGE motif will bind more tightly to Keap1 
than the endogenous DLG motif.  
 When EGFP-Nrf2-doubleETGE was transfected along with Keap1-
mCherry, we still saw a FRET interaction characterised by a reduction in EGFP 
lifetime (Figure 4.6). Interestingly, the lifetime of this doubleETGE mutant was 
reduced when compared with wild type Nrf2 (2093 ps vs. 2155 ps), suggesting 
there was more FRET with this new mutant (Tables4.1, 4.2). Interestingly, this 
reduced lifetime corresponded to an increase in the interaction at 21% FRET 
efficiency (Figure 4.7). Together these data establish that the two FRET  
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Table 4.2. The combined lifetimes of wild type and mutant EGFP-Nrf2 transfected 
cells. The table above shows the individual fluorescence lifetimes for all cells co-
transfected with Keap1-mCherry and either EGFP-Nrf2 (yellow), EGFP-Nrf2-
doubleETGE (red) or EGFP-Nrf2ΔDLG (green). The cells are ordered by EGFP lifetime 
from shortest to longest. The table clearly shows that cells transfected with EGFP-Nrf2-
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doubleETGE (which binds tightly to both members of the Keap1 dimer) have the 
shortest lifetime, while those transfected with EGFP-Nrf2ΔDLG (which binds to only one 
member of the Keap1 dimer) have the longest lifetimes. The cells that were transfected 
with wild type EGFP-Nrf2 have lifetimes between these mutants. These data suggest 
that in wild type cells, the population of Keap1-Nrf2 complexes is found as a mixture of 
tight and weak interactions, which when combined and averaged across the cell gives a 
lifetime between that of the tightly- and weakly-interacting mutants. 
 
 
efficiency populations are not produced by a single conformation of the Keap1-
Nrf2 complex, but instead that this complex is found in two distinct states. 
 Because Keap1 forms a dimer, our data to this point were limited by the 
fact that it was not clear with which of the two Keap1-mCherry proteins the 
EGFP fluorophore was interacting to produce the 13% FRET efficiency signal. 
The knowledge of which pair of fluorophores were interacting may give us a 
greater insight into the structure of the Keap1-Nrf2 complex.The 13% FRET 
efficiency population in EGFP-Nrf2∆DLG transfected cells could be produced in 
two different ways (Figure 4.8). It could be produced by an interaction between 
either the Keap1 protein which is bound to the ETGE motif of Nrf2 (FRET in cis 
because the two proteins which generate FRET are directly bound to one 
another), or to the other member of the Keap1 dimer which is unbound to Nrf2, 
but which normally binds to the DLG motif when it is present (FRET in trans, 
because this Keap1 and Nrf2 combination are not directly bound together). 
 In order to determine with which member of the Keap1 dimer EGFP-
Nrf2∆DLG interacts with to generate FRET, we made a mutant of Keap1 which is 
unable to dimerise, named Keap1-mono-mCherry (Figure 4.3D). When plasmids 
encoding these two proteins were transfected into cells, the lifetime of EGFP was 
reduced relative to the control, showing that FRET took place (Figure 4.9A,B, 
Table 4.1). Interestingly, when the lifetime data were used to calculate the FRET 
efficiency, we found that the 13% FRET efficiency interaction was maintained 
between EGFP-Nrf2∆DLG and Keap1-mono-mCherry, and that the 21% FRET 
efficiency population was completely absent, showing that the 13% FRET 
efficiency population corresponds to FRET between EGFP and the Keap1 protein 
which binds to the ETGE motif of Nrf2 (Figure 4.9C,D). 
 All of the data presented in Figures 4.2-4.9 concern the interaction 
between Nrf2 and Keap1 in the cytoplasm, as this has previously been suggested  
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Figure 4.6. Fluorescence lifetime imaging of EGFP-Nrf2-doubleETGE. HEK293 cells 
were transfected with either EGFP- Nrf2-doubleETGE + mCherry (A, B) or EGFP- Nrf2-
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doubleETGE + Keap1-mCherry (C, D). The left column shows the EGFP image from 
which the lifetime data are derived. The middle column shows a pictorial representation 
of the EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, 
ranging from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right 
column shows the lifetime data from each pixel of the image plotted on a graph, with 
lifetime on the x-axis and frequency on the y-axis. Graphs A-D clearly show that the 
lifetime of EGFP-Nrf2-doubleETGE in the presence of mCherry alone (A, B) is 
significantly longer than in the presence of Keap1-mCherry (C, D) indicating that there is 
a FRET interaction between the two fusion proteins. This lifetime change is shown in the 
images in the second column, in which A and B are blue, and C and D are yellow, 




to be the main site of the Keap1-Nrf2 interaction (Watai et al. 2007). 
Interestingly, we also observed a weak EGFP signal in the nucleus (with an 
intensity 10-fold lower than the cytoplasm) and wished to analyse it to 
determine whether Nrf2 is also able to bind to Keap1 in the nuclear 
compartment. In accordance with the literature, we also found a weak nuclear 
Keap1 signal (as shown in the confocal microscopy images in Figure 4.10), 
highlighting the fact that both proteins are present in the nucleus and thus may 
be able to interact there (Nguyen et al. 2005, Watai et al. 2007, Sun et al. 2011, 
Kaspar et al. 2012). 
 As shown in Table 4.3, in the nucleus of EGFP-Nrf2 + Keap1-mCherry co-
transfected cells the lifetime of EGFP fluorescence is 2203 ps. This is significantly 
shorter than in the absence of Keap1 (p = 1.56E-18), demonstrating a FRET 
interaction between EGFP-Nrf2 and Keap1-mCherry in the nucleus. Interestingly, 
when a comparison is made between the lifetime of EGFP fluorescence in the 
cytoplasm and nucleus of the same cell, it is clear that in all cases the lifetime in 
the nucleus is significantly longer (Table 4.3, p = 1.759E-9).  
 In order to determine whether the longer lifetime in the nucleus 
corresponds to a change in the conformation of the Keap1-Nrf2 complex, we 
calculated the FRET efficiency of the interaction in both the cytoplasm and 
nucleus of individual cells (Figure 4.11). The left column of Figure 4.11 shows 
the FRET efficiency image of the cell, the central column shows a graph of the 
FRET efficiency of the cytoplasm, whilst the right column shows a graph of the 
FRET efficiency of the nucleus. Strikingly, in contrast to the cytoplasm, the FRET 
efficiency in the nucleus only contains the interaction at 13% FRET efficiency,  
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Figure 4.7. FRET efficiency derived from EGFP-Nrf2-doubleETGE lifetime data. 
HEK293 cells were transfected with either EGFP-Nrf2-doubleETGE + mCherry (A, B) or 
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EGFP-Nrf2-doubleETGE + Keap1-mCherry (C, D) and imaged 24 hours later. The left 
column shown the EGFP image from which the FRET efficiency data are derived. The 
middle column shows a pictorial representation of the FRET efficiency where the colour 
of the cell corresponds to the FRET efficiency, ranging from 0% to 30% as indicated on 
the legend below the image. The right column shows the FRET efficiency from each pixel 
of the image plotted on a graph, with FRET efficiency on the x-axis and frequency on the 
y-axis. Graphs A-B show that the FRET efficiency in EGFP-Nrf2-doubleETGE and 
mCherry co-transfected cells is 0%, which corresponds with the blue colour of the cells 
in A and B.  In EGFP-Nrf2-doubleETGE and Keap1-mCherry co-transfected cells (C, D), 
the FRET efficiency graphs show two distinct peaks, a small one at 13% and a larger one 
at 21% FRET efficiency, suggesting that there is one major FRET interaction between 
the EGFP and mCherry fluorophores within the Keap1-Nrf2-doubleETGE complex. The 
distribution of the two FRET efficiency populations is shown pictorially in the central 
column of C and D, where the predominant colour is yellow (corresponding to the 21% 
population), which is distributed evenly throughout the cell, along with a small amount 







Figure 4.8. The alternate mechanisms through which the 13% FRET efficiency 
population can be generated. The cartoons show the interaction between EGFP-
Nrf2ΔDLG and Keap1-mCherry, where Keap1 is shown in blue, mCherry in red, Nrf2 in 
yellow and EGFP in green. The FRET interaction which generates the 13% FRET 
efficiency population could be generated in two different ways: either between the EGFP 
fluorophore and the mCherry fused to the Keap1 protein which is bound to the ETGE 
motif (left, FRET in cis), or between the EGFP fluorophore and the mCherry fused to the 
Keap1 protein which is not bound to Nrf2 (right, FRET in trans). 
 
 
suggesting that Nrf2 binds to the Keap1 dimer through only the ETGE motif in 
the nucleus. 
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In order to study the nuclear complex more closely, we also calculated the 
EGFP lifetime and FRET efficiency for the Nrf2 mutants Nrf2∆DLG and Nrf2-
doubleETGE (Tables 4.4, 4.5, Figures 4.12, 4.13). In the case of EGFP-
Nrf2∆DLG the lifetime is longer in the nucleus than in the cytoplasm, however 
the 13% FRET efficiency population is maintained (Table 4.4, Figure 4.12).  In 
the case of EGFP-Nrf2-doubleETGE, again the lifetime is increased, and the FRET 
efficiency changes to include a higher proportion of the interaction at 13% 
relative to the cytoplasm (Table 4.5, Figure 4.13). Interestingly, both Nrf2 
mutants only interact with Keap1 through their high affinity ETGE motifs, and 
yet both show an increased lifetime in the nucleus, and in the case of Nrf2-
doubleETGE, a reduction in the interaction at 21% FRET efficiency. Together 
these data suggest that in the nucleus, the Keap1 dimer binds to the ETGE motif 
of Nrf2 with a lower affinity, potentially because Keap1 is engaged in binding 
with another protein or proteins. These other protein(s) appear to be able to 
completely displace the DLG motif of wild-type Nrf2, and can also compete for 
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Figure 4.9. FRET efficiency derived from EGFP-Nrf2∆DLG lifetime data. HEK293 
cells were transfected with EGFP-Nrf2∆DLG + Keap1-mono-mCherry and both the 
lifetime (A, B) and FRET efficiency (C, D) were calculated. A, B show the fluorescence 
lifetime data. The left column shows the EGFP image from which the lifetime data are 
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derived. The middle column shows a pictorial representation of the EGFP lifetime where 
the colour of the cell corresponds to the lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as 
indicated on the legend below the image. The right column shows the lifetime data from 
each pixel of the image plotted on a graph, with lifetime on the x-axis and frequency on 
the y-axis. Graphs A-B clearly show that the lifetime of EGFP-Nrf2∆DLG in the presence 
of Keap1-mono-mCherry is significantly shorter than in the presence of mCherry alone 
(Figure 4.3 A,B) indicating that there is a FRET interaction between the two fusion 
proteins. C, D show the FRET efficiency data for EGFP- Nrf2∆DLG + Keap1-mono-
mCherry co-transfected cells.The left column shows the EGFP image from which the 
FRET efficiency data are derived. The middle column shows a pictorial representation of 
the FRET efficiency where the colour of the cell corresponds to the FRET efficiency, 
ranging from 0% to 30% as indicated on the legend below the image. The right column 
shows the FRET efficiency from each pixel of the image plotted on a graph, with FRET 
efficiency on the x-axis and frequency on the y-axis. The FRET efficiency graphs (C, D) 
shows one peak at 13% FRET efficiency, indicating that there is a single FRET 
interaction between the EGFP and mCherry fluorophores within the Keap1-mono-
Nrf2∆DLG complex. This FRET efficiency population is shown pictorially in the central 





Cytoplasmic Lifetime (ps) Nuclear Lifetime (ps) 
Cell 1 2152 2201 
Cell 2 2173 2215 
Cell 3 2152 2194 
Cell 4 2173 2222 
Cell 5 2138 2180 
Cell 6 2138 2187 
Cell 7 2152 2187 
Cell 8 2159 2180 
Cell 9 2110 2145 
Cell 10 2138 2173 
Cell 11 2166 2236 
Cell 12 2187 2236 
Cell 13 2152 2215 
Cell 14 2166 2243 
Cell 15 2145 2215 
Cell 16 2152 2215 
AVERAGE 2153 2203 
SD 18 27 
Paired T-test p = 1.759E-9 
 
Table 4.3. FLIM data for the cytoplasm and nucleus of EGFP-Nrf2 transfected cells. 
The table shows the lifetime data for 16 individual cells co-transfected with EGFP-Nrf2 + 
Keap1-mCherry. The lifetime was separately calculated in the cytoplasm and nucleus of 
each cell, and a paired T-test was carried out which shows that the lifetime in the 


















Figure 4.10. Cellular localisation of Nrf2 and Keap1 fusion proteins. HEK293 cells 
were co-transfected with the EGFP-Nrf2 and Keap1-mCherry expression plasmids and 
the localisation of the resulting fluorescence was monitored using confocal microscopy. 
The EGFP channel is shown in the left column, and the mCherry channel in the right 
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column. In all three cells the distribution of both EGFP-Nrf2 and Keap1-mCherry is 
similar, with a higher intensity signal for both fusion proteins in the cytoplasm, and a 
































 The aim of this part of the study was to use the FLIM data to investigate 
the dynamism of the Keap1-Nrf2 interaction in the basal state, by analysing the 
FRET efficiency of the interaction. To our knowledge, the only previous example 
of use of this approach is that of Lleres et al 2009. In this paper, the authors 
identified 3 distinct FRET efficiency populations in histone labelled chromatin, 
and found that the relative proportions of these populations changes during 
mitosis as the chromatin changes its compaction state. In the case of the 
interaction between EGFP-Nrf2 and Keap1-mCherry, we also saw distinct FRET 
efficiency populations (Figure 4.2). Furthermore, we have advanced the 
methodology employed in Lleres et al’s original study by determining the 
identity of each of the two distinct FRET populations. 
 The interaction between Nrf2 and Keap1 is shown schematically in 
Figure 4.3A. The low affinity DLG, and high affinity ETGE motifs of Nrf2 each 
bind to a member of the Keap1 dimer. This double binding is believed to be 
required in order to correctly orientate the lysine residues in the helix between 
the DLG and ETGE motifs for ubiquitination by the Keap1-dependent E3 
ubiquitin ligase (McMahon et al. 2006, Tong et al. 2006a). The FRET efficiency of 
the interaction between wild type EGFP-Nrf2 and Keap1-mCherry is shown with 
a cartoon of the protein complexes(Figure 4.14), and clearly shows 2 distinct 
populations of FRET efficiency, one at 21% and the other at 13%. Using equation 
4.2, these FRET efficiency values can be converted to the physical distances of 56 
Å and 64 Å, respectively. This suggests that the protein complex of Keap1 and 
Nrf2 is found in two distinct conformations, one in which the EGFP and mCherry 
fluorophores are 56 Å apart, and the other, in which they are 64 Å apart. This 
idea is initially quite puzzling when considering the current understanding of the 
interaction in the basal state (Figure 4.3A), and suggests that the interaction 
between Keap1 and Nrf2 is more complex than previously thought. 
 In order to try to understand what the two FRET efficiency interactions 
may represent, our first approach was to mutate the low affinity DLG motif in 
Nrf2, so that Nrf2 can bind to Keap1 through the ETGE motif alone, and test 
whether this has any impact on the FRET efficiency (Figure 4.15A). We found 
that this interaction generated only the 13% FRET efficiency population,  
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Figure 4.11. FRET efficiency derived from cytoplasmic and nuclear EGFP-Nrf2 
lifetime data. HEK293 cells were transfected with EGFP-Nrf2 + Keap1-mCherry and 
imaged 24 hours later. The left column shows a pictorial representation of the FRET 
efficiency where the colour of the cell corresponds to the FRET efficiency, ranging from 
0% to 30% as indicated on the legend below the image. The central column shows the 
FRET efficiency from each pixel of the cytoplasm plotted on a graph, with FRET 
efficiency on the x-axis and frequency on the y-axis. The right column shows the FRET 
efficiency from each pixel of the nucleus plotted on a graph, with FRET efficiency on the 
x-axis and frequency on the y-axis. In all cells A-D, the FRET efficiency graphs of the 
cytoplasmic compartment show two distinct peaks, one at 13% and the other at 21% 
FRET efficiency, suggesting that there are two different FRET interactions between the 
EGFP and mCherry fluorophores within the Keap1-Nrf2 complex. In contrast, in all cases 
A-D the FRET efficiency in the nucleus contains only the FRET efficiency population at 
13%, suggesting that in the nucleus there is a single FRET interaction between the EGFP 
and mCherry fluorophores within the Keap1-Nrf2 complex. 
 
 
demonstrating that Nrf2 binding to Keap1 though the ETGE motif alone 
represents the 13% FRET efficiency population. Interestingly, because the DLG 
mutant Nrf2 never forms the 21% FRET efficiency interaction, it suggests that 
when Nrf2 is bound to Keap1 by both the ETGE and DLG motifs this must 
represent the 21% FRET efficiency interaction. In addition, because wild type 




Cytoplasmic Lifetime (ps) Nuclear Lifetime (ps) 
Cell 1 2236 2250 
Cell 2 2229 2236 
Cell 3 2208 2222 
Cell 4 2194 2257 
Cell 5 2208 2243 
Cell 6 2236 2299 
Cell 7 2250 2285 
Cell 8 2229 2264 
Cell 9 2222 2257 
Cell 10 2229 2268 
AVERAGE 2224 2258 
SD 17 23 
Paired T-test p = 0.000307 
 
Table 4.4. FLIM data for the cytoplasm and nucleus of EGFP-Nrf2ΔDLG transfected 
cells. The table shows the lifetime data for 16 individual cells co-transfected with EGFP-
Nrf2ΔDLG + Keap1-mCherry. The lifetime was separately calculated in the cytoplasm 
and nucleus of each cell, and a paired T-test was carried out which shows that the 
lifetime in the nucleus is significantly longer than in the cytoplasm (p = 0.000307). 
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Figure 4.12. FRET efficiency derived from cytoplasmic and nuclear EGFP-
Nrf2ΔDLG lifetime data. HEK293 cells were transfected with EGFP-Nrf2ΔDLG + Keap1-
mCherry and imaged 24 hours later. The left column shows a pictorial representation of 
the FRET efficiency where the colour of the cell corresponds to the FRET efficiency, 
ranging from 0% to 30% as indicated on the legend below the image. The central 
column shows the FRET efficiency from each pixel of the cytoplasm plotted on a graph, 
with FRET efficiency on the x-axis and frequency on the y-axis. The right column shows 
the FRET efficiency from each pixel of the nucleus plotted on a graph, with FRET 
efficiency on the x-axis and frequency on the y-axis. In all cells, the FRET efficiency 
graphs of the cytoplasmic compartment show one peak at 13% FRET efficiency, 
suggesting that there is a single FRET interaction between the EGFP and mCherry 
fluorophores within the Keap1- Nrf2ΔDLG complex. The FRET efficiency in the nucleus 
also contains only the FRET efficiency population at 13%, suggesting that, as with the 
cytoplasm, in the nucleus there is a single FRET interaction between the EGFP and 






Cytoplasmic Lifetime (ps) Nuclear Lifetime (ps) 
Cell 1 2082 2096 
Cell 2 2054 2061 
Cell 3 2082 2089 
Cell 4 2089 2103 
Cell 5 2117 2180 
Cell 6 2096 2124 
Cell 7 2096 2138 
Cell 8 2096 2103 
Cell 9 2103 2117 
Cell 10 2075 2096 
Cell 11 2110 2124 
Cell 12 2089 2124 
Cell 13 2117 2156 
AVERAGE 2093 2116 
SD 18 31 
Paired T-test p = 0.000326 
 
Table 4.5. FLIM data for the cytoplasm and nucleus of EGFP-Nrf2-doubleETGE 
transfected cells. The table shows the lifetime data for 13 individual cells co-
transfected with EGFP-Nrf2-doubleETGE + Keap1-mCherry. The lifetime was separately 
calculated in the cytoplasm and nucleus of each cell, and a paired T-test was carried out 
which shows that the lifetime in the nucleus is significantly longer than in the cytoplasm 
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Figure 4.13. FRET efficiency derived from cytoplasmic and nuclear EGFP-Nrf2-
doubleETGE lifetime data. HEK293 cells were transfected with EGFP-Nrf2-
doubleETGE + Keap1-mCherry and imaged 24 hours later. The left column shows a 
pictorial representation of the FRET efficiency where the colour of the cell corresponds 
to the FRET efficiency, ranging from 0% to 30% as indicated on the legend below the 
image. The central column shows the FRET efficiency from each pixel of the cytoplasm 
plotted on a graph, with FRET efficiency on the x-axis and frequency on the y-axis. The 
right column shows the FRET efficiency from each pixel of the nucleus plotted on a 
graph, with FRET efficiency on the x-axis and frequency on the y-axis. In both A and B, 
the FRET efficiency graphs of the cytoplasmic compartment show two distinct peaks, a 
major peak at 21% FRET efficiency and a minor peak at 13% FRET efficiency, suggesting 
that there is predominantly one FRET interactions between the EGFP and mCherry 
fluorophores within the Keap1-Nrf2-doubleETGE complex. In contrast, the FRET 
efficiency in the nucleus contains a more equal distribution between the 21% and 13% 
FRET efficiency populations, indicating that there are two distinct FRET interactions 
between the EGFP and mCherry fluorophores within the Keap1-Nrf2-doubleETGE 
complex in the nucleus. 
 
 
populations it implies that the Keap1-Nrf2 complex is found in 2 distinct states in 
cells, one in which the only the ETGE motif is bound to Keap1 (the “open 
conformation”), and one in which both the DLG and ETGE motifs are bound (the 
“closed conformation”). The idea that a single Keap1-Nrf2 complex conformation  
could generate both FRET efficiency interactions was rejected through the use of 
a mutant Nrf2 with two high affinity ETGE motifs (Figure 4.15B). This mutant 
Nrf2 bound more tightly to Keap1, and increased the abundance of the 21% 
FRET efficiency population relative to the 13%.  
Together these data show that in wild type Nrf2, the presence of the 
weakly binding DLG motif is required for the formation of the 13% FRET 
efficiency population (when it is unbound) and for the formation of the 21% 
FRET efficiency population (when it is bound, Figure 4.14). These data suggest 
that nature has chosen a more elaborate mechanism through which Nrf2 is 
regulated by Keap1; Nrf2 is not simply bound or unbound, but can also be found 
in a third, half-bound state, which we call the “open conformation”.  
 Interestingly, the open conformation is the predominant state in which 
the Keap1-Nrf2 complex is found in the nucleus (Figure 4.11). The fact that the 
DLG motif is never bound to Keap1 in the nucleus suggests that some other 
protein is able to outcompete it in that compartment. Interestingly, both the 
Nrf2-doubleETGE and the Nrf2∆DLG mutants also show a longer lifetime in the 




Figure 4.14. The open and closed conformations of the Keap1-Nrf2 complex. The 
interactions between Keap1 and Nrf2 are shown schematically above the FRET 
efficiency distribution. In the images, Keap1 is shown in blue, mCherry in red, Nrf2 in 
yellow and EGFP in green. On the left, the Keap1-Nrf2 complex is shown in the open 
conformation, in which only the ETGE motif of Nrf2 is bound to the Keap1 dimer. This 
conformation generates the 13% FRET efficiency population shown in the graph. On the 
right, the closed conformation is shown, where both the DLG and ETGE motifs of Nrf2 
are bound to the Keap1 dimer. This conformation generates the 21% FRET efficiency 
population shown below in the graph. 
 
 
the additional nuclear partner of Keap1 is also able to compete with the ETGE 
motif for binding, as both of these Nrf2 mutants only contain high affinity ETGE 
motifs, yet both exhibit reduced binding (Figures 4.11, 4.12, Tables 4.4, 4.5). 
 Previous studies have shown that at least some of the cellular pool of 
Keap1 is able to enter the nucleus (Nguyen et al. 2005, Watai et al. 2007, Sun et 
al. 2011, Kaspar et al. 2012). Interestingly, in addition to Nrf2, Keap1 has also 
been shown to bind to two nuclear proteins, Prothymosin-α and Palb2, either of  
 






















Figure 4.15. Complexes of mutant Nrf2 and Keap1 with corresponding 
representative FRET efficiency graphs. In the left column the different combinations 
of mutant Nrf2 and wild type or mutant Keap1 proteins used in Chapter 4, and the ways 
in which they interact, are shown schematically in the cartoons. In the right column, 
representative FRET efficiency graphs are shown for the combinations of proteins 
shown in the adjacent cartoon. In all images, Keap1 is shown in blue, mCherry in red, 
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Nrf2 in yellow and EGFP in green. A. Shows the interaction between Nrf2ΔDLG and wild-
type Keap1. This mutant of Nrf2 interacts with the Keap1 dimer through only its high 
affinity ETGE motif, and generates a single FRET efficiency interaction at 13%. B.Shows 
the interaction between Nrf2-doubleETGE and wild-type Keap1. This mutant interacts 
with Keap1 through two high affinity ETGE motifs, and generates a FRET efficiency 
profile with a major peak at 21% and a minor peak at 13% FRET efficiency. C. Shows the 
interaction between Nrf2ΔDLG and Keap1-mono-mCherry. This Keap1 mutant cannot 
dimerise, and generates a FRET efficiency distribution with one peak at 13% FRET 
efficiency.     
 
which could be responsible for the displacement of the DLG motif of Nrf2 in the 
nucleus. 
Prothymosin-α is a ubiquitous protein which is involved in cellular 
proliferation and protection against apoptosis (Karapetian et al. 2005, Niture et 
al. 2009). The crystal structure of the ENGE motif of Prothymosin-α bound to the 
Kelch domain of Keap1 has been solved and shows that the proteins bind at the 
same site as both the ETGE and DLG motifs of Nrf2 (Padmanabhan et al. 2008). 
Palb2 is a DNA repair protein, and contains a conserved ETGE motif through 
which it competes for binding of Keap1 with Nrf2 in the nucleus (Ma et al. 2012).  
Both of these proteins have previously been shown to bind to Keap1 at the same 
site as the ETGE and DLG motifs of Nrf2, and thus either or both proteins could 
be responsible for the loss of DLG binding in the nucleus and absence of the 





















Chapter 5: High-resolution analysis of the 



















In Chapter 4 we presented data which suggested that in the basal state 
the Keap1-Nrf2 complex is found in two distinct states, the open and closed 
conformations. The existence of an open conformation has previously been 
proposed (but never shown) independently by the Yamamoto and Hayes labs 
(McMahon et al. 2006, Tong et al. 2006a).  They suggested that binding of 
inducers leads to the release of the low affinity DLG motif from the Keap1 dimer, 
resulting in the inhibition of Nrf2 ubiquitination (Figure 1.4). This mechanism is 
known as the “hinge and latch model” of Nrf2 regulation, and was proposed in 
order to explain why Nrf2 contains binding motifs with such differing affinities 
for Keap1 (the DLG motif binds Keap1 with a 100-fold lower affinity than the 
ETGE motif).  
Interestingly, in the hinge and latch model, the position in which the latch 
is unhooked directly corresponds to the “open conformation” which we observe 
Keap1 and Nrf2 form in the basal state. The experiments in Chapter 4 are 
concerned with the interaction between Keap1 and Nrf2 in the basal state, but 
we also wished to examine whether the relative proportions of the open and 
closed conformations are affected by the addition of inducers and the activation 
of the pathway. This will allow us to directly test the hinge and latch model to 
determine whether it is correct, or whether a new model is required to fully 




 The aim of this part of the study is to use FLIM-generated FRET efficiency 
data to investigate how the interaction between Keap1 and Nrf2 changes (if at 









 In order to determine what effect, if any, inducers have on the 
conformation of the Keap1-Nrf2 complex, we wished to calculate the FRET 
efficiency of the interaction in the induced state and compare it to the basal state. 
Because variation is seen in the FRET efficiency distribution between cells in the 
basal state (Figure 4.2), we wished to image the same cell in both the basal and 
induced state, to obtain a more accurate picture of the effects of inducers in 
individual cells.  
 In response to inducers, Nrf2 accumulates within 1 hour, and thus we 
reasoned that this would be a good time point at which to study the Keap1-Nrf2 
interaction (Figure 3.2) (McMahon et al. 2003, Nguyen et al. 2003). Because this 
experimental approach would involve imaging the same cell twice over a period 
of 1 hour, it was essential to establish that the EGFP lifetime is stable over this 
time period independent of the activity of inducers. As shown in Figure 5.1A,B 
and Table 5.1, the lifetime of EGFP-Nrf2 was unchanged when imaged twice, one 
hour apart, in the basal state. Importantly, the FRET efficiency distribution was 
also unaffected by repeated imaging (Figure 5.1C,D), showing that imaging a cell 
twice affects neither the EGFP lifetime nor the FRET efficiency distribution in 
EGFP-Nrf2 + Keap1-mCherry co-transfected cells. 
 We have previously shown that in response to inducers, Nrf2 is not 
released from Keap1, as the lifetime of EGFP-Nrf2 is still reduced compared with 
the control when inducers are added (Chapter 3). Therefore, we anticipated that 
inducers may lead to a change in the conformation if the Keap1-Nrf2 complex, 
but not to the dissociation of the proteins. Figure 5.2 shows representative data 
from EGFP-Nrf2 + Keap1-mCherry co-transfected cells, imaged before and 1 hour 
after 5 μM SFN treatment. In the left column of Figure 5.2, the EGFP image is 
shown from which the lifetime and FRET efficiency data are derived. In the 
central column, the corresponding false-colour images of the cells are shown 
depicting either the EGFP lifetime (A, B) or FRET efficiency (C, D), with the colour 
of the cell corresponding to the legend beneath the image. In the right column, 
the graph of either the EGFP lifetime (A, B) or FRET efficiency (C, D) is shown, 
with the lifetime (or FRET efficiency) from each pixel of the cytoplasm plotted on 
the x-axis, and the frequency on the y-axis. From Figure 5.2A,B, it is clear that in  
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Figure 5.1. The lifetime and FRET efficiency of EGFP-Nrf2 transfected cells imaged 
twice in an 1 hour period. HEK293 cells were transfected with EGFP-Nrf2 + Keap1-
mCherry and both the lifetime (A, B) and FRET efficiency (C, D) were calculated. A, B 
show the fluorescence lifetime data from a single cell imaged twice, the second image 
being taken 1 hour after the first. The left column shows the EGFP image from which the 
lifetime data are derived. The middle column shows a pictorial representation of the 
EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, ranging 
from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right column 
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shows the lifetime data from each pixel of the image plotted on a graph, with lifetime on 
the x-axis and frequency on the y-axis. Graphs A-B clearly show that the lifetime of 
EGFP-Nrf2 is stable over a 1 hour period in the basal state. C, D show the FRET efficiency 
data for a single EGFP- Nrf2 + Keap1-mCherry co-transfected cell data which was 
imaged twice, the second image being taken 1 hour after the first.The left column shown 
the EGFP image from which the FRET efficiency data are derived. The middle column 
shows a pictorial representation of the FRET efficiency where the colour of the cell 
corresponds to the FRET efficiency, ranging from 0% to 30% as indicated on the legend 
below the image. The right column shows the FRET efficiency from each pixel of the 
image plotted on a graph, with FRET efficiency on the x-axis and frequency on the y-axis. 
The FRET efficiency graphs (C, D) show that the FRET efficiency distribution in the basal 
state is stable over a 1 hour period. The FRET efficiency distributions are shown 
pictorially in the central column of C and D, where the green and yellow colours are 
distributed evenly across the cell. 
 
 
the induced state, the graph of the lifetime of EGFP-Nrf2 in the cytoplasm is 
shifted to the left compared to the basal state, corresponding to a reduced 
lifetime in the induced state. This means that the EGFP and mCherry fluorphores 
are closer together in the induced state, suggesting that there is a tighter 
interaction between Keap1 and Nrf2, and more FRET upon the addition of SFN. 
Interestingly, Table 5.2 shows that this effect is very reproducible and that the 
reduction in EGFP-Nrf2 lifetime after 1 hour treatment with 5 μM SFN treatment 
is statistically significant (p = 0.009). 
 
 T1 Lifetime (ps) T1 + 1 hr Lifetime (ps) 
Cell 1 2138 2131 
Cell 2 2117 2117 
Cell 3 2166 2159 
Cell 4 2145 2138 
Cell 5 2103 2103 
Cell 6 2152 2152 
AVERAGE 2136.8 2133.3 
 
Table 5.1. Lifetime of EGFP-Nrf2 in individual cells imaged twice, 1 hour apart. 
HEK293 cells were co-transfected with EGFP-Nrf2 and Keap1-mCherry and imaged 24 
hours later. The table shows the lifetime of EGFP fluorescence in cells imaged twice in 
the basal state, with 1 hour between images. The table shows that the EGFP-Nrf2 
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Figure 5.2. The lifetime and FRET efficiency in the cytoplasm of EGFP-Nrf2 
transfected cells imaged before and after treatment with SFN. HEK293 cells were 
transfected with EGFP-Nrf2 + Keap1-mCherry, and both the lifetime (A, B) and FRET 
efficiency (C-F) in the cytoplasmic compartment were calculated. A, B show the 
fluorescence lifetime data from a single cell imaged twice, once in the basal state (A) and 
once after 1 hour treatment with 5μM SFN (B). The left column shows the EGFP image 
from which the lifetime data are derived. The middle column shows a pictorial 
representation of the EGFP lifetime where the colour of the cell corresponds to the 
lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated on the legend below the 
image. The right column shows the lifetime data from each pixel of the image plotted on 
a graph, with lifetime on the x-axis and frequency on the y-axis. Graphs A-B clearly show 
that the lifetime of EGFP-Nrf2 is reduced after treatment with SFN for 1 hour. C-F show 
the FRET efficiency data for individual EGFP-Nrf2 + Keap1-mCherry co-transfected cells 
which were imaged twice, once in the basal state (C, E) and once after 1 hour treatment 
with 5μM SFN (D, F). The left column shown the EGFP image from which the FRET 
efficiency data are derived. The middle column shows a pictorial representation of the 
FRET efficiency where the colour of the cell corresponds to the FRET efficiency, ranging 
from 0% to 30% as indicated on the legend below the image. The right column shows 
the FRET efficiency from each pixel of the image plotted on a graph, with FRET efficiency 
on the x-axis and frequency on the y-axis. The FRET efficiency graphs (C-F) show that 
the FRET efficiency distribution is altered by SFN, which leads to an increase in the 
interaction at 21% FRET efficiency. The FRET efficiency distributions are shown 
pictorially in the central column of C-F, where an increase in the amount of yellow 
relative to green can be seen in response to SFN.  
  
 
Gratifyingly, this reduction in lifetime upon SFN treatment is coupled with 
a change in the FRET efficiency. As shown in Figure 5.2C and 5.2E, in the basal 
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state the cytoplasmic Keap1-Nrf2 complex was found equally distributed in the 
open (13% FRET efficiency population) and closed conformations (21% FRET 
efficiency population). However, after treatment with SFN, the FRET efficiency 
dramatically shifts to favour the closed conformation (Figure 5.2D,F).  
 This result was not specific to the Cys-151 targeting inducer SFN, as STCA, 
which targets Cys-273 and Cys-288 of Keap1, produced comparable results.  
After 1 hour treatment with 10 μM STCA, the lifetime of EGFP-Nrf2 in the 
cytoplasm was significantly reduced (Figure 5.4A,B, Table 5.3), and the FRET 
efficiency distribution was shifted to favour the 21% FRET efficiency population, 
corresponding to the closed conformation (Figure 5.4C,D). 
 Interestingly, the effect of inducers on the lifetime of EGFP-Nrf2 and the 
conformation of the Keap1-Nrf2 complex was not restricted to the cytoplasm. 
SFN treatment lead to a significant decrease in EGFP-Nrf2 lifetime in the nucleus, 
which was correlated with a modest increase in the proportion of the Keap1-

















Cell 1 2215 2103 2264 2124 
Cell 2 2138 2089 2180 2138 
Cell 3 2152 2110 2194 2159 
Cell 4 2198 2173 2271 2257 
Cell 5 2166 2117 2208 2124 
Cell 6 2131 2096 2187 2117 
AVERAGE 2167 2115 2217 2153 
SD 34 30 40 53 
Paired  
T-test 
p = 0.009 
 
p = 0.017 
 
Table 5.2. Lifetime of EGFP-Nrf2 in individual cells imaged before and after SFN 
treatment. HEK293 cells were co-transfected with EGFP-Nrf2 and Keap1-mCherry and 
imaged 24 hours later. The table shows the lifetime of EGFP fluorescence in the 
cytoplasm and nucleus of cells imaged in the basal state, and again after 1 hour 
treatment with 5 μM SFN. The table shows that treatment with SFN leads to a significant 
reduction in the EGFP-Nrf2 lifetime in both the cytoplasmic and nuclear compartments.  
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Figure 5.3. The nuclear FRET efficiency of EGFP-Nrf2 transfected cells imaged 
before and after treatment with SFN. HEK293 cells were transfected with EGFP-Nrf2 
+ Keap1-mCherry, from which the FRET efficiency of the interaction between these 
fusion proteins in the nucleus was calculated. A-D show the FRET efficiency data for 
individual EGFP-Nrf2 + Keap1-mCherry co-transfected cells which were imaged twice, 
once in the basal state (A, C) and once after 1 hour treatment with 5μM SFN (B, D). The 
left column shown the EGFP image from which the FRET efficiency data are derived. The 
middle column shows a pictorial representation of the FRET efficiency where the colour 
of the cell corresponds to the FRET efficiency, ranging from 0% to 30% as indicated on 
the legend below the image. The right column shows the FRET efficiency from each pixel 
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of the image plotted on a graph, with FRET efficiency on the x-axis and frequency on the 
y-axis. The FRET efficiency graphs (A-D) show that the FRET efficiency distribution is 




 Together, these data suggest that inducers function by promoting the 
formation of the closed conformation of the Keap1-Nrf2 complex. In order to 
gain an alternate perspective on how the two complexes relate to each other, and 
to understand how the two conformations can be interconverted, we wished to 
manipulate the Keap1-Nrf2 pathway with a chemical which does not bind 
directly to Keap1, and thus does not directly influence the Keap1-Nrf2 complex. 
As Nrf2 is targeted by Keap1 for degradation by the proteasome, we decided to 
inhibit this degradation through use of the proteasomal inhibitor MG132.  
 When used to treat EGFP-Nrf2 + mCherry transfected cells, 10 μM MG132 
had no effect on the lifetime of EGFP, demonstrating that it doesn’t have any 
FRET-independent effects on the EGFP fluorophore (Table 5.4).   Unexpectedly, 

















Cell 1 2152 2089 no data 2131 
Cell 2 2138 2103 2236 2145 
Cell 3 2117 2096 no data 2124 
Cell 4 2117 2075 no data no data 
AVERAGE 2131 2091 N/A 2133 
SD 17 12 N/A 11 
Paired  
T-test 




Table 5.3. Lifetime of EGFP-Nrf2 in individual cells imaged before and after STCA 
treatment. HEK293 cells were co-transfected with EGFP-Nrf2 and Keap1-mCherry and 
imaged 24 hours later. The table shows the lifetime of EGFP fluorescence in the 
cytoplasm and nucleus of cells imaged in the basal state, and again after 1 hour 
treatment with 10 μM STCA. The table shows that treatment with STCA leads to a 
significant reduction in the EGFP-Nrf2 lifetime in the cytoplasm (p = 0.019).  
 
 
EGFP Image EGFP Lifetime EGFP Lifetime 
   
 149 
 
A. Cell 1 
 
1.9 ns               2.6 ns  
 
 








EGFP Image FRET Efficiency FRET Efficiency 
 
 
C. Cell 2 
 
 















Figure 5.4. The lifetime and FRET efficiency in the cytoplasm of EGFP-Nrf2 
transfected cells imaged before and after treatment with STCA. HEK293 cells were 
transfected with EGFP-Nrf2 + Keap1-mCherry, and both the lifetime (A, B) and FRET 
efficiency (C-D) in the cytoplasmic compartment were calculated. A, B show the 
fluorescence lifetime data from a single cell imaged twice, once in the basal state (A) and 
once after 1 hour treatment with 10μM STCA (B). The left column shows the EGFP image 
from which the lifetime data are derived. The middle column shows a pictorial 
representation of the EGFP lifetime where the colour of the cell corresponds to the 
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lifetime of EGFP, ranging from 1.9 ns to 2.6 ns as indicated on the legend below the 
image. The right column shows the lifetime data from each pixel of the image plotted on 
a graph, with lifetime on the x-axis and frequency on the y-axis. Graphs A-B clearly show 
that the lifetime of EGFP-Nrf2 is reduced after treatment with STCA for 1 hour. C-D show 
the FRET efficiency data for a single EGFP-Nrf2 + Keap1-mCherry co-transfected cell 
which was imaged twice, once in the basal state (C) and once after 1 hour treatment 
with 10μM STCA (D). The left column shows the EGFP image from which the FRET 
efficiency data are derived. The middle column shows a pictorial representation of the 
FRET efficiency where the colour of the cell corresponds to the FRET efficiency, ranging 
from 0% to 30% as indicated on the legend below the image. The right column shows 
the FRET efficiency from each pixel of the image plotted on a graph, with FRET efficiency 
on the x-axis and frequency on the y-axis. The FRET efficiency graphs (C,D) show that 
the FRET efficiency distribution is altered by STCA, which leads to an increase in the 
interaction at 21% FRET efficiency. The FRET efficiency distributions are shown 
pictorially in the central column of C,D, where an increase in the amount of yellow 
relative to green can be seen in response to STCA. 
 
 
lead to a reduction in the cytoplasmic EGFP-Nrf2 lifetime and the accumulation 
of the complex in the closed conformation (Table 5.5, Figure 5.5, 5.6). 
Interestingly, even in cells in which in the basal state the majority of the Keap1-
Nrf2 complex is found in the open conformation, MG132 treatment was still able 
to promote the formation of the closed conformation (Figure 5.6C,D). It is 
interesting to note that MG132 was also able to reduce the lifetime of EGFP-Nrf2 
in the nucleus, where it can promote the formation of the closed conformation, 















 In order to gain a thorough understanding of the mechanism through 
which Nrf2 is regulated by Keap1, we wished to study this interaction in both the 
basal (Chapter 4) and induced states (Chapter 5). We wanted to extend our 
single cell FLIM-based approach to examine the effects of inducers in individual 
cells, and importantly, we wished to study the interaction between Keap1 and 
Nrf2 in the same cell both in the basal and induced state. We believe that this 
approach is best suited to study the effects of inducers as it minimises the 
consequences of cellular heterogeneity caused by transient transfection of the 
fusion proteins. The validity of this approach is predicated on the idea that the 
lifetime and FRET efficiency are constant within a cell over a 1 hour period, so 
that any effects observed after the treatment with inducers for 1 hour were 
dependent on the activity of the inducer on Keap1, and not on the time that the 
image was taken, or the fact that the cell had already been imaged previously. 
Thankfully, both the lifetime of EGFP-Nrf2 and the FRET efficiency distribution 
were constant over a 1 hour time period, thus our multiple imaging approach 
could be used to assay the effects of inducers on the Keap1-Nrf2 complex 
(Figure 5.1, Table 5.1). 
 Interestingly, we found that both SFN and STCA led to a significant 
decrease in the EGFP-Nrf2 lifetime (Table 5.2, 5.4). A lower EGFP lifetime 
means that EGFP and mCherry fluorphores are closer together, which suggests 
that the Keap1-Nrf2 complex undergoes a conformational change in response to 
inducers such that the distance between the fluorophores is reduced, allowing 
more FRET to occur. Importantly, this lifetime decrease correlated with a change 
in FRET efficiency, and this change in FRET efficiency corresponded to a change 
in the relative abundances of the complexes identified in the basal state, and not 
the formation of a different Keap1-Nrf2 complex. In the cytoplasm, both SFN and 
STCA changed the FRET efficiency distributions. In the basal state the Keap1-
Nrf2 complex was found equally in the open and closed conformations, whilst in 
cells treated with inducers, this changed so that the closed conformation was the 
dominant complex in which the Keap1 and Nrf2 were found (Figure 5.2, 5.4). 
The fact that different inducers which target different cysteine residues of Keap1 
(SFN binds to Cys-151, STCA bind to Cys-273 and -288) both function in the  
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Figure 5.5. The cytoplasmic lifetime in EGFP-Nrf2 transfected cells imaged before 
and after treatment with MG132. HEK293 cells were transfected with either EGFP-
Nrf2 + mCherry (A,B), or EGFP-Nrf2 + Keap1-mCherry (C,D), and the lifetime of EGFP 
fluorescence was calculated. A,B show the fluorescence lifetime data of cells imaged in 
the presence of MG132 and absence of Keap1-mCherry. C,D show the fluorescence 
lifetime data from a single cell imaged twice, once in the basal state (C) and once after 1 
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hour treatment with 10μM MG132 (D). The left column shows the EGFP image from 
which the lifetime data are derived. The middle column shows a pictorial representation 
of the EGFP lifetime where the colour of the cell corresponds to the lifetime of EGFP, 
ranging from 1.9 ns to 2.6 ns as indicated on the legend below the image. The right 
column shows the lifetime data from each pixel of the image plotted on a graph, with 
lifetime on the x-axis and frequency on the y-axis. Graphs A,B show that in the absence 
of FRET, MG132 has no effect on the lifetime of EGFP-Nrf2. Graphs C-D clearly show that 
the lifetime of EGFP-Nrf2 is reduced after treatment with MG132 for 1 hour.  
 
 
same way suggest that the phenomenon which we observed is not inducer or 
cysteine specific, and may point to a general mechanism though which inducers 
stabilise Nrf2 (Figure 5.8). 
 Interestingly, we found that in the nucleus SFN also leads to a decrease in 
EGFP lifetime and a modest increase in formation of the closed conformation 
(Table 5.3, Figure 5.4). We were unable to determine the effect of STCA on the 
lifetime of EGFP-Nrf2 in the nucleus due to the challenges presented in working 
with nuclear lifetime data. In the basal state, EGFP-Nrf2 in predominantly found 
in the cytoplasm (Figure 4.9), and thus the imaging conditions were optimised 
for data collection in the cytoplasmic compartment. On average, the signal is 10-
fold lower in the nucleus, which makes analysing the data more difficult as the  
contribution of noise to the overall signal is much greater when the intensity of 
the signal is lower. The intensity of signal required to calculate the FRET 
efficiency is even greater than that required for the lifetime, as the FRET 
efficiency is calculated using a two-component analysis which requires more 
 
 
 Inducer Lifetime (ps)  N SD T-test 
EGFP-Nrf2 + mCherry None        2375  13 12 
EGFP-Nrf2 + mCherry 10 μM MG132        2379   5  18 
 
p > 0.05 
 
Table 5.4. FLIM data for EGFP-Nrf2 transfected cells treated with MG132 in the 
absence of Keap1-mCherry. The table shows the lifetime, number of cells imaged and 
standard deviation of the lifetime for EGFP-Nrf2 + mCherry co-transfected HEK293 cells 
in the presence and absence of 10 μM MG132. The data clearly show that the treatment 
of cells with MG132 for 1 hour has no effect on the lifetime of EGFP-Nrf2. 
 
 




A. Cell 1 
 
 















C. Cell 2 
 
 















Figure 5.6. The FRET efficiency in the cytoplasm of EGFP-Nrf2 transfected cells 
imaged before and after treatment with MG132. HEK293 cells were transfected with 
EGFP-Nrf2 + Keap1-mCherry, from which the FRET efficiency in the cytoplasmic 
compartment were calculated. A-D show the FRET efficiency data for individual EGFP- 
Nrf2 + Keap1-mCherry co-transfected cells which were imaged twice, once in the basal 
state (A, C) and once after 1 hour treatment with 10μM MG132 (B, D). The left column 
shows the EGFP image from which the FRET efficiency data are derived. The middle 
column shows a pictorial representation of the FRET efficiency where the colour of the 
cell corresponds to the FRET efficiency, ranging from 0% to 30% as indicated on the 
 155 
legend below the image. The right column shows the FRET efficiency from each pixel of 
the image plotted on a graph, with FRET efficiency on the x-axis and frequency on the y-
axis. The FRET efficiency graphs (A-D) show that the FRET efficiency distribution is 
altered by MG132, which leads to a profound increase in the interaction at 21% FRET 
efficiency. The FRET efficiency distributions are shown pictorially in the central column 
of A-D, where an increase in the amount of yellow relative to green can be seen in 
response to MG132. 
 
data. This may in part explain why the reduction in lifetime of EGFP-Nrf2 in the 
nucleus in response to inducers is coupled with a modest change in the FRET 
efficiency, whilst similar reductions in cytoplasmic lifetime are coupled with 
more significant changes to the FRET efficiency distributions (compare Figure 
5.2 with Figure 5.3).  
Whilst in most cases it was possible to calculate the EGFP-lifetime and 
FRET efficiency distribution in the nucleus, it could not be done universally. 
Thus, from the cells imaged prior to STCA treatment, a reliable nuclear lifetime 
could not be established and thus the effect of the inducer in the nucleus could 

















Cell 1 2180 2103 2250 2208 
Cell 2 2145 2117 2201 2180 
Cell 3 2173 2124 N/A N/A 
Cell 4 2145 2068 2187 N/A 
Cell 5 2166 2089 2215 2152 
Cell 6 2152 2138 2222 2215 
Cell 7 2173 2103 2236 2180 
AVERAGE 2162 2106 2219 2187 
SD 14 21 23 25 
Paired  
T-test 
p = 0.000324 
 
p = 0.0229 
 
Table 5.5. Lifetime of EGFP-Nrf2 in individual cells imaged before and after MG132 
treatment. HEK293 cells were co-transfected with EGFP-Nrf2 and Keap1-mCherry and 
imaged 24 hours later. The table shows the lifetime of EGFP fluorescence in the 
cytoplasm and nucleus of cells imaged in the basal state, and again after 1 hour 
treatment with 10 μM MG132. The table shows that treatment with MG132 leads to a 
significant reduction in the EGFP-Nrf2 lifetime in both the cytoplasmic and nuclear 
compartments.  
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Figure 5.7. The nuclear FRET efficiency of EGFP-Nrf2 transfected cells imaged 
before and after treatment with MG132. HEK293 cells were transfected with EGFP-
Nrf2 + Keap1-mCherry, from which the FRET efficiency of the interaction between these 
fusion proteins in the nucleus was calculated. A-D show the FRET efficiency data for 
individual EGFP-Nrf2 + Keap1-mCherry co-transfected cells which were imaged twice, 
once in the basal state (A, C) and once after 1 hour treatment with 10μM MG132 (B, D). 
The left column shows the EGFP image from which the FRET efficiency data are derived. 
The middle column shows a pictorial representation of the FRET efficiency where the 
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colour of the cell corresponds to the FRET efficiency, ranging from 0% to 30% as 
indicated on the legend below the image. The right column shows the FRET efficiency 
from each pixel of the image plotted on a graph, with FRET efficiency on the x-axis and 
frequency on the y-axis. The FRET efficiency graphs (A-D) show that the FRET efficiency 
distribution is altered by MG132, which leads to a modest increase in the interaction at 
21% FRET efficiency.  
 
 
average nuclear lifetime of EGFP-Nrf2 was 2203 ps (Table 4.2), and in the 3 cells 
in which it was possible to calculate the nuclear lifetime after the addition of 
STCA, it was 2133 ps (Table 5.3). This suggests that the trend of inducer activity 
leading to a decrease in the EGFP-Nrf2 lifetime may also be true in the nucleus of 
cells treated with STCA.  
 Together these results present a stark contrast to the existing models of 
Nrf2 regulation, particularly to the widely accepted hinge and latch model. The 
hinge and latch model was proposed when the second binding site of Nrf2 was 
discovered (McMahon et al. 2006, Tong et al. 2006a). It was noted that the DLG 
motif binds with a 100-fold lower affinity than the ETGE motif, and yet this motif 
is absolutely required for the physiological regulation of Nrf2 by Keap1. In the 
absence of the DLG motif, through either targeted deletion by researchers or by 
point mutations in cancer, Nrf2 is no longer ubiquitinated by the Keap1-
dependent E3-ubiquitin ligase (McMahon et al. 2006, Shibata et al. 2008a). 
Together, the fact that the DLG motif shows weaker binding to Keap1, coupled 
with the idea that loss of DLG binding to Keap1 results in Nrf2 stabilisation, led 
to the formulation of the hinge and latch model (Figure 1.4). The hinge and latch 
model was proposed despite the fact that there was no experimental evidence to 
support the existence of the “open latch” conformation of the Keap1-Nrf2 
complex in the induced state (Tong et al. 2006a, Tong et al. 2006b). Our FRET 
efficiency data can directly visualise this complex as it corresponds exactly to the 
13% FRET efficiency population. However, in contrast to the hinge and latch 
model, our data clearly show no accumulation of the Keap1-Nrf2 complex in the 
13% FRET efficiency population. Instead our data suggest that inducers function 
by promoting the formation of the 21% FRET efficiency population, which 
represents the closed conformation, and thus that inducers lead to the DLG motif  
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Figure 5.8. The impact of inducers and proteasomal inhibition on the 
conformation of the Keap1-Nrf2 complex. Row A depicts, in cartoon form, the Keap1-
Nrf2 complex in the basal state. Our data show that in the basal state, the Keap-Nrf2 
complex is distributed equally in the open and closed conformations. A FRET efficiency 
distribution corresponding to this is shown on the left.  B shows how the distribution 
between the two conformations is altered by inducers and the proteasomal inhibitor 
MG132. Under these conditions, the complex shifts to favour the closed conformation 
(shown by a relative increase in size of the closed conformation relative to the open 
conformation). This shift is reflected in the FRET efficiency distribution, which shows a 




of Nrf2 binding more tightly to Keap1, not less, as postulated by the hinge and 
latch model.  
 As shown in Chapter 4, in the basal state, the Keap1-Nrf2 complex is 
found in both an open and closed conformation. From these data alone it is 
unclear whether these two states existed in equilibrium with one another, with 
both states being required for ubiquitination of Nrf2, or as two points in a cycle, 
where one conformation is formed and then progresses to the second 
conformation to allow the ubiquitination process. The inducer data showed that 
inducers promote the formation of the closed conformation, however this 
stabilisation could occur by either a change in the equilibrium dynamics, or an 
alteration in the binding cycle, both of which could manifest themselves as an 
increase in the interaction at 21% FRET efficiency. For this reason we chose to 
stabilise Nrf2 using the proteasomal inhibitor MG132, which does not bind 
directly to Keap1, yet stabilises Nrf2 by blockings its degradation by the 
proteasome. This allowed us to investigate how the two conformations of the 
Keap1-Nrf2 complex relate to one another. If MG132 has no effect on the Keap1-
Nrf2 complex, it will suggest that the two conformations are in equilibrium with 
one another. However, if the two states of the complex represent two points on a 
cycle, then blocking the cycle by inhibiting Nrf2’s degradation will lead to the 
accumulation of the complex at the later point of the cycle.  
 When we treated cells with MG132, we saw a reduction in the lifetime of 
EGFP-Nrf2 coupled with an increase in the FRET efficiency distribution at the 
21% interaction (Table 5.5, Figure 5.5, 5.6). Interestingly, in cells in which the 
Keap1-Nrf2 complex is almost exclusively in the open conformation in the basal 
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state, inhibition of the proteasome leads to a dramatic shift in the FRET efficiency 
distribution, from mostly 13% to mostly 21% (Figure 5.6C,D), suggesting that 
the interaction between Keap1 and Nrf2 forms a cycle, in which the 21% FRET 
efficiency population (closed conformation) is the later point in the cycle, and 
thus the 13% population (open conformation) represents the initial position of 
the cycle. As inducers also lead to the accumulation of the Keap1-Nrf2 complex in 
the closed conformation, our data suggest that they too function to inhibit the 
cycle of Nrf2 ubiquitination by Keap1.  
 We observed that even in the nucleus, MG132 is able to reduce the 
lifetime of EGFP-Nrf2 and increase the abundance of the closed conformation 
(Table 5.5, Figure 5,7). As MG132 only increases the amount of Nrf2 in the 
nucleus, and doesn’t directly modify Keap1, these data suggest that the Keap1-
Nrf2 complex is able to form the closed conformation in the nucleus. The main 
reason that this does not occur in the basal state is most likely because of the low 
levels of Nrf2 which mean that it is outcompeted for binding to Keap1 by other 
nuclear protein such as Prothymosin-α or Palb2 (Padmanabhan et al. 2008, Ma et 
al. 2012). This suggests that the function of the other Keap1-binding proteins in 
the nucleus is to compete with the DLG motif of Nrf2, and thus reduce the 
efficiency of Keap1 in the nucleus relative to the cytoplasm to allow basal level 



































Chapter 6: Establishment of a FRAP-based 





























 In addition to studying the interaction between Keap1 and Nrf2 using 
FRET/ FLIM, we also wished to use an independent single cell analysis method 
that would support or dispute our FRET results. The method we chose was the 
microscopy-based technique fluorescence recovery after photobleaching (FRAP). 
This method measures the rate of diffusion of proteins, and allows the 
determination of dynamic changes within the complex in which a protein is 
found as conditions within the cell change (Reits et al 2001). The principal 
behind FRAP is shown in cartoon form in Figure 6.1. The cells are first 
transfected with an expression plasmid of the protein of interest fused to GFP, so 
that the protein’s localisation and movement can be visualised. Next, a laser is 
used to photo-bleach a small area in the cell resulting in the loss or reduction of 
fluorescence in the bleached region. Due to the natural diffusion of the proteins 
within the cell, this bleached region will recover its fluorescence as the proteins 
from the surrounding regions diffuse into the bleached spot. As such this method 
measures the diffusion rate of the fusion protein. Interestingly, if the protein of 
interest is found within a complex, FRAP allows the user to evaluate the status of 
this complex as the cellular conditions change. This is due to the properties of 
diffusion, whereby smaller proteins diffuse faster than larger proteins or protein 
complexes. Thus if the activity of a drug leads to the dissociation of a protein 
complex, this can be measured by FRAP as the individual members of the 
dissociated complex will diffuse faster in the presence of the drug. FRAP has 
been used to study a wide variety of cellular processes, from the localisation 
changes of the transcription factor β-catenin, to the mechanism of RNA splicing 
(Krieghoff et al. 2006, Lleres et al. 2010). 
 In addition to using FRAP to study the interaction between Nrf2 and 
Keap1, this technique is also well suited to test one of the other models of Nrf2 
activation, that of the dissociation of Keap1 from Cullin-3 (Figure 1.3). This 
technique will allow us to complement the existing biochemical data with a live 
cell imaging approach to test whether inducers function to dissociate the Keap1-





Figure 6.1. Fluorescence recovery after photobleaching (FRAP). This microscopy 
technique measures the rate at which fluorescently labelled proteins are able to diffuse 
in live cells. This is shown in cartoon form above, where a cell is transfected with an 
expression plasmid for GFP the expression of which is distributed evenly across the 
cytoplasm. A laser is then used to photobleach a small area in the cell. The cell is then 
rapidly imaged after the bleach event, during which time the surrounding GFP diffuses 
into the bleached area and the fluorescence signal is recovered. This allows the user to 
study the diffusion dynamics of the protein to which GFP is fused. If the fusion protein is 
found in a protein complex which can dissociate upon the addition of a drug, this can be 




 The aim of this part of the project was to use FRAP to study the impact of 










 Our first aim was to validate this technique by ectopically expressing 
Nrf2-EGFP and Keap1-mCherry in HEK293 cells (at exactly the same 
experimental conditions as those used for the FRET experiments), and then 
exposing the cells to an inducer to measure whether there was any dissociation 
of Keap1 and Nrf2. Our previous FRET data had suggested that there is no 
dissociation of Keap1 and Nrf2 in response to inducers, and we expected to see a 
similar result with the FRAP experiments. 
 As shown in Figure 6.2A-C, cells were imaged before the bleach event, 
during the bleach event and after the recovery of fluorescence in the bleached 
spot.  Figure 6.2D,E shows the localisation of Nrf2-EGFP and Keap1-mCherry, 
which is largely cytoplasmic, and consequently all bleach events were carried out 
in the cytoplasm also. Figure 6.2F shows the fluorescent recovery plotted 
against time within the bleached spot. It shows that before the bleaching, the 
fluorescence was 1.0 (or 100%), it was then bleached to 60% of its original 
intensity before quickly recovering to 85% of its original intensity as 
surrounding Nrf2-EGFP diffused into the bleached area. From this recovery 
graph, we can extract the value of T½, the time taken for the fluorescence 
intensity to recover to half of its maximum recovery intensity, and this T½value 
can be used to compare different cells with different starting EGFP intensities.   
 Figure 6.2A-F shows an example of a cell imaged in the basal state, whilst 
Figure 6.2G-L is a representative of cells which have been exposed to 0.1 μM 
CDDO for 1 hr. Table 6.1 shows the summary of the FRAP data for this 
experiment. In the basal state, the T½ recovery time was 0.592s, and in the 
presence of 0.1 μM CDDO it was 0.681s (p>0.05). Thus there was no significant 
difference between the rate at which Nrf2-EGFP was able to diffuse into the 
bleached spot in the absence or the presence of the inducer, indicating that 
Nrf2’s ability to diffuse is not altered in the induced state, and thus that it is not 
released from Keap1. 
 We then wished to determine whether inducers lead to the dissociation of 
the Keap1-dependent E3-ubiquitin ligase, which consists of Keap1, Cullin-3 






































L. Recovery dynamics 
 
Figure 6.2. FRAP experiments to study the interaction between Keap1 and Nrf2.  
HEK293 cells were transfected with Nrf2-EGFP + mCherry-Keap1, and imaged 24 hours 
later. Six images in the panel above display the data from a single experiment, with A-F 
showing a representative example of data in the basal state, and G-L showing 
 166 
representative data for cells treated with 0.1 μM CDDO for 1 hour. Each cell was imaged 
three times pre-bleach (A), and 30 times post bleach (B) to capture the recovery of EGFP 
fluorescence (C). D and E show the localisation of EGFP-Nrf2 and mCherry-Keap1, whilst 
the recovery dynamics are plotted in the graph shown in F. From this graph, the T½ 
value was calculated as the amount of time required for half of the maximal intensity of 
fluorescence to be recovered. 
 
of Keap1-EGFP and mCherry-Cul3 and transfected them in HEK293 cells to 
examine their diffusion dynamics using FRAP.  
 Importantly, before this was done we needed to determine whether 
Keap1-EGFP and mCherry-Cul3 interact in cells. In order to do this, we expressed 
the Keap1 fusion protein in either the presence or the absence of mCherry-Cul3. 
If Keap1-EGFP is able to interact with mCherry-Cul3, then its diffusion time 
should be slower when mCherry-Cul3 is present compared to when it is absent. 
Representative cells from these experiments are shown in Figure 6.3, where in 
A-F data are shown from Keap1-EGFP and mCherry co-transfected cells, whilst in 
the example shown in G-L the cells were co-transfected with Keap1-EGFP and 
mCherry-Cul3. By comparing 3E and 3K it is clear that the fusion of Cul3 to 
mCherry changes the localisation of the fluorophore from whole cell to 
cytoplasmic. Due to the co-localisation of Keap1 and Cul3 (Figure 6.3J, K), all of 
the bleach spots were produced in the cytoplasm. As shown in Table 6.2, in the 
absence of Cul3, the T½value of Keap1-EGFP was 0.29 s, and when mCherry-Cul3 
was co-transfected the T½was increased to 0.347. This difference was 
statistically significant (p = 0.022) showing that, when expressed, Keap1-EGFP 
and mCherry-Cul3 do bind to one another in live cells. 
 
 Inducer  T½ (s)   N     SD T-test 
Nrf2-EGFP + Keap1-mCherry None   0.592  23  0.178 
Nrf2-EGFP + Keap1-mCherry 0.1 μM CDDO   0.681  28  0.224 
 
p > 0.05 
 
Table 6.1. FRAP data for Nrf2-EGFP transfected cells. The table shows the recovery 
time (T½), number of cells imaged and standard deviation of the recovery time for Nrf2-
EGFP + Keap1-mCherry co-transfected HEK293 cells in the basal state and after 1 hour 
treatment with the inducer CDDO (0.1 μM). The recovery time of Nrf2-EGFP is 
unaffected by addition of the inducer (p > 0.05) showing that the Keap1-Nrf2 complex 







































L. Recovery dynamics 
 
Figure 6.3. FRAP experiments to demonstrate that Keap1-EGFP and mCherry-Cul3 
interact in live cells.  HEK293 cells were transfected with either Keap1-EGFP + 
mCherry (A-F) or Keap1-EGFP + mCherry-Cul3 (G-L) and imaged 24 hours later. Six 
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images in the panel above display the data from a single experiment. Each cell was 
imaged three times pre-bleach (A), and 30 times post bleach (B) to capture the recovery 
of EGFP fluorescence (C). D and E show the localisation of Keap1-EGFP and free 
mCherry, whilst the recovery dynamics are plotted in the graph shown in F. From this 
graph, the T½ value was calculated as the amount of time required for half of the 
maximal intensity of fluorescence to be recovered. A comparison of E and K shows that 




 We then wished to determine whether inducers lead to the dissociation of 
Keap1 from Cul3. If inducers function through the dissociation of the Keap1-
dependent E3-ubiquitin ligase, then we would expect to see a decrease in the 
T½value after inducer treatment. Firstly we imaged cells in the basal state, and 
then we added the inducers to the cell culture medium, incubated the cells for 1 
hour and imaged the same dish again. Representative images are shown in 
Figure 6.4 and 6.5 and the data are summarised in Table 6.2. We found that the 
T½value was unaffected by the inducers SFN, STCA, CDDO and H2O2, suggesting 
that 
 
 Inducer  T½ (s) N    SD T-test 
Keap1-EGFP + mCherry None   0.290  41  0.073 
Keap1-EGFP + mCherry-Cul3 None   0.347  15  0.098 
 
p = 0.022 
 
Keap1-EGFP + mCherry-Cul3 None   0.320  20  0.075 
Keap1-EGFP + mCherry-Cul3 5 μM SFN   0.334       22  0.053 
 
p > 0.05 
 
Keap1-EGFP + mCherry-Cul3 None   0.347  15  0.098 
Keap1-EGFP + mCherry-Cul3 10 μM STCA   0.367       27  0.090 
 
p > 0.05 
 
Keap1-EGFP + mCherry-Cul3 None   0.374  18  0.085 
Keap1-EGFP + mCherry-Cul3 0.1 μM CDDO   0.372  30  0.096 
 
p > 0.05 
 
Keap1-EGFP + mCherry-Cul3 None   0.416      29  0.087 
Keap1-EGFP + mCherry-Cul3 400 μM H2O2   0.385  20  0.061 
 
p > 0.05 
 
Table 6.2. FRAP data for Keap1-EGFP transfected cells. The table shows the recovery 
time (T½), number of cells imaged and standard deviation of the recovery time for 
Keap1-EGFP + mCherry, and Keap1-EGFP + mCherry-Cul3 co-transfected HEK293 cells. 
In the basal state, the recovery time of Keap1-EGFP is lower in the presence of free 
mCherry than in the presence of mCherry-Cul3 (p = 0.022), demonstrating that Keap1-
EGFP interacts with mCherry-Cul3 in cells. In Keap1-EGFP + mCherry-Cul3 co-
transfected cells, the addition of the inducers SFN, STCA, CDDO and H2O2 has no effect on 
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the recovery time, suggesting that the Keap1-Cul3 complex is not dissociated after 1 




































L. Recovery dynamics 
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Figure 6.4. FRAP experiments to study the interaction between Keap1 and Cul3.  
HEK293 cells were transfected with Keap1-EGFP + mCherry-Cul3, and imaged 24 hours 
later. Six images in the panel above display the data from a single experiment, with A-F 
showing a representative example of data in the basal state, and G-L showing 
representative data for cells treated with 400 μM H2O2 for up to 1 hour. Each cell was 
imaged three times pre-bleach (A), and 30 times post bleach (B) to capture the recovery 
of EGFP fluorescence (C). D and E show the localisation of Keap1-EGFP and mCherry-
Cul3, whilst the recovery dynamics are plotted in the graph shown in F. From this graph, 
the T½ value was calculated as the amount of time required for half of the maximal 
intensity of fluorescence to be recovered.  
 
 
inducers of different types do not function through the dissociation of the Keap1-





























 The aim of the FRAP experiments were two-fold. Firstly we wished to use 
a complementary method to FRET/ FLIM to study the dynamics of the Nrf2- 
Keap1 interaction in response to inducers, and secondly we wished to study how 
inducers impact the Keap1-dependent E3-ubiquitin ligase complex. 
 There were a number of experimental differences between the FRAP and 
FLIM experiments, despite the fact that the overall experimental design was 
similar. In the FLIM experiments, the length of time of the image acquisition step 
was very long at 90 s. This contrasts sharply with FRAP, which requires 
numerous images at regular intervals. As a result, the FRAP exposure times per 
image were very short (50 ms) which means that a much brighter image is 
required for FRAP than FLIM, where long exposure times are sympathetic to 
weakly fluorescent cells. In the case of Nrf2-EGFP expression, the exposure time 
is crucial, as Nrf2 is targeted for degradation by Keap1, and thus is present at low 
levels, even when ectopically expressed. The short exposure time required for 
FRAP combined with the low level of Nrf2-EGFP expression meant that carrying 
out the FRAP experiments with Nrf2-EGFP and Keap1-mCherry was very 
difficult, and because of this the only inducer which was analysed was CDDO. 
 A second difference between the FLIM and FRAP experiments was the 
way we imaged the cells pre- and post-induction. For the FLIM data, we wanted 
to image the same cell before and after the inducer was added to see how the 
FRET efficiency changed. This method is not compatible for use in FRAP 
experiments, because the photo-bleaching is a destructive event which reduces 
the total fluorescence signal from the cell, and this fluorescence reduction would 
influence a second measurement if the same cell was to be imaged both before 
and after inducer treatment. For this reason, cells were not imaged both before 
and after the inducers were added, and instead those cells which were imaged in 
the basal state were avoided post-induction. 
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In good agreement with the FLIM data, the FRAP data of EGFP-Nrf2 and 
Keap1-mCherry co-transfected cells showed that the two proteins do not 

























































R. Recovery dynamics 
 
Figure 6.5. FRAP experiments to study the interaction between Keap1 and Cul3.  
HEK293 cells were transfected with Keap1-EGFP + mCherry-Cul3, and imaged 24 hours 
later. Six images in the panel above display the data from a single experiment, with A-F 
showing a representative example of data for cells treated with 10 μM STCA for 1 hour, 
G-L showing representative data for cells treated with 0.1 μM CDDO for 1 hour, and M-R 
showing data for cells treated with 5 μM SFN for 1 hour. Each cell was imaged three 
times pre-bleach (A), and 30 times post bleach (B) to capture the recovery of EGFP 
fluorescence (C). D and E show the localisation of Keap1-EGFP and mCherry-Cul3, whilst 
the recovery dynamics are plotted in the graph shown in F. From this graph, the T½ 
value was calculated as the amount of time required for half of the maximal intensity of 
fluorescence to be recovered.  
 
results correlate well with previously published data, in which the interaction 
between Nrf2 and Keap1 has been shown to be maintained in response to a 
variety of inducers (Zhang et al. 2004, Eggler et al. 2005), which shows that the 
regulation of Nrf2 by Keap1 is more complex than the simple sequestration-
release model (Figure 1.2) of Nrf2 by Keap1 in the cytoplasm. 
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 It has previously been proposed that inducers function through the direct 
dissociation of Keap1-dependent E3-ubiquitin ligase (Figure 1.3) (Zhang et al. 
2004, Gao et al. 2007, Rachakonda et al. 2008, Hur et al. 2010), particularly those 
inducers which target C-151 of Keap1. As there is currently no crystal structure 
of either the full-length Keap1 protein, or the Cul3-BTB domain interface, it is 
difficult so say with any certainty where the C151 residue is located. However, 
based on the published structures of the BTB-domain protein PLZF and the Cul-1 
interacting protein Skp1, it has been suggested thatβ-strand-3 and α-helix-5 
within the BTB domain are both important for BTB-Cul-3 interactions (Ahmad et 
al. 1998, Zheng et al. 2002, Zipper and Mulcahy 2002, Xu et al. 2003). 
Interestingly, C151 is located either within or adjacent to α-helix-5, which 
suggests that, based on its location, modification of C151 may disrupt Keap1-
Cul3 binding.  
As this model of Nrf2 regulation was not tested in our FRET experiments, 
we decided to test it using FRAP. Due to the increased stability of Keap1-EGFP 
compared with Nrf2-EGFP, Keap1-EGFP gave a much brighter image, and 
therefore inducers of several different types could be tested for their ability to 
dissociate Keap1 and Cul3. Because we wished to determine whether the 
dissociation of Keap1 from Cul3 caused the stabilisation of Nrf2, we chose the 
physiologically relevant time point of 1 hr after which to study the effects of 
inducers.  Interestingly, we found that none of the inducers tested produced a 
change in the T½value of Keap1-EGFP (Table 6.2). Therefore, in contrast to 
previously published data, we must conclude from the FRAP experiments that 
none of the 4 inducers tested lead to the dissociation of Keap1 from Cul-3 after 1 
hour of treatment. 
 The previously published data that led to the model of Keap1-Cul3 
dissociation is based on co-IP experiments, where inducers were found to cause 
a modest reduction in the intensity of the pulled-down protein when either 
Keap1 or Cul-3 are used as the bait (Zhang et al. 2004, Gao et al. 2007, 
Rachakonda et al. 2008, Hur et al. 2010). Interestingly, although a range of 
inducers have been used to show this reduction in binding, the occurrence of 
dissociation has never been rigorously established. If inducers function primarily 
to dissociate the Keap1-Cul3 complex, then this dissociation should precede Nrf2 
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stabilisation. If true, this causality should be demonstrated experimentally, 
where the co-IP experiment showing reduced binding of Keap1 to Cul3 should be 
done at a time point prior to Nrf2 stabilisation. To date this has not been done. 
The published co-IP experiments show reduced binding between Keap1 and Cul3 
at 2 hours for oxidised n-3 fatty acids, 2 hours for IAB and 5 hours for tBHQ and 
SFN (Zhang et al. 2004, Gao et al. 2007, Rachakonda et al. 2008, Hur et al. 2010). 
In contrast, inducers stabilise Nrf2 within 30 minutes (McMahon et al. 2003, 
Nguyen et al. 2003), and thus the published data do not adequately show that 
dissociation of the Keap1-Cul3 complex leads to stabilisation of Nrf2 as causality 
has not been demonstrated. We therefore conclude that, at least during the initial 
phase of Nrf2 stabilisation, inducers function to inactivate Keap1, and not by 
dissociating the Keap1-dependent E3 ubiquitin ligase. 
Even though inducers did not alter the T½value in Keap1/Cul3 co-
transfected cells, there was a degree of variability among experiments. Thus, 
Table 6.2 shows that in the basal state, the T½value of Keap1-EGFP + mCherry-
Cul3 varies from 0.320 to 0.416 s. This difference can be explained by differences 
in the microscope set-up. Before each experiment, the laser must be correctly 
aligned so that the bleach spot is as circular as possible to maximise the 
effectiveness of the bleaching. This alignment is performed manually and is 
responsible for the differences in bleaching seen among cells from different 
experiments. For example, in the experiment shown in Figure 6.4H,L the bleach 
reduced the intensity to 30% of the pre-bleach level, whilst in Figure 6.5H,L the 
bleached spot is at 70% of the pre-bleach level. Every effort was made to 
minimise these differences, but due to the fact that the alignment is carried out 
by hand, variations are inevitable. For this reason and in order to reduce the 
variation within a single experimental set, the basal controls were always imaged 
at the same time and with the same laser alignment as the induced samples. 
In order to study the interaction between Keap1 and Cullin-3 using FRAP 
we had to tag both proteins with fluorphores. In the case of Keap1, the addition 
of a fluorophore at the C-terminus has been shown to have a minimal effect on 
the proteins function (Chapter 3). In the case of Cullin-3, the addition of any tag 
to either the N- or C-terminus inhibits the activity of the protein due to the 
location of the tag within the E3 ligase complex. Whilst it would be preferable 
 176 
that the Cullin-3 fusion protein was functional, it does not change the conclusion 
drawn from these experiments. The aim of the Keap1 FRAP experiments was to 
determine whether the interaction between Keap1 and Cullin-3 changes in 
response to inducers. We have shown that the Keap1 and Cullin-3 fusion 
proteins are able to bind to one another in cells, and that this interaction in not 
altered by the addition of inducers (Table 6.2). The fact that our Cullin-3 fusion 
does not form a functional E3 ligase is unfortunate, but is not essential for these 
experiments, as the aim of the experiment was not to test the functionality of the 






























































































 The overall aim of this project was to investigate the spatio-temporal 
dynamics of the regulation of the Keap1-Nrf2 interactions in individual cells by 
use of microscopy-based techniques. By analysing cellular processes at the 
single-cell level, the investigator can make discoveries which could be otherwise 
masked by cellular heterogeneity if tackled at the cell population level (Spiller et 
al. 2010). For example, single-cell analysis has revealed that the activation of the 
NF-κB pathway leads to a change in localisation of the transcription factor RelA, 
such that it oscillates between the cytoplasic and nuclear compartments due to 
the formation of a negative feedback loop between NF-κB and its negative 
regulator IκB (Nelson et al. 2004, Ashall et al. 2009). As these oscillations are 
asynchronous, this process can only be studied at the single cell level. Similarly, 
single cell analysis has been used to study the dynamics of the p53 response in 
the basal and induced state (Loewer et al. 2010). The authors found that in 
response to DNA damage, the p53 level followed a regular pulse-like pattern, 
with ~5 peaks over a 24-hour period. Interestingly, it was shown that in the 
absence of stressors, the p53 level also followed a pulse-like pattern, but with 1-
2 pulses per 24 hours. As in the case of NF-κB, because these pulses of p53 
stability are asynchronous between cells, they can only be detected in individual 
cells. 
 It has previously been suggested that the interaction between Keap1 and 
Nrf2 may be dynamic, and that this dynamism may be modulated by inducers 
(Figures 1.2-1.7). For this reason we decided to establish a single cell FLIM/ 
FRET system in which to study the interaction between Keap1 and Nrf2 in both 
the basal and induced state (Chapter 3). We found that in the basal state, Keap1 
is able to bind to Nrf2, and that this interaction is maintained in the induced state 
(Tables 3.2, 3.3). We used FRAP to study the Keap1-Cul3 interaction (which 
together with Rbx1 form the E3-ubiquitin ligase responsible for targeting Nrf2 
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for ubiquitination), and found that the Keap1-Cul3 complex is not dissociated by 
inducers prior to Nrf2 stabilisation (Chapter 6).  
 Due to the high resolution of the FLIM/ FRET data, coupled with the use 
of various mutant forms of Nrf2 and Keap1, we were able to show that the 
Keap1-Nrf2 complex exists in two distinct conformations in the basal state, an 
open conformation, corresponding to Nrf2 bound to a single member of the 
Keap1 dimer, and a closed conformation, in which Nrf2 is bound to both 
members of the Keap1 dimer (Chapter 4).  Interestingly, we found that inducers 
shift the balance in favour of the closed conformation (Figures 5.2, 5.4). In order 
to gain a deeper understanding of the relationship between the two 
conformations, we also inhibited the degradation of Nrf2 though use of the 
proteasomal inhibitor MG132. As with the inducers, MG132 causes accumulation 
of the Keap1-Nrf2 complex in the closed conformation, despite the fact that, to 
our knowledge, MG132 does not bind directly to Keap1 (Figure 5.6). These data 
suggest to us that the interaction between Keap1 and Nrf2 follows a cycle, whose 
function is to maintain Nrf2 at a low level in the basal state, but has the ability to 
rapidly stabilise Nrf2 when its cytoprotective properties are required, and allows 
for multiple forms of regulation (see below). 
 Our new cyclical model of Nrf2 regulation by Keap1 is shown 
schematically in Figure 7.1A. Newly translated Nrf2 (in yellow) binds first 
through its high affinity ETGE motif to one member of a free Keap1 dimer (in 
blue) to form the open conformation. It has previously been shown that when 
the ETGE motif alone is bound to the Keap1, Nrf2 is not targeted for 
ubiquitination by the E3-ubiquitin ligase (McMahon et al. 2006), and therefore 
whilst in the open conformation, Nrf2 is not ubiquitinated. After a period of time 
in the open conformation, Nrf2 progresses to form the closed conformation 
through the binding of the low affinity DLG motif to the other member of the 
Keap1 dimer. The formation of the closed conformation aligns Nrf2’s lysine 
residues, located in the α-helix between the DLD and ETGE motifs, in such a way 
as to make ubiquitination possible. Thus, in the closed conformation, Nrf2 is 
polyubiquitinated, and subsequently released for degradation by the 
proteasome. The free Keap1 dimer is then able to bind to newly synthesized Nrf2 
and the cycle begins again. 
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 This model is supported experimentally by the data from cells treated 
with MG132 (Figure 5.6A). If the open and closed states were in equilibrium 
with one another, then blocking the destruction of Nrf2 by the proteasome 







Figure 7.1. Cyclical model of the ubiquitination of Nrf2. A. In the basal state, newly 
translated Nrf2 (in yellow) binds to a free Keap1 dimer (in blue) through its ETGE motif 
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to form the open conformation (1). After a period of time in the open conformation, the 
DLG motif binds to the second member of the Keap1 dimer to form the closed 
conformation (2). Once in the closed conformation, Nrf2 can be targeted for 
ubiquitination by the Keap1-dependent E3-ubiquitin ligase (3). Once ubiquitinated, Nrf2 
is released from Keap1 and degraded by the proteasome. The free Keap1 dimer is then 
able to bind to newly translate Nrf2 and the cycle begins again (4). B. Inducers function 
to uncouple the formation of the closed conformation from ubiquitination (2). This 
means that Nrf2 is not released from Keap1 (3), free Keap1 is not regenerated, and 
newly translated Nrf2 is able to translocate to the nucleus and turn on the expression of 
cytoprotective genes (4).  
 
 
would be observed in either the lifetime of EGFP or the FRET efficiency of the 
interaction. As the MG132 treatment leads to an accumulation in the closed 
conformation, the data suggest that the different conformations are not in 
equilibrium, but that instead, they represent two distinct phases of a cycle. 
Inhibition of the proteasomal degradation of Nrf2 blocks the cycle, which leads to 
the accumulation of the Keap1-Nrf2 complex in the later stage of the cycle – in 
the closed conformation. 
 Inducers function to inhibit the ubiquitination of Nrf2 (Zhang et al. 2004, 
Kobayashi et al. 2006). Our data show that, at first glance paradoxically, this is 
coupled with the formation of the closed conformation of the Keap1-Nrf2 
complex (Figures 5.2, 5.4), the same conformation that in the basal state is 
associated with the ubiquitination of Nrf2 (Figure 7.1A). This raises an 
important question: how can these two seemingly contradictory facts be 
reconciled?  
 We would suggest that the closed conformation in the basal and induced 
states are not identical, or more accurately, they are identical with respect to the 
relationship between the Kelch domain of Keap1 and Nrf2, but not with respect 
to Nrf2 with the rest of the Keap1-dependent E3-uqibuitin ligase (Figure 7.2). In 
the basal state, the closed conformation orientates the lysine residues of Nrf2 so 
that they can be ubiquitinated by the E2 ubiquitin-conjugating enzyme that is 
bound to the E3. The direct binding of inducers to reactive cysteine residues of 
Keap1 leads to conformational changes in Keap1 (Dinkova-Kostova et al. 2005a) 
such that, whilst Nrf2 is still bound to Keap1 through both its ETGE and DLG 
motifs, it is no longer correctly aligned with the E2 ubiquitin-conjugating 
enzyme, and thus ubiquitination does not occur. This results in the Keap1-Nrf2 
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complex accumulating in the closed conformation (Figure 7.1B), where, without 
ubiquitination, Nrf2 is effectively “trapped”, and cannot be released by the Keap1 
dimer. An interesting corollary of our model is that ubiquitination not only 
marks Nrf2 for proteasomal degradation, but also for release from Keap1. 
 
Figure 7.2 A comparison between the closed conformations in the basal and 
induced states. The cartoons above show a comparison between the closed 
conformations in the basal (A) and induced (B) state. In the images, Keap1 is shown in 
blue, mCherry in red, Nrf2 in yellow, EGFP in green and the E2 ubiquitin-conjugating 
enzyme in orange. A. The closed conformation in shown in the basal state, where Nrf2 is 
correctly aligned for ubiquitin transfer from the E2 to the lysine residues in the helix 
located between the DLG and ETGE motifs. B. The closed conformation in the induced 
state. Inducers bind directly to Keap1, leading to a conformational change in Keap1 and 
the misalignment of Nrf2 relative to the E2 enzyme. As a result of this misalignment, 
Nrf2 is not ubiquitinated by the E2 ubiquitin-conjugating enzyme, free Keap1 cannot be 
regenerated, and the newly synthesized Nrf2 is stabilised in the cell.  
 
 
One prediction that can be made based on this model is that in the 
absence of new translation, inducers will have no effect on Nrf2 stabilisation. 
This has been shown to be the true by multiple groups, suggesting that de novo 
translation of Nrf2 is required for cytoprotection (Sekhar et al. 2000, Kobayashi 
et al. 2006, Shay et al. 2012). In tumour samples, gain-of-function mutations have 
been found in both the ETGE and DLG motifs, emphasising the importance of the 
two-site binding of Nrf2 to Keap1 (Shibata et al. 2008a). This correlates well with 
our model, where the loss of either motif will lead to stabilisation of Nrf2, due to 
the inability of the complex to form the closed conformation and allow the cycle 
to proceed. 
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 One interesting feature of our model is the existence of the open 
conformation in the basal state. For what reason may this state exist, and why is 
the closed conformation not formed immediately upon Nrf2 binding to Keap1 
through the high affinity ETGE motif? Analysis of the sequence of the Nrf2  
 
 
Figure 7.3.Folding status of human Nrf2 protein. The protein sequence of full-length 
human Nrf2 was analysed using the FoldIndex software (Prilusky et al. 2005). The image 
shows the Nrf2 sequence on the x-axis and the foldIndex value on the y-axis, where 
positive values (in green) indicate a folded region, and negative values (in red) indicate 
an unfolded region of the protein. The DLG and ETGE motifs of Nrf2 are located in the 
first 100 amino acids of the protein, and are thus in an unfolded region.  
 
 
protein suggests that the Neh2 domain (which contains both the ETGE and DLG 
motifs) may be unfolded in the native state, and thus it may take time for the DLG 
motif to form the correct β-hairpin conformation required to bind to Keap1 
(Figure 7.3)(Tong et al. 2007). Alternatively, the open conformation may be 
formed due to other proteins competing with the DLG motif of Nrf2 for Keap1 
binding in the basal state (see below). Either way, it appears that the formation 
of the open conformation is an important feature of the Keap1-Nrf2 complex. 
We believe that the existence of the open conformation provides the cell 
with advantages, as it allows Nrf2 activity to be regulated by other signalling 
pathways (Figure 7.4). It has recently been shown that both p21 (in the case of 
p53 activation) and p62 (in the case of autophagy inhibition) are also able to 
regulate Nrf2 activity. They do this by directly binding to regions of the Keap1-
Nrf2 complex that are exposed in the open conformation, but may be hidden in 
the closed conformation: p21 binds to the DLG motif of Nrf2, and p62 competes 
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with the DLG motif for binding to the Kelch domain of Keap1 (Chen et al. 
2009,Komatsu et al. 2010). In both cases, p21 and p62 inhibit the formation of 
the closed conformation, leading to the stabilisation of Nrf2. Thus, we believe 
that the  
 
Figure 7.4. Regulation of Nrf2 by p21 and p62. In the basal state, newly translated 
Nrf2 (in yellow) binds to a free Keap1 dimer (in blue) through its ETGE motif to form the 
open conformation (1). In the case of either autophagy inhibition, p62 (in orange) or in 
the case of p53 activation, p21 (in purple) bind to motifs in the Keap1-Nrf2 complex 
which are exposed in the open conformation (2). This means that Nrf2 cannot form the 
closed conformation, and thus cannot be targeted for ubiquitination by Keap1, which 
disrupts the cycle and results in the stabilisation of Nrf2 (3). 
 
 
Keap1-Nrf2 complex forms the open conformation to allow the cell to regulate 
cytoprotective gene expression through multiple pathways. 
We believe that the responsiveness of the Keap1-Nrf2 pathway is fine 
tuned by the relative levels of Keap1 and Nrf2 proteins within the cell. The cycle 
of Nrf2 ubiquitination may be balanced such that the Keap1-dependent E3-
ubiquitin ligase is functioning at its maximal capability in the basal state, and 
that the amount of newly-translated Nrf2 exactly matches the capacity of the E3 
ligase to target it for degradation. This “tipping point” state and lack of buffering 
capacity allows the pathway to respond exceedingly quickly to the cellular 
environment and allows the cell to rapidly upregulate cytoprotective genes.  
The idea that the cycle is finely balanced is well supported by existing 
data. In pancreatic cancer, a modest (less than 2-fold) K-Ras-dependent increase 
in transcription of Nrf2 leads an increase in Nrf2 protein levels and transcription 
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of cytoprotective genes (DeNicola et al. 2011). This suggests that in the basal 
state, the Nrf2 cycle operates at a level close to saturation, and that any increase 
in the transcription or translation of Nrf2 overloads Keap1, which in turn allows 
newly translated Nrf2 to translocate to the nucleus and turn on expression of 
target genes. Conversely, a reduction in the level of Keap1 also leads to an 
increase in Nrf2 protein levels (Taguchi et al. 2010), which reinforces the idea 
that the system has little spare capacity, presumably to allow for rapid 
upregulation of Nrf2-dependent genes when required by the cell.  
The proposition that the binding of Nrf2 to Keap1, and the subsequent 
ubiquitination of Nrf2, follows a cycle is not without precedent. It has previously 
been suggested that the formation and dissociation of E3-ubiquitin ligases 
follows a cyclical pattern regulated by the ubiquitin-like protein Nedd8 (Cope 
and Deshaies 2003). This suggests that regulatory cycles might be a common 
mechanistic theme in protein ubiquitination and degradation. 
Interestingly, the weak EGFP-Nrf2 signal in the nucleus could, in most 
cases, also be analysed. Here we found that in the basal state, the Keap1-Nrf2 
complex exists exclusively in the open conformation (Figure 4.11). Both 
inducers and inhibition of the proteasome were able to promote the formation of 
the closed complex in the nucleus (Figures 5.3, 5.7), suggesting that although 
the closed conformation can be formed there, under normal circumstances it 
does not, presumably as other proteins such as Prothymosin-α or Palb2 compete 
with the DLG motif of Nrf2 for binding to Keap1. The absence of the closed 
conformation in the nucleus at basal state suggests that in this compartment, 
Nrf2 is not targeted for ubiquitination by Keap1. This makes biological sense, as 
Nrf2-dependent transcription does occur in the basal state (McMahon et al. 
2001), and if Keap1 was too efficient then this basal transcription would not 





 From the model presented in Figure 7.1, a number of testable predictions 
can be made which would either support or refute our model. Firstly, if the 
binding of Nrf2 to Keap1 follows a cycle, then inhibiting the entry of newly 
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synthesised Nrf2 into the cycle should lead a reduction in the amount of the 
complex in the open conformation relative to the closed conformation. When 
these experiments were carried out using cycloheximide to inhibit the 
translation of Nrf2, we observed an increase in interaction in the closed 
conformation, as would be predicted from our model. In addition, from Figure 
7.4 it is suggested that competition for binding to Keap1 with the DLG motif of 
Nrf2 will lead to an increase in the Keap1-Nrf2 complex bound in the open 
conformation. In order to test this, we used the small molecule HB229, which 
binds directly to the Kelch domain of Keap1, to compete with the DLG motif of 
Nrf2 for Keap1 binding, and in these experiments we observed an increased 
EGFP-Nrf2 lifetime, and an increase in the interaction in the open conformation. 
This suggests that by competing for binding of Keap1 with the DLG motif of Nrf2, 
small molecules, or proteins such as p21 or p62 inhibit the formation of the 
closed conformation and thus inhibit the ubiquitination of Nrf2. 
 In order to improve upon and support our model of the interaction 
between Keap1 and Nrf2, future experiments should be carried out using an 
independent methodology to validate our FLIM results. One powerful method 
that has the potential to complement our FRET data is fluorescence cross-
correlation spectroscopy (FCCS), another microscopy-based single cell analysis 
technique which could be used to study the Keap1-Nrf2 complex. 
 FCCS involves imaging a small volume (1 pixel of a confocal image) within 
a cell over a short period of time, and measuring the fluctuations of the 
fluorescence signal through the volume (Bacia and Schwille 2007). As 
fluorescent proteins diffuse into and out of the imaged region, the intensity of the 
signal fluctuates about a mean value, and thus FCCS allows the user to determine 
the average level of fluorescence in the cell, and by extension, the concentration 
of any fusion protein which is fluorescently labelled. Interestingly, FCCS allows 
the user to track two fluorescent channels at once, which allows the user to study 
the binding kinetics within a protein complex. This is because FCCS measures 
three variables, the diffusion of the two different coloured fluorophores (eg EGFP 
and mCherry), and the co-diffusion of EGFP and mCherry together. If co-diffusion 
is observed (that is, if a fluctuation in the green channel occurs at exactly the 
same time at the red channel), it suggests that the fusion proteins are diffusing 
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together through the imaged volume as a complex. Because the data generated 
from FCCS are numerical it can be used to study the binding kinetics of protein 
complexes in live cells (for an example see equation 7.1). FCCS has been used to 
study a variety of cellular processes, including signal transduction through the 
MAP Kinase pathway (Maeder et al. 2007, Slaughter et al. 2007). 
 
   Kd =  [Green][Red]Equation 7.1 
                   [Bound] 
 
where:    Kd = dissociation constant of the green and red protein complex 
[Green] = concentration of green labelled proteins not in a  
complex  with  red labelled proteins 
 [Red] = concentration of red labelled proteins not in a complex 
with green labelled proteins 
 [Bound] = concentration of the complex between green and red 
labelled proteins 
 
 Because FCCS measures fluctuations in the fluorescence signals, a low 
fluorescence intensity provides the best data, as when the signal is weak a small 
fluctuation in the intensity has a larger effect on the measured signal. For 
example, if each EGFP protein gives an intensity value of 1 and, on average, only 
5 EGFP proteins are present in a given pixel, then the diffusion of a single protein 
out of this pixel will reduce the intensity by 20%. However, if the overall 
intensity of the EGFP signal in the cell is high, and on average 100 EGFP proteins 
are present in each pixel, then the diffusion of a single protein out of the imaged 
pixel will reduce the intensity by only 1%, thus greatly reducing the sensitivity of 
the technique.  
 For this reason, FCCS would not only complement the existing FLIM data, 
but would also improve upon one of the flaws of the model as it is currently 
presented: the fact that the current data are derived from an overexpression 
system.  
 To extend the current project, and to better understand the physiological 
interaction between Keap1 and Nrf2, EGFP and mCherry fusion proteins of 
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Keap1 and Nrf2 would be knocked into the endogenous Keap1 and Nrf2 loci in a 
well characterised cell line which responds well to inducers, such as Hepa1c1c7 
cells. This would mean that the level of the fusion proteins would be tightly 
regulated by endogenous transcriptions factors, and would accurately model the 
physiological response to inducers and stress. 
 In this system, we would knock-into the Nrf2 locus both wild type Nrf2 
and the two binding mutants used in the FRET experiments. We would expect 
the 2xETGE mutant to bind most tightly to Keap1 (and thus have the lowest Kd), 
the ΔDLG to bind weakly to Keap1 (and thus have the highest Kd), and for wild 
type Nrf2 to have a Kd value between the two mutants, showing that both the 
open and closed conformations are present in the basal state. We could then use 
this basal data as a reference point to study the interaction between Keap1 and 
Nrf2 in response to inducers. If the FCCS data supported the FLIM data, we 
would expect to see that the accumulation of the Keap1-Nrf2 complex in the 
closed conformation in the induced state corresponds with a reduced Kd in the 
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